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1 SUMMARY 
1.1 Scope of the submission 
The remit of the Evidence Review Group (ERG) is to comment on the clinical and cost 
effectiveness evidence submitted to the National Institute for Health and Care Excellence 
(NICE) as part of the Single Technology Appraisal (STA) process. Clinical and economic 
evidence has been submitted to NICE by Takeda UK Ltd in support of the use of brentuximab 
vedotin (ADCETRIS), hereafter referred to as BV, for patients with relapsed or refractory 
cluster of differentiation 30-positive lymphoproliferative disorders (CD30+ LPDs) cutaneous T-
cell lymphoma (CTCL) following skin directed therapies and/or at least one systemic therapy. 
The European Commission granted an extension of the marketing authorisation valid 
throughout the European Union for BV to include the treatment of adult patients with CD30+ 
CTCL after at least one prior systemic therapy on 15 December 2017.  
1.2 Critique of the decision problem in the company submission 
The focus of the company submission (CS) is a subgroup of the licensed population, namely 
patients with advanced stage CTCL. The company’s rationale for this approach is that patients 
with advanced stage CTCL constitute the population most relevant to NHS clinical practice. 
Clinical advice to the ERG is that these patients are the most likely candidates for treatment 
with systemic therapies.  
CTCL is a heterogeneous disease with many different subtypes. Only patients with mycosis 
fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) were included 
in the ALCANZA trial, the company’s main source of clinical evidence.  
The company considers that the relevant comparators to BV are methotrexate (MTX) and 
bexarotene (BEX), which are described by the company, and in treatment guidelines, as 
Category A systemic therapies. It is anticipated by the company that Category B therapies 
would be used after BV in the treatment pathway (if required at all). Category B therapies 
include single or multi-agent chemotherapy regimens and total skin electron beam therapy. 
Clinical advice to the ERG is that (i) Category A therapies are the most relevant comparators 
to BV for patients with MF and (ii) Category B therapies would normally be preferred to 
Category A therapies for patients with advanced stages of pcALCL who have received at least 
one prior systemic therapy and are fit enough to tolerate the drugs. However, clinical advice 
is that MTX and BEX are likely to be appropriate comparators to BV for the patients included 
in the ALCANZA trial with pcALCL who were not fit for Category B drugs.  
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The company highlights that allogeneic stem cell transplant (alloSCT) may be a treatment 
option for some patients, namely those who have a good response to prior treatment. 
Therefore, for a proportion of patients, the company modelled alloSCT following treatment with 
BV or a comparator in its base case economic model. 
1.3 Summary of the clinical evidence submitted by the company 
The ALCANZA trial is an international, open-label, randomised, phase III, multicentre trial of 
BV versus treatment of physician’s choice (PC) of MTX or BEX in patients with MF or pcALCL 
and was the only relevant randomised controlled trial (RCT) of BV identified by the company’s 
literature searches. Evidence from three single-arm observational studies were also included 
in the CS, two of which were prospective phase II studies. The observational studies included 
patients with subtypes other than MF or pcALCL, including Sézary syndrome (SS) and 
lymphomatoid papulosis (LyP). Where reported (in the RCT and two observational studies), 
most patients had advanced stage MF.  
A total of 131 patients were enrolled into the ALCANZA trial between 13 August 2012 and 31 
July 2015 and randomly assigned (1:1) centrally by an interactive voice and web response 
system to receive BV (n=66) or PC (n=65). Randomisation was stratified by baseline disease 
diagnosis (MF or pcALCL). BV was administered intravenously at a dose of 1.8mg/kg once 
every 3 weeks, for a maximum of 48 weeks (i.e., 16 x 3-weekly cycles). In the PC arm, patients 
received oral MTX 5mg to 50mg once per week or oral BEX 300mg/m² once per day. Patients 
received MXT or BEX for up to 48 weeks. Patients were defined as having advanced stage 
CTCL if they had a diagnosis of MF stage IIB or pcALCL. In total, 49 patients treated with 
BV and 46 patients treated with PC were classified as having advanced stage CTCL at 
baseline (n=95; 73% of all patients in the trial). 
The ALCANZA trial primary outcome was objective global response lasting at least 4 months 
(ORR4), described by the company as a relatively new outcome measure used to assess the 
impact of therapy on the unique symptomatic burden of CTCL. This outcome captures 
objective response rate (ORR) and duration of response as a single measure. Other trial 
outcomes included ORR, progression-free survival (PFS), safety outcomes and health-related 
quality of life (HRQoL) outcomes. Overall survival (OS) was not a pre-specified outcome; 
however, OS data were collected and are reported in the CS. All analyses of efficacy, safety 
and HRQoL outcomes for patients with advanced stage CTCL (n=95) were conducted after a 
median follow-up of 33.9 months.  
The ALCANZA trial has shown that, for patients with advanced stage CTCL, compared with 
treatment with PC, BV results in increased ORR4 (59% versus 9%), increased ORR (69.4% 
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versus 17.4%) and improved median PFS (16.5 months versus 3.5 months). The company 
notes that OS data were extremely immature and confounded by subsequent anticancer 
therapy received on disease progression. Subsequent treatment, which includes treatment 
switching, for patients with advanced stage CTCL was reported for 55% of patients in the BV 
arm and 63% of patients in the PC arm (46% of PC patients with advanced stage CTCL 
received subsequent anticancer treatment with BV). The company reports that, compared with 
treatment with PC, treatment with BV results in longer median OS (41.6 months and 43.6 
months respectively) but highlights that these results are highly uncertain. 
In the subgroup of patients with advanced stage CTCL in the ALCANZA trial, more patients 
treated with BV reported any-grade treatment-related adverse events (TRAEs), treatment-
related serious adverse events (TRSAEs) and discontinuations due to adverse events (AEs) 
than patients with advanced stage CTCL treated with PC. On the other hand, there were more 
grade 3 treatment-emergent (TEAEs) reported by patients in the PC arm than were reported 
by patients in the BV arm. Peripheral neuropathy was the most common TEAE associated 
with BV for all patients treated with BV (reported by 67% of all patients at an earlier follow-up, 
median of 22.9 months) and was also the most common grade ≥3 TEAE for patients with 
advanced stage CTCL (14%). Grade ≥3 TEAEs were uncommon for patients treated with MTX 
but grade ≥3 hypertriglyceridemia was reported by a quarter of patients with advanced stage 
CTCL treated with BEX. 
HRQoL findings presented in the CS from the ALCANZA trial for patients with advanced stage 
CTCL show that patients in the BV arm, but not in the PC arm, experienced clinically important 
reductions in skin symptoms as measured by the Skindex-29 questionnaire. Results from 
analyses of European Quality of Life 5-Dimension-3 Level Version (EQ-5D-3L) data were not 
statistically significant different between treatment arms.  
The company assessed the feasibility of performing indirect comparisons to obtain (i) 
estimates of effectiveness of treatment with BV versus interferon alpha (IFN-α), another 
Category A therapy, and (ii) estimates of effectiveness of BV versus standard of care for 
patients with SS/LyP. It was not possible to conduct these indirect comparisons due to 
insufficient data being available. 
Efficacy and safety results from two phase II studies, which included a small number of 
patients with SS and LyP, were reported narratively in the CS. Notably, ORR was 100% for 
17 patients with LyP (8 of whom had LyP plus MF or LyP plus pcALCL) compared to 54% for 
28 patients with MF only in one of the studies and 70% for 27 patients with MF and 67% for 3 
patients with SS in the other. The findings for PFS and AEs were reported only for all patients 
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with CTCL and not by individual subtype in both studies and were consistent with results from 
the ALCANZA trial. These studies did not report OS.  
1.4 Summary of the ERG’s critique of submitted clinical effectiveness 
evidence 
Clinical advice to the ERG is that, in the NHS, IFN-α is commonly prescribed to patients with 
MF before, or after, MTX or BEX. Furthermore, clinical advice is that all Category A therapies 
are considered to have equal efficacy. Therefore, the lack of a comparison of the effectiveness 
of BV versus IFN-α is not considered by the ERG to be a major limitation of the evidence base. 
As the ALCANZA trial was stratified by baseline disease diagnosis, but not by disease stage, 
the subgroup of patients with advanced stage CTCL is not, technically, a randomised patient 
population. However, the proportions of patients with MF and pcALCL in the subgroup of 
patients with advanced stage CTCL are similar in both treatment arms; approximately two-
thirds of patients with advanced stage CTCL had been diagnosed with MF (BV: n=33, PC: 
n=31) and approximately a third had been diagnosed with pcALCL (BV: n=16, PC: n=15). 
Clinical advice to the ERG is that the previous treatments received by the patients with 
advanced stage CTCL appear to be broadly in line with NHS clinical practice in England. 
Treatment with BV is indicated for patients who had at least one prior systemic therapy. In the 
ALCANZA trial, most patients (62%) with advanced stage CTCL had received one (42%) or 
two (20%) prior systemic therapies and a quarter had received four or more prior systemic 
therapies. The median number of prior systemic therapies was two and the maximum number 
of prior systemic therapies that patients had received was 11. 
On examination of data from the subgroup of patients in the ALCANZA trial with advanced 
stage CTCL, the ERG observed a sudden increase in PFS events in the BV arm between 64 
weeks (14.7 months) and 77 weeks (17.7 months) of follow-up. The ERG considers this 
phenomenon is likely to be as a consequence of the timing of PFS assessments. Patients 
were required to cease treatment with BV after 16 cycles (approximately 48 weeks) and were 
then followed for survival every 12 weeks for a minimum of 24 months after the end of 
treatment (EOT) visit.  A number of patients in the BV arm who finished treatment at 48 weeks 
without having progressed would not have been followed up until 12 weeks after their EOT 
visit. Therefore, patients who progressed between their EOT visit and the assessment 12 
weeks later would all have been recorded as having progressed at the 12-week assessment 
point (approximately 60 weeks after starting treatment) Since the recording of progression 
events between the EOT visit and the follow-up assessment 12 weeks later may well have 
been delayed for some patients, the ERG considers that median PFS may have been 
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overestimated in the BV arm. The ERG also highlights that the median time to subsequent 
anticancer therapy in the BV arm was lower (14.2 months) than the median PFS in the BV 
arm (16.5 months).  
The ERG notes that the Cox proportional hazards (PH) method was used to estimate the 
hazard ratios (HRs) for the outcomes of PFS and time to subsequent anticancer therapy. 
However, following examination of data collected from the subgroup of patients in the 
ALCANZA trial with advanced stage CTCL, the ERG considers that the PH assumption may 
be violated for both these outcomes. Since HRs are not an appropriate summary of treatment 
effect when the PH assumption does not hold, the ERG considers that the reported HRs for 
PFS and time to subsequent anticancer therapy for this subgroup should be interpreted with 
caution. 
The ERG agrees with the company that OS results from the ALCANZA trial should be 
interpreted with caution due to confounding, the small number of patients included in the 
analysis and the small number of events that had occurred. The ERG also agrees with the 
company that none of the available methods of crossover adjustment are suitable for the 
ALCANZA trial and that it is not possible to obtain a robust estimate of the comparative 
efficacy, in terms of OS, of treatment with BV versus PC. 
Safety data from the ALCANZA trial show that for patients with advanced stage CTCL, 
treatment with BV was not associated with new or unexpected toxicities and that the majority 
of reported AEs were grade 1 or grade 2 in severity. Clinical advice to the ERG is that 
peripheral neuropathy is the most common and clinically significant AE associated with 
treatment with BV. The ERG notes that the only TRAE that resulted in death occurred in the 
BV arm. However, this patient did not meet the trial eligibility criteria as the patient had 
elevated liver function test results at baseline and their enrolment, therefore, constituted a 
major protocol violation. 
The ERG highlights that, in addition to Skindex-29 symptom and EQ-5D-3L data, Skindex-29 
emotional and functioning domain data and Functional Assessment of Cancer Therapy-
General (FACT-G) questionnaire data from the ALCANZA trial have been presented in the 
published paper and in the European Public Assessment Report (EPAR) for BV. These results 
are presented for all patients in the trial, not just for patients with advanced stage CTCL. 
Nonetheless, the ERG highlights that no statistically significant or clinically meaningful 
differences between treatment arms were reported for these HRQoL measures. The ERG, 
therefore, concurs with the European Medicines Agency that no firm conclusions with regard 
to the impact of BV on HRQoL can be drawn. 
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The ERG considers that the company’s indirect comparison feasibility assessments were 
appropriate and agrees with their conclusion that it was not possible to conduct an indirect 
comparison of treatment with BV versus IFN-α or of BV versus standard of care for patients 
with SS/LyP. 
Limited evidence for efficacy of BV by different CTCL subtypes is available from observational 
study data presented in the EPAR for BV, alongside that of ORR from the two phase II studies. 
These data show that findings for ORR and median PFS observed in the non-randomised 
studies for different subtypes of CTCL are generally consistent across studies, and in line with 
the findings reported in the ALCANZA trial, albeit from small numbers of patients. Of the 218 
patients in these non-randomised studies, 147 (67%) had MF, 19 (9%) had SS, 5 (2%) had 
pcALCL, 22 (10%) had LyP only, 22 (10%) had mixed subtypes (most commonly LyP and MF, 
n=18 [8%]) and 3 (1%) had other CTCL subtypes. It is therefore difficult to draw conclusions 
from these studies. 
1.5  Summary of cost effectiveness evidence submitted by the 
company 
The company developed a de novo partitioned survival model in Microsoft Excel to compare 
the cost effectiveness of treatment with BV versus PC for patients with advanced stage CTCL 
(i.e., MF stage IIB and pcALCL) who have been previously treated with at least one systemic 
therapy. The model structure comprises five mutually exclusive health states: pre-progression, 
non-stem cell transplant (SCT) post-progression, Allogeneic SCT, Allogeneic SCT relapse and 
dead. The model time horizon is set to 45 years and has a 1-week cycle length. The model 
perspective is that of the UK NHS. As recommended by NICE, outcomes are measured in 
quality adjusted life years (QALYs), and both costs and QALYs are discounted at an annual 
rate of 3.5%. 
In the model, data from the ALCANZA trial are used as the basis for estimating patient survival 
and patient utility. Resource use and costs are estimated based on information from the 
ALCANZA trial, skin systemic anticancer therapy treatment protocols, other published sources 
and advice from clinical experts. A Department of Health Patient Access Scheme (PAS) 
discount is applied to the cost of BV and full list prices are used to represent the cost of BEX 
and MTX. 
The company uses fully parametric curves to estimate outcomes for PFS and OS for treatment 
with BV and PC. The company uses PFS Kaplan-Meier (K-M) data from the ALCANZA trial to 
generate two Weibull curves, one to estimate PFS for patients treated with BV and one to 
estimate PFS for patients treated with PC. The company fitted a single log-logistic curve to 
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OS K-M data from the PC arm of the ALCANZA trial to estimate long-term survival for both 
patients treated with BV and those treated with PC.  
The company base case analysis includes the assumption that a proportion of patients who 
achieve a complete or partial response to treatment with BV or PC will receive an alloSCT 
after 18 weeks of treatment. Post-alloSCT outcomes are estimated by fitting parametric curves 
to digitised overall survival (OS) and disease-free survival (DFS) data.  
Complete time on treatment (ToT) data are available from both arms of the ALCANZA trial. 
The company has adjusted these data to fit within the weekly-cycle structure of the model to 
directly estimate the length of time patients receive treatment in both arms of the model.  
HRQoL data were collected during the ALCANZA trial. In the base case analysis, the company 
uses the results of a longitudinal mixed-effects regression model to adjust the EQ-5D-3L data 
collected during the trial to take into account progression status and Skindex-29 symptom 
domain score. The utility values used in the pre-progression health state differ by primary 
treatment, whilst in the progressed disease health state, the same utility value was used 
irrespective of primary treatment. The utility values in the alloSCT health states and in the 
post-progression health states were obtained from published sources. 
Results from the company’s base case comparison, using the PAS price for BV, show that 
treatment with BV dominates PC, being both cheaper (********** and more effective (+1.2 life 
years, **** QALYs). The company carried out a wide range of deterministic sensitivity 
analyses. The most influential parameters were the cost of CTCL end-stage care, the utility 
values of patients 3 months post-alloSCT, the cost of medium Allevyn dressings and the 
choice of utility value associated with the post-progression health state.  
The company’s mean probabilistic sensitivity analysis (PSA) results show that treatment with 
BV dominates treatment with PC. However, compared with the deterministic analysis results, 
the incremental costs from the PSA are *********************. The company presents the results 
of PSA iterations to show that, when the cost effectiveness of treatment with BV is compared 
with PC, there is a *** probability of treatment with BV being cost effective at a threshold of 
£30,000 per QALY gained. 
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1.6 Summary of the ERG’s critique of cost effectiveness evidence 
submitted 
1.6.1 ERG’s preferred approach to estimating cost effectiveness 
The ERG’s preferred approach to estimating cost effectiveness within the confines of the 
existing model structure is to remove alloSCT from the treatment pathway and to adjust 
several parameter values used in the company model. 
Removal of alloSCT from the treatment pathway 
Results from the company base case analysis show that treatment with BV yields 1.2 years of 
incremental life gain when compared with PC. This survival gain is due entirely to the inclusion 
of alloSCT in the company model as, in the ALCANZA trial, there was no statistically 
significantly OS gain in favour of treatment with BV compared with PC. The ERG does not 
consider the inclusion of alloSCT in the base case analysis to be appropriate due to the lack 
of robust evidence relating to alloSCT effectiveness, outcomes following alloSCT in patients 
with advanced stage CTCL who have received prior treatment with BV, and the place of 
alloSCT in the treatment pathway. Due to these limitations, the ERG has removed alloSCT 
from the company’s base case treatment pathway. 
ERG revised parameter values 
The ERG has implemented revised values in the company submitted model for the following 
parameters: utility values from the ALCANZA trial, AE disutility values and oral chemotherapy 
costs. 
1.6.2 Areas of uncertainty 
Parts of the model structure limit the ERG’s ability to investigate the impact of varying 
assumptions about survival; however, restructuring the model is not within the ERG’s remit. 
There are also parameter values relating to the post-progression health state that the ERG 
does not consider to be adequately supported by evidence, but for which it has not been able 
to identify robust alternatives. The ERG therefore considers there is substantial uncertainty in 
the reliability of the results of the cost effectiveness model. 
Post-progression health state 
The outcomes of the company model are very sensitive to any assumptions that affect the 
relative time that patients in the BV and PC model arms spend in the post-progression health 
state, specifically in the highly resource-intensive end-stage care phase. The ERG does not 
consider that there is robust evidence to support the assumptions that underpin the company’s 
modelling of the post-progression health state, or that the company has provided reliable 
alternatives to the assumptions implemented therein.  
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Post-progression resource use 
The ERG highlights that there is a lack of published evidence describing post-progression 
resource use (for example, which specific services and resources are needed, for how long, 
and the costs of these resources). Clinical advice to the ERG is that the post-progression 
resource use implemented in the company model may not adequately represent clinical 
practice in the NHS in England. 
Assumption of equal OS resulting in zero OS gain 
The company has assumed in the base case analysis (including alloSCT) that treatment with 
BV and treatment with PC are equally effective in terms of OS, since the results of the 
ALCANZA trial do not show a statistically significant OS difference for the comparison of 
treatment with BV compared with PC. The company argues that the limitations of the OS data 
from the ALCANZA trial (small numbers of patients and events, and high rates of crossover) 
prevent robust estimates of OS gain being generated. The ERG agrees that there is 
insufficient evidence from the ALCANZA trial to make robust claims about lifetime OS gain. 
Clinical advice to the ERG is that there is no robust evidence to either support or refute the 
assumption of zero OS gain as implemented in the company submitted model. 
The ERG notes that the company’s assumption of equal OS resulting in zero OS gain may 
appear to be a conservative approach. However, modelling zero OS gain alongside a PFS 
gain for treatment with BV means that, after progression, patients treated with BV die more 
quickly than patients treated with PC. Consequently, patients treated with BV spend less time 
in the highly resource-intensive end-stage care phase than patients treated with PC. This 
means that the costs accruing to the BV arm are lower than the costs accruing to the PC arm. 
Populations and pathways in the company model  
The company states that the populations that are represented in the model are patients with 
advanced stage MF and patients with pcALCL. However, as noted in the joint submission to 
the National Institute for Health and Care Excellence (NICE) from the Royal College of 
Pathologists and the British Society for Haematology as part of this appraisal, treatment 
decisions are made according to each patient’s needs and the expertise of the centre. The 
relevance of the treatment pathways included in the model to the subgroup of patients with 
advanced stage MF and, in particular, patients with pcALCL is therefore unknown. 
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1.6.3 Model inflexibility and structural issues 
The company has used a payoff approach to model patient outcomes after progression. The 
payoff approach imposes limitations on the flexibility of the company model and does not allow 
for specific parameters and/or assumptions to be investigated thoroughly. The ERG 
acknowledges that the company base case model – including alloSCT – benefits from the 
simplification introduced by the payoff approach. However, due to the limitations of the model, 
the ERG has only been able to produce a limited range of cost effectiveness results. For 
example, the ERG was unable to explore the sensitivity of the model results to the use of 
different parametric survival functions. There are also issues with the calculation of mean post-
progression survival and the probability of transitioning into the post-progression health state. 




 The company provided a detailed submission that met the requirements of NICE’s 
scope for the clinical effectiveness analysis. The ERG’s requests for additional 
information were addressed to a good standard. 
 The company’s main source of clinical evidence is the ALCANZA trial. The ERG 
considers that the ALCANZA trial is a well-designed and good quality trial.  
 The ALCANZA trial compares the efficacy of treatment with BV versus MTX or BEX 
(PC arm). MTX and BEX can be considered as standard of care for patients with MF 
in the NHS. 
 The ALCANZA trial includes patients with two subtypes of CTCL (MF and pcALCL) 
and clinical advice to the ERG is that these patients are representative of patients who 
would be treated with MTX or BEX in clinical practice in England. 
 Although the focus of the CS is only on patients with advanced stage CTCL 
(approximately 75% of the ALCANZA trial population), results for this subgroup are 
consistent with the results for the overall trial population. 
 The inclusion of ORR4 as an endpoint in the ALCANZA trial captures ORR and 
duration of response as a single measure. This is a more appropriate and stringent 
measure of treatment success than ORR. 
Cost effectiveness evidence 
 The company provided a detailed submission that fulfilled the requirements of NICE’s 
scope for the base case analysis. The ERG’s requests for further clinical information 
were met to a good standard. 
 The company model utilises the best available PFS, OS and ToT evidence for 
treatment with BV and PC in a population with advanced stage CTCL from the 
ALCANZA trial.
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1.7.2 Weaknesses and areas of uncertainty 
Clinical evidence 
 RCT evidence is only available for two subtypes of CTCL: MF and pcALCL. There is 
limited supportive evidence from observational data presented in the EPAR for BV for 
patients with the other subtypes of CTCL. It is difficult to obtain clinical effectiveness 
evidence for these other patients given the rarity of CTCL, particularly subtypes other 
than MF. 
 OS data from the ALCANZA trial are immature and confounded by subsequent 
anticancer therapy and treatment switching, meaning that the reliability of results from 
analysis of OS data are highly uncertain. 
 The company’s statistical approach to the analysis of data from the ALCANZA trial is 
mostly appropriate. However, the PH assumption required for use of the Cox PH model 
is subject to uncertainty for PFS and time to subsequent anticancer therapy. This 
means it is not possible to know whether the reported HRs overestimate or 
underestimate the effect of BV versus PC. 
 Median PFS may be overestimated in the BV arm due to the timing of assessments 
following EOT. 
 ORRs for patients in the PC arm of the ALCANZA trial are lower than have been 
previously reported in the literature, albeit they are typically from single-arm 
observational studies. The reasons for this discrepancy are unknown. 
 Despite there being some evidence for improvement in skin symptoms from treatment 
with BV, results from analyses of HRQoL data are inconclusive.  
 Treatment with BV is indicated for patients who had at least one prior systemic therapy. 
In the ALCANZA trial, most (62%) patients with advanced stage CTCL had received 
one (42%) or two (20%) prior systemic therapies, and a quarter had received four or 
more prior systemic therapies. 
 While MTX and BEX are likely to be appropriate comparators to BV for the patients 
with MF included in the ALCANZA trial, clinical advice to the ERG is that Category B 
therapies would normally be preferred to Category A therapies for patients with 
advanced stages of pcALCL who have received at least one prior systemic therapy 
and are fit enough to tolerate the drugs. 
Cost effectiveness evidence 
 Many of the areas of uncertainty in the model are related to the underlying clinical data 
and are, therefore, difficult to resolve. For example, the condition is rare, there are 
several subtypes and the treatment pathway is complicated. 
 The inclusion of alloSCT as an option in the treatment pathway is based on weak 
evidence and generates more uncertainty in a disease area that, due to its rarity and 
diversity in presentation, is already highly uncertain. 
 There is no robust evidence for OS from the ALCANZA trial, so it is not possible to 
determine whether there is an OS gain from treatment with BV versus PC.  
 The assumption of zero OS gain in the company model leads to patients treated with 
BV dying more quickly on progression than patients treated with PC, which may or 
may not be clinically plausible. The company has not robustly tested this assumption. 
 The payoff approach used to structure the modelling of the post-progression health 
state prevents the production of reliable results when alternative OS assumptions are 
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implemented. There is considerable uncertainty surrounding the resource use, costs 
and time spent in the post-progression health state. 
 The incremental costs generated by the PSA are substantially ****** than the 
incremental costs generated by the deterministic sensitivity analyses. 
1.8 Summary of exploratory and sensitivity analyses undertaken by the 
ERG 
1.8.1 ERG revisions to the company base case analysis 
The ERG’s preferred approach to estimating cost effectiveness is to remove alloSCT from the 
treatment pathway and to adjust several of the parameter values used in the company model. 
The ERG made these revisions to the company base case analysis and the results show that 
******************************************. Implementing the ERG’s revisions to the company base 
case comparison decreases incremental costs by ******************* and incremental QALYs 
by *************** 
These ERG revisions have a substantial impact on the ***************** yielded by the company 
base case analysis; however, treatment with BV **************** over treatment with PC once 
the ERG’s revisions are implemented. The ERG cannot be certain of the magnitude of the 
impact that these revisions would have if substantial changes were made to the structure of 
the company model. 
1.8.2 ERG scenarios 
The ERG notes that there are assumptions included in the model for which there is neither 
robust evidence nor extensive sensitivity analyses. The ERG has produced three scenarios to 
test the sensitivity of the model to alternative, plausible assumptions. These assumptions are: 
changes to the post-progression pathway (Scenario 1); changes to resource use frequencies 
(Scenario 2); and assuming an OS gain for treatment with BV (Scenario 3). 
Using the ERG’s revised base case (removal of alloSCT and use of alternative parameter 
values) combined with implementing each of the ERG’s scenarios separately yields ICERs 
per QALY gained that are positive. The ICERs per QALY gained for the comparison of 
treatment with BV versus PC generated by the ERG’s scenarios are 
*********************************************************************************************************
** 
The ERG cautions that i) the scenarios are intended to highlight the sensitivity of the model to 
plausible alternatives to the company assumptions that the ERG does not consider are 
supported by robust evidence, and ii) the structure of the model is inflexible which means that 
the scenario analyses may produce potentially meaningless results.  
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1.9 Cost effectiveness conclusions 
The ERG’s analyses highlight the high level of uncertainty around the company base case 
cost effectiveness results. The ERG cautions that the ICERs per QALY gained for the 







Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 24 of 172 
2 BACKGROUND  
2.1 Critique of company’s description of underlying health problem  
The company’s description of the underlying health problem is succinctly summarised in 
Section A.1 of the company submission (CS) summary document. Additional information is 
provided in Section B1.1 and Section B1.2 of the CS. The Evidence Review Group (ERG) 
considers that the company’s description accurately reflects the underlying health problem. 
Key points are summarised in Box 1 and further details are provided in Sections 2.1.1 to 2.1.4 
of this ERG report.  
Box 1 Key points from the company’s description of underlying health problem 
Description of disease 
 CTCL is a rare disease which consists of a heterogeneous group of nHLs involving the skin and 
which rarely have evidence of extracutaneous disease at the time of diagnosis [1-3].  
 While early stage/localised disease is considered indolent, approximately 25% of patients will 
progress to advanced stage disease during the course of their life [4]. 
 Advanced stage disease is associated with a poor prognosis, negative impact on daily functioning 
and HRQoL [5, 6] and significantly decreased survival versus early stage disease [7, 8]. 
 CTCL is nearly always incurable and for patients with advanced stage disease, death ultimately 
occurs due to disease recurrence, overwhelming sepsis and bone marrow depletion [9]. 
 
Epidemiology 
 The age-standardised incidence of CTCL was 0.75 per 100,000 in England in 2013 [10]. 
 CTCL is more common in men than women, with a ratio of approximately 1.6:1 [10].  
 
Burden of disease 
 In addition to typical cancer-related burden, advanced CTCL is characterised by aggressive, 
devastating lesions (e.g., disfiguring tumours, ulceration, erythroderma), visceral spread, and 
possible blood involvement (circulating Sézary cells) [7, 11]. 
 Chronic skin manifestations and systemic symptoms cause severe pain, unrelenting itching, 
alopecia, chronic skin infections, and disfigurement [6, 11-14] depression, frustration, anger, 
anxiety and worry about dying from CTCL [15].  
 Patients with CTCL may also become self-conscious due to the visibility of symptoms, especially 
when their disease affects exposed areas such as their face and hands [11]. 
 Carers of patients with CTCL also experience the demands of caring as well as negative impacts 
on intimacy, family dynamics and emotional wellbeing [16]. 
 As patients with CTCL tend to have longer survival than other malignancies [7, 8], patients spend 
substantial time in resource-intensive, end-stage care [12, 17].  
CTCL=cutaneous T-cell lymphoma; HRQoL=health-related quality of life; nHL=non-Hodgkin lymphoma 
Source: CS, adapted from summary document, Section A.1 and CS, Sections B.1.3.1 and B.1.3.2 
 
The impact of cutaneous T-cell lymphoma (CTCL) on health-related quality of life (HRQoL) is 
explored at some length in the CS (Section B.1.3.2 Burden to patients, carers and society, 
pp31-39). Some of the issues relating to the burden of CTCL, including the impact on HRQoL 
are summarised by the ERG in Box 1. The ERG concurs that the burden of CTCL on patients 
and carers, including HRQoL, can be high but notes that the issues highlighted in Box 1 tend 
to be most pertinent for patients with advanced stage CTCL. 
While CTCL is nearly always incurable, as stated in the CS (p28), overall survival (OS) varies 
by CTCL subtype and disease stage. The ERG also notes that disease burden is worse for 
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people with more advanced stage CTCL than for those with earlier stages of CTCL. Further 
information relating to subtype, age at diagnosis, disease stage and prognosis is presented in 
Sections 2.1.1 to 2.1.3 of this ERG report. 
2.1.1 Subtypes of cutaneous T-cell lymphoma  
As noted in Box 1, CTCL constitutes a rare, heterogeneous group of non-Hodgkin lymphomas 
(nHLs) [1, 7]. In 2005 a number of subtypes of CTCL were classified by the World Health 
Organization (WHO) - European Organization for Research and Treatment of Cancer 
(EORTC) [7]. The focus of the CS is on the following subtypes of CTCL:  
 Mycosis fungoides (MF) and MF’s leukaemic variant, Sézary syndrome (SS) 
 Primary cutaneous cluster of differentiation 30-positive lymphoproliferative disorders 
(CD30+ LPDs):  
o Primary cutaneous anaplastic large cell lymphoma (pcALCL)  
o Lymphomatoid papulosis (LyP).  
As highlighted in the CS (p23), MF is the most common subtype of CTCL, occurring in more 
than half of patients with CTCL (54% to 55%) [7, 10]. SS is much rarer (2% to 4%) [7, 10]. The 
reported incidence of CD30+ LPDs varies from 10% [10] to 26% [7]. The former estimate is 
from a Public Health England (PHE) study of 1659 people newly diagnosed with CTCL in 
England, between 2009 and 2013. The latter estimate by Willemze et al 2005 is based on data 
from 1476 patients with CTCL registered at the Dutch and Austrian Cutaneous Lymphoma 
Group between 1986 and 2002. These data were presented by the authors [7] in order to 
“…illustrate the clinical significance of the WHO-EORTC classification” (p3769). This study 
also separately presents estimates for pcALCL and LyP: 10% and 16% respectively.  
In addition to the subtypes focussed on by the company, other subtypes of CTCL also exist 
(e.g. subcutaneous panniculitis-like T-cell lymphoma [SPTL]). The complete list of WHO-
EORTC classifications of CTCL are summarised in Table 1 of the published paper by Willemze 
et al 2005 [7]. The ERG highlights that it is possible for patients to have more than one of 
some of the subtypes of CTCL at the same time [18, 19].  
2.1.2 Age of patients with cutaneous T-cell lymphoma 
Wilcox et al 2016 [2] highlight (p152) that “The incidence of CTCL increases significantly with 
age, with a median age at diagnosis in the mid-50s and a fourfold increase in incidence 
appreciated in patients over 70.” The analysis conducted by PHE [10]  found that, of the 1659 
people newly diagnosed with CTCL in England between 2009 and 2013, approximately half 
were aged 50 to 74 years, approximately a quarter of patients were aged ≤50 years and 
approximately a quarter of patients were aged ≥75 years. 
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2.1.3 Prognosis of patients with cutaneous T-cell lymphoma 
Clinical advice to the ERG is that it is often difficult to predict prognosis for patients who receive 
a CTCL diagnosis. Reasons for this include the fact that CTCL is a heterogeneous and rare 
condition and because many patients who present are older adults who often have 
comorbidities. Furthermore, many patients will have had symptoms attributed to eczema or 
parapsoriasis for many years before obtaining a definitive diagnosis. Wilcox et al 2016 [2] have 
noted that while, typically, the median time from symptom onset to diagnosis has been 
reported to be 3 to 4 years, for some patients, time from symptom onset to diagnosis may 
exceed four decades. However, it should also be noted that the 5-year OS rate has been 
reported as 88% for patients with MF, 24% for patients with SS [7], ≥83% for patients with 
pcALCL [20] and ≥90% for patients with LyP [3, 21, 22].  
The disease stage of MF/SS can be categorised as early stage or advanced stage, based on 
tumour-node-metastasis-blood (TNMB) (see Appendix 1, Section 9.1.1, Figure 15). Early 
stage MF (stages IA to IIA) usually presents with cutaneous patches and plaques [23]. 
Advanced stage MF (stages IIB to IVB) is characterised by skin tumours, erythroderma, and 
nodal or visceral involvement. SS presents only in advanced stage disease with extreme 
pruritus, erythroderma, lymphadenopathy and circulating Sézary cells [21].  
Following meetings of the International Society for Cutaneous Lymphomas (ISCL) and the 
cutaneous lymphoma task force of the EORTC, it was concluded that the TNMB designations 
and descriptions helpful in MF/SS are not applicable for CTCL other than MF/SS [24]. Thus, 
the ISCL and the cutaneous lymphoma task force of the EORTC have established a 
consensus proposal for a TNM classification system (i.e. tumour, node, metastasis) applicable 
for other subtypes of CTCL (see Appendix 1, Section 9.1.2, Table 37) [24]. Due to the clinical 
and pathologic heterogeneity of CTCL, the authors highlight that this is meant to be primarily 
an anatomic documentation of disease extent and should not to be used as a prognostic guide 
[24]. Patients with pcALCL generally present with solitary or grouped, rapidly growing, and 
ulcerating large tumours or thick plaques (CS, p27); most patients with pcALCL, therefore, 
have localised disease [22, 25]. Extracutaneous spread (i.e., metastasis) is uncommon for 
patients with pcALCL; it is reported to occur in 13% of patients with pcALCL [22, 25]. Patients 
with LyP typically present with recurrent nodules and papules at distant sites which become 
necrotic before resolving to form an atrophic scar [21, 25] 
The OS rates of patients with advanced stage MF, SS or pcALCL with regional or generalised 
involvement are much lower than those reported for patients with early stage disease (see 
Appendix 1, Section 9.1 of this ERG report). Generally, 5-year OS rates are approximately 
50%, or lower, for patients with advanced stage MF and SS (being lower still for patients with  
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 stage IV disease) [8, 26, 27]. Patients with pcALCL with regional lymph node involvement 
have been reported to demonstrate a 5-year OS rate of 76% [3]. Liu et al 2003 report disease-
specific 5-year OS of 50% for generalised pcALCL (versus 91% for localised pcALCL) [22].  
2.2 CD30-positive cutaneous T-cell lymphoma 
The patient population under consideration in the current Single Technology Appraisal (STA) 
is patients with relapsed or refractory CD30-positive (CD30+) CTCL. CD30 is a surface protein 
expressed by activated (but not resting) T and B cells [28], previously known as Ki-1 antigen 
[29]. As stated by the company, classical Hodgkin lymphoma (HL), systemic anaplastic large 
cell lymphoma (sALCL), and subtypes of CTCL express CD30 as an antigen on the surface 
of their malignant cells, independent of disease stage (CS summary document, Table 1; CS, 
Table 2). While all patients with CD30+ LPDs have (per definition) a strong and homogenous 
CD30 expression, for other CTCL subtypes CD30 expression may be much lower and at 
variable levels [30]. Findings from a large, retrospective, multi-centre study of 1275 patients 
reported by Scarisbrick et al 2015 [27] suggest that 23% of patients with MF/SS have CD30+ 
CTCL.  
Techniques for measuring CD30 expression vary in sensitivity, reliability and reproducibility 
[31] and there is no consensus on the definition of CD30 positivity [27, 31]. The definition of 
CD30+ used in the study by Scarisbrick et al 2015 [27] was ≥10% of tumoral cells stained 
positively and it is reported that it was only possible to test for CD30+ in 639 (50%) of cases 
[27]. Advice to the ERG is that this definition of CD30+ is universally accepted in UK clinical 
practice, that tests for CD30 are routinely carried out in NHS clinical practice and CD30 testing 
is conducted at a centralised laboratory for a number of regions in the UK. 
2.3 Company’s overview of current service provision  
The company’s overview of current service provision is summarised in Section A.2 of the CS 
summary document. In addition, more information is provided in Section B.1.3.3 of the CS. 
Key points are summarised in Box 2 and discussed further in Sections 2.3.1 to 2.3.4 of this 
ERG report. It should be noted that, as highlighted in the CS (p39), due to the rarity and 
complexity of CTCL, all patients with early stage MF refractory to skin-directed therapy (SDT) 
and late-stage MF/SS are treated at one of seven supra-regional centres in the UK (all based 
in England: Birmingham, Leeds, Liverpool, London, Manchester, Newcastle and Nottingham).  
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Box 2 Key points from the company’s overview of current service provision 
Current treatment options 
 Patients with CTCL are managed primarily according to the subtype of CTCL and the stage of 
disease [32-34].  
 Treatment either targets the skin (skin-directed) or the entire body (systemic); treatments may be 
used alone or in combination to provide the greatest benefit to the patient whilst minimising 
treatment-related toxicity [2, 25, 35]. 
 
Clinical pathway for advanced stage CTCL 
 The current UK treatment pathway for advanced CTCL consists of initial systemic with Category 
A agents. As the disease progresses, Category A therapies become ineffective and the next stage 
of treatment is with Category B therapies [25, 34].  
 Category B agents can only be taken for a short period of time (e.g., to a maximum of 6 months) 
due to drug-related toxicities. Patient co-morbidity may preclude the use of some Category B 
systemic therapies (e.g. CHOP due to neutropenia and the high sepsis susceptibility of CTCL 
patients). 
 Overall, toxicity of treatment must always be balanced against the goals of disease control and 
improvement/maintenance of HRQoL. 
 Current standard of care systemic therapies are characterised by low response rates, and short-
lived durations of response [1, 36]. 
 While recent evidence demonstrates that alloSCT may achieve durable remissions and prolonged 
survival, this procedure can only be performed in patients who achieve at least a partial response 
to their induction/bridging therapy [37, 38].  
 Because of the aforementioned ineffectiveness of current treatments, few patients become 
eligible for alloSCT with existing therapies. 
alloSCT=allogeneic stem-cell transplant; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone; CTCL=cutaneous 
T-cell lymphoma; HRQoL=health-related quality of life  
Source: CS, adapted from summary document, Section A.1 and CS, Section B.1.3.3 
 
Clinical advice to the ERG supports the company’s overview of service provision, i.e., that 
patients with CTCL are managed primarily according to the subtype of CTCL and the stage of 
disease, based on published guidelines [25, 32-34]. However, as the company notes (CS, 
p40) due to the limited efficacy of available systemic agents, the paucity of comparative data, 
and the lack of consensus on a preferred systemic therapy, the initial choice of treatment is 
generally made by the treating clinician on an individual patient basis [35, 36]. The ERG notes 
that evidence used to inform guidelines for subtypes of CTCL other than MF is often derived 
from anecdotal evidence. As noted in the joint submission to the National Institute for Health 
and Care Excellence (NICE) from the Royal College of Pathologists and the British Society for 
Haematology [39] as part of this appraisal, treatment decisions are made according to each 
patient’s needs and the expertise of the centre (p4). Further consideration of available 
treatment options is presented in Sections 2.3.1 to 2.3.3 of this ERG report. Much of the 
information presented in the CS and, therefore, considered in these sections, is based on 
forthcoming British Association of Dermatologists (BAD)/United Kingdom Cutaneous 
Lymphoma Group (UKCLG) guidelines for CTCL [40].  
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2.3.1 Treatment for early stage disease 
2.3.2 Clinical advice to the ERG is that, in line with published guidelines [25, 32-35] 
*******************************************************************************, and as stated in the 
CS (p26), early stage CTCL tends to be managed expectantly (i.e. “watch and wait”) or with 
SDT. SDT can include application of topical treatments (e.g. corticosteroids), localised 
radiotherapy, psoralens + ultraviolet A light therapy (PUVA, also known as phototherapy), 
narrow-band ultraviolet B (UVB, another type of phototherapy) or a combination of these 
treatments. In the EORTC guidelines for treating CD30+ LPDs [25], the recommended 
treatment for patients with localised pcALCL is surgical excision and/or radiotherapy, while for 
patients with localised LyP, it is observation, phototherapy or topical steroids. 
*********************************************************************************************************
*********************************************************************************************************
*******************Total skin electron beam therapy (TSEB), which is considered to be the most 
intensive SDT, is typically reserved as a treatment option for patients with extensive 
generalised disease and severe skin symptoms, i.e., advanced stage CTCL [41]. However, in 
the BAD/UKCLG guidelines published in 2003 [33], PUVA in combination with interferon alpha 
(IFN-α, a type of immunotherapy) or TSEB were recommended as treatments for resistant 
early stage MF. The recent EORTC guidelines recommend systematic therapies (including 
Category A therapies – see Table 1) or TSEB for patients with resistant early stage MF. 
*********************************************************************************************************
***********************************************************************Systemic therapies for 
advanced stage disease 
The treatment pathway described in Box 2 of this ERG report represents a generalised version 
of the treatment pathway presented in published guidelines [32, 33] 
************************************************************************************** i.e., typically 
Category A therapies are initially given to patients, and then Category B therapies. This is 
consistent with clinical opinion received by the ERG. The types of Category A and Category 
B therapies available are summarised in Table 1. Although methotrexate (MTX) is a 
chemotherapy drug, it is classified as a Category A therapy as opposed to a Category B 
therapy which includes chemotherapy regimens.   
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Table 1 Category A and Category B therapies 
Category A therapies Category B therapiesa 
Interferon alpha (IFN-α)  
Methotrexate (MTX) 
Bexarotene (BEX) 
Extracorporeal photopheresis (ECP) 
Single agent chemotherapy regimens, most notably 
gemcitabine or pegylated liposomal doxorubicin (not 
available at all centres) 
Multi-agent chemotherapy regimens, most notably 
cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) 
Total skin electron beam therapy (TSEB) 
a Willemze et al 2013 [32] note that other agents like the fusion toxin denileukin diftitox and histone deacetylase inhibitors, such 
as vorinostat and romidepsin, have been approved in the United States by the Food and Drug Administration (FDA) for treatment 
of patients with relapsed and refractory CTCL, but have not yet been registered for CTCL in Europe. Thus, these agents were 
not considered in the EORTC consensus guidelines published in 2017 [34] 
CTCL=cutaneous T-cell lymphoma; EORTC=European Organization for Research and Treatment of Cancer; FDA=Food and 
Drug Administration 
Source: CS summary document, Figure 1, CS, Figure 14 and published guidelines [25, 32-35] and review [41] 
Extracorporeal photopheresis (ECP) is not listed as a Category A therapy in the CS but clinical 
advice to the ERG is that it may be used in NHS clinical practice for treating SS. Indeed, ECP 
is only recommended for treating SS [32, 33, 35, 41]. The specific systemic therapies 
recommended in published guidelines [25, 32-35] for each line of treatment differ by CTCL 
stage and subtype. *********************************************************************************** 
********************************************************************************************************* 
However, generally, Category A therapies are preferred prior to Category B therapies.  
Typically, where a Category B therapy instead of a Category A therapy may be considered 






While the company states that bexarotene (BEX), a retinoid, is the only Category A therapy 
currently licensed for CTCL in Europe (CS summary document Table 2; CS, Table 1), clinical 
advice to the ERG is that, in general, choice of treatment often depends on the adverse events 
(AEs) associated with therapies. Hence, clinical advice to the ERG is that BEX is rarely used 
first-line in NHS clinical practice because it is considered to have a worse safety profile than 
either IFN-α or MTX. Furthermore, the ERG notes, BEX is only indicated for treating CTCL in 
adult patients refractory to at least one systemic treatment [42]. Clinical advice to the ERG is 
that IFN-α may increase the risk of fatigue and depression, but MTX can be carcinogenic for 
some patients. Thus, typically IFN-α or MTX is prescribed first and if a patient experiences 
disease progression, the other of these two Category A therapies is used. After further disease 
progression, patients will typically then receive BEX or a Category B therapy. Therefore, the 
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ERG considers that the company’s approach to labelling Category A therapies as first-line 
treatments and Category B therapies as second-line treatments (Figure 1 of the CS summary 
document and Figure 14 of the CS) is slightly misleading.  
Clinical advice to the ERG is that, in clinical practice, systemic therapies are rarely given in 
combination with other systemic therapies due to the increased toxicities associated with 
combination therapies. However, patients continue to use topical moisturisers, steroids and 
topical radiotherapy as required.  
Regarding the efficacy of current treatment options, the company highlights (CS, p40) that 
efficacy is often supported by data from outdated studies and/or is supported by low levels of 
evidence, as recognised by the authors of treatment guidelines [33, 35]. Response to Category 
A therapies reported in the European Public Assessment Report (EPAR) for brentuximab 
vedotin (BV) (p8) vary from 30% to 60% for patients with advanced stage MF (or up to 87% 
for first-line treatment of pcALCL with MTX) [30]; in the CS, rates of between 33% to 86% are 
cited for patients with CTCL [43-53]. Response rates to the Category B therapies, gemcitabine 
or pegylated liposomal doxorubicin, are reported in the EPAR for BV [30] to vary from 40% to 
80% for patients with advanced stage MF; the company cites rates of between 33% to 86% 
for patients with CTCL [54-58]. Clinical advice to the ERG is that response to treatment tends 
to be longer with Category A therapies than with Category B therapies, as is also suggested 
by data from the publications [36, 55, 57] cited in the CS (p41). As noted by the company, 
Category B agents can only be taken for a short period of time (maximum of 6 months) due to 
drug-related toxicities (CS, p41). 
2.3.3 Allogeneic stem-cell transplant  
The company highlights that allogeneic stem-cell transplant (alloSCT) may be a treatment 
option for some patients, namely those who have a good response to prior treatment. 
Transplants for CTCL which are performed in the UK use a reduced-intensity conditioning 
(non-myeloablative) regimen called the Stanford Protocol (CS, p44). The regimen consists of 
TSEB, total lymphoid irradiation and conditioning with anti-thymocyte globulin prior to 
transplant [59, 60], as shown in Figure 13 of the CS. The protocol does not include use of are 
used in both historical and other reduced-intensity conditioning regimens (company response 
to clarification question C3). 
The company highlights (CS, p43) that, to date, the use of alloSCT in the NHS has been 
“modest” ***** [61]. This is attributed to the inability of currently available treatment agents to 
provide sufficient response rates to enable patients to qualify for transplant (i.e., achieving at 
least a partial response [PR] with systemic therapy prior to alloSCT) [62]. The company also  
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acknowledges (CS, p45) that alloSCT eligibility is restricted by age, co-morbidities and the 
ability to find a suitable donor. Clinical advice to the ERG is that another potential barrier is 
the patient’s willingness to undergo a transplant; patients may be unwilling to have an alloSCT 
given that their disease is stable and that there are risks involved with the operation. In 
addition, many patients with CTCL are older adults who may not wish to have a transplant if 
they have already had many years of treatment with other therapies. As noted by the company 
(CS, p44), the leading centres for alloSCT in the UK are located in London and Birmingham.   
Clinical advice to the ERG is that, currently, it is highly unlikely that a patient who has only had 
treatment with a Category A therapy would be a candidate for alloSCT. The company’s 
depiction of the treatment pathway (CS summary document, Figure 1, CS, Figure 14) supports 
this view. Nonetheless, the company states (p45) that, with modern advances in matching 
patients with donors and in advancements in alloSCT procedures (i.e., adoption of the 
Stanford Protocol), UK clinical experts estimate that 40% of all patients in the UK with CTCL 
who achieve a PR or better could undergo an alloSCT. Clinical advice to the ERG is that this 
is likely to be a very high estimate, particularly given the barriers to alloSCT highlighted above. 
The company also states (CS, p43) that alloSCT is the only potentially curative treatment for 
CTCL, however, no evidence is presented to support this assertion. 
2.4 Brentuximab vedotin  
As described in the summary of product characteristics (SmPC) (pp12-13) [63], CS summary 
document (Table 1) and CS (Table 2), BV is an antibody drug conjugate (ADC) that delivers 
an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing 
tumour cells. The CD30-targeted mechanism of action means that BV can overcome chemo-
resistance (CD30 is consistently expressed in patients who are refractory to multi-agent 
chemotherapy). 
The ERG notes that the company envisages BV as a treatment option for patients with 
advanced stage CTCL after Category A therapies and before Category B therapies (CS 
summary document, Figure 1; CS Figure 14), i.e., it could delay the need for Category B 
therapies in the treatment pathway. BV is also considered to have a role as a bridging or 
induction therapy to alloSCT, assuming a patient has had at least a PR whilst on treatment 
with BV, i.e., in some cases, it could also displace Category B therapies in the treatment 
pathway (CS summary document, p6 and Figure 1; CS pp13, 44, 46, 98 and Figure 14). 
2.5 Number of patients eligible for treatment with BV 
The company has not presented an estimate of the number of patients that it expects will be 
treated with BV each year. However, the company notes that CTCL affects <2.2 in 10,000 
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people in the EU (2012 estimate), and thus meets European Union criteria for designation as 
an orphan disease (i.e., <5 people per 10,000) [64]. The ERG attempted to estimate how many 
patients may be eligible for treatment with BV each year but concluded that there is 
considerable uncertainty as to how many patients would be eligible for treatment with BV in 
England each year (See Appendix 2, Section 9.2 for details).  
Clinical advice received by the ERG is that, to date, in the Liverpool supra-regional centre, BV 
has been used to treat two patients with CTCL by the compassionate use programme 
(personal communication with Arvind Arumainathan, 12 October 2018). It is unclear how many 
more patients each year would be considered for treatment with BV should BV be 
recommended by NICE for treating CTCL. 
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3 CRITIQUE OF COMPANY’S DEFINITION OF DECISION 
PROBLEM 
A summary of the ERG’s main comments on the decision problem outlined in the final scope 
issued by NICE [65] and addressed within the CS is presented in Table 2. Each parameter is 
discussed in more detail in the text following the table (Section 3.1 to Section 3.6). 
Table 2 ERG comment on how the company’s decision problem matches the NICE scope 
Parameter 
Specification in the final scope issued 
by NICE 
ERG comment on decision problem 
addressed by the company 
Intervention BV As per scope 
Population People with relapsed or refractory CD30+ 
CTCL following SDTs and/or at least one 
systemic therapy  
Population differs from the licensed 
population. Within the CS, the company 
focusses on patients with advanced stage 
CTCL (i.e., narrower than the EMA licence) 
following SDTs and/or who have had at least 
one systemic therapy  
Comparator 
(s) 
Established clinical management without 
BV  
It is anticipated that Category B therapies 
would be used after BV in the treatment 
pathway (if required at all) and, therefore, 
Category A therapies (including BEX and 
MTX) are the most appropriate comparators 
Outcomes The outcome measures to be considered 
include: OS, PFS, response rates, AEs and 
HRQoL 
As per the NICE scope; the primary outcome 
considered in the ALCANZA trial of BV [66] 
was ORR4  
Economic 
analysis 
The reference case stipulates that the cost 
effectiveness of treatments should be 
expressed in terms of incremental cost per 
QALY 
The reference case stipulates that the time 
horizon for estimating clinical and cost 
effectiveness should be sufficiently long to 
reflect any differences in costs or outcomes 
between the technologies being compared 
Costs will be considered from an NHS and 
PSS perspective  
The availability of any patient access 
schemes for the intervention or comparator 
technologies will be taken into account 




If the evidence allows, consideration will be 
given to subgroups based on cancer 
histology 
No subgroup analyses by histology were 
presented in the CS for patients with 
advanced stage CTCL but were provided 
during clarification (for ORR4) 
 If the evidence allows, the economic 
analysis should model stem-cell 
transplantation further down the treatment 
pathway 
In the company’s base case cost 
effectiveness analysis includes stem-cell 
transplantation following treatment with BV 
and PC for some patients with advanced 
stage CTCL 
 Guidance will only be issued in accordance 
with the marketing authorisation  
Clinical and cost effectiveness evidence is 
presented for patients with advanced stage 
CTCL, a subgroup of the licensed population 
AEs=adverse effects of treatment; BEX=bexarotene; BV=Brentuximab vedotin; CD30+=CD30-positive; CS=company 
submission; CTCL=cutaneous T-cell lymphoma; EMA=European Medicines Agency; ERG=Evidence Review Group; 
HRQoL=health-related quality of life; MTX=methotrexate; NICE=National Institute for Health and Care Excellence; 
ORR4=objective global response lasting at least 4 months; OS=overall survival; PFS=progression-free survival; PSS=Personal 
Social Services; SDT=skin directed therapy; QALY=quality adjusted life year 
Source: NICE scope [65] CS summary document, adapted from Table 2, CS, adapted from Table 1 and ERG comment (see also 
Sections 3.1 to 3.6) 
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3.1 Intervention 
The intervention is BV (ADCETRIS, Takeda) as per the final scope issued by NICE [65]. 
Relevant to the current appraisal, BV is indicated for the treatment of adult patients with CD30+ 
CTCL after at least one prior systemic therapy [63]. BV currently has three other marketing 
indications in Europe (see Box 3). The European Commission granted an extension of the 
marketing authorisation valid throughout the European Union for BV to include the treatment 
of adult patients with CD30+ CTCL after at least one prior systemic therapy on 15 December 
2017.  
Box 3 Marketing indications for brentuximab vedotin (ADCETRIS) in Europe 
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin 
lymphoma (HL):  
1. following autologous stem-cell transplant (ASCT) or  
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a 
treatment option.  
 
ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse 
or progression following ASCT.  
 
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic 
anaplastic large cell lymphoma (sALCL).  
 
ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma 
(CTCL) after at least one prior systemic therapy. 
Source: Summary of Product Characteristics for brentuximab vedotin [63] 
BV has been recommended by NICE as a treatment option for relapsed or refractory CD30+ 
HL [67] and sALCL [68]. NICE guidance is in development for BV as a treatment option for 
previously untreated advanced HL [69]. 
The recommended dose of BV is 1.8 mg/kg administered as an intravenous infusion (IV) over 
30 minutes every 3 weeks [63]. Patients with CTCL may receive up to a maximum of 16 cycles 
(i.e., 48 weeks) of treatment. The list price for BV is £2,500 per 50mg vial (excluding VAT) (CS 
summary document, Table 1; CS, Table 2). However, a Patient Access Scheme (PAS) has 
been agreed with the Department of Health and the discounted price of BV is ****** per vial, a 
straight discount of ****(CS summary document, Table 1; CS, Table 2).   
3.2 Population 
As highlighted in Section 3.1, the licence for BV relevant to the current appraisal is for the 
treatment of adult patients with CD30+ CTCL who have received at least one prior systemic 
therapy. However, the focus of the CS is a subgroup of this population, namely patients with 
advanced stage CTCL. The company’s rationale for limiting the population is that only patients 
with advanced stage CTCL will be candidates for treatment with BV in NHS clinical practice. 
The company states that this view is based on UK clinician feedback and also that it reflects 
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the positioning of the technology in the UK guidelines (CS summary document, Table 2; CS, 
Table 1). Clinical advice to the ERG concurs that patients with advanced stage CTCL are the 
most likely candidates for treatment with BV. However, the ERG highlights that the licence for 
BV does not preclude treatment with BV for patients with early stage disease, providing the 
patient has received at least one prior systemic therapy.  
The ERG also highlights that while BV is licensed for patients with all subtypes of CTCL, the 
company has only presented evidence for patients with MF/SS or CD30+ LPDs (see Section 
4.2 of this ERG report). 
3.3 Comparators 
Position of BV in the treatment pathway 
The company considers that the relevant comparators to BV are MTX and BEX (two Category 
A therapies). These two therapies form the comparator arm (physician’s choice [PC]) of the 
ALCANZA trial [66]. The company has not compared the clinical or cost effectiveness of BV 
with IFN-α (another Category A therapy). The company assessed the feasibility of indirectly 
comparing BV with IFN-α but concluded that this was not possible due to a lack of relevant 
data (see Section 4.10 of this ERG report). Clinical advice to the ERG is that, in NHS clinical 
practice, IFN-α may be used before or after MTX or BEX (see Section 2.3.2). Furthermore, 
clinical advice to the ERG is that all Category A therapies are generally considered to have 
equal clinical efficacy. Therefore, the lack of evidence for comparing the effectiveness of 
treatment with BV versus IFN-α is not considered by the ERG to be a major limitation of the 
evidence base.  
It is anticipated by the company that Category B therapies would be used after BV in the 
treatment pathway (if required at all) and, therefore, Category A therapies (including BEX and 
MTX) are the most appropriate comparators. However, while the ERG considers Category A 
therapies to be the most appropriate comparators for treating MF, 
*********************************************************************************************************
**************************************************************************************************  
Clinical advice to the ERG is that (i) Category A therapies are the most relevant comparators 
to BV for patients with MF and (ii) Category B therapies would normally be preferred to 
Category A therapies for patients with advanced stages of pcALCL who have received at least 
one prior systemic therapy and are fit enough to tolerate the drugs. However, clinical advice 
is that MTX and BEX are likely to be appropriate comparators to BV for the patients included 
in the ALCANZA trial with pcALCL who might have had earlier stage disease or who were not 
fit for Category B drugs.  
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The company’s base case cost effectiveness analysis accounts for the fact that some patients, 
depending on their response to systemic therapy, will receive an alloSCT. In this respect, 
choosing Category A therapies as comparators is problematic, since clinical advice to the ERG 
is that patients would rarely receive an alloSCT immediately after treatment with a Category 
A therapy (see Section 2.3.3).  
Dosing schedules and duration of treatment 
Clinical advice to the ERG is that MTX is used off-label for treating CTCL. MTX is administered 
orally in tablet form to patients with CTCL at a dose of 5mg to 50mg once a week and that, 
usually, patients receive MTX until disease progression or until they can no longer tolerate the 
drug.  
BEX is indicated for the treatment of skin manifestations of advanced stage CTCL in adult 
patients refractory to at least one systemic treatment [42]. BEX is available in 75mg capsules 
and taken orally each day. The recommended starting dose of BEX is 300mg/m2/day. The 
dose of BEX is based on the patient’s body surface area (BSA). Normally, patients receive 
BEX until disease progression or until they can no longer tolerate the drug. The dose is 
adjusted depending on the patient’s response to treatment or side effects.  
Like MTX, IFN-α is used off-label for treating CTCL in NHS clinical practice. It is administered 
as a subcutaneous injection. Various treatment and dose escalation schedules are used. 
Typically, patients start their treatment by receiving 3 million units three times weekly and the 
dose is escalated if there is a lack of response or reduced if AEs occur (AEs tend to be dose 
dependent) [34]. 
3.4 Outcomes 
The outcomes listed in the final scope issued by NICE [65] are outcomes commonly evaluated 
in studies of oncology treatments and are addressed by the company. Typically, OS and 
HRQoL are considered to be the most important outcomes from studies of oncology 
treatments. In relation to CTCL, however, the company states (CS summary document, p5; 
CS, p29) that the primary goals of treatment are disease control and amelioration of symptoms 
to maintain or improve HRQoL. Therefore, prolonging objective response rates (ORRs) and 
progression-free survival (PFS) are meaningful primary outcomes [70] (CS summary 
document, Table 2; CS, Table 1). The company argues that “OS is not generally considered 
when determining treatment success in CTCL” (CS summary document, p16; CS, p115). The 
company further argues that evaluation of OS is not feasible in most clinical trials of CTCL 
because the expected survival of patients exceeds the duration of the study [70]. Nonetheless, 
OS data have been collected as part of the ALCANZA trial [66] and are reported in the CS.  
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The primary outcome in the ALCANZA trial [66] is ORR4, a relatively new outcome measure 
used to assess the impact of therapy on the unique symptomatic burden of CTCL (CS, p30). 
ORR4 captures ORR and duration of response (DOR) as a single measure [66, 71]. The 
company argues that this is a more appropriate and stringent measure of treatment success 
than ORR (CS, p67). The ERG concurs with the company’s view. The approach used in the 
ALCANZA trial [66] to determine ORR4 is provided in Box 4 (see also Box 5 and Box 6). 
Box 4 Objective global response lasting ≥4 months (ORR4) 
 ORR4 was determined by independent review (by IRF) of the GRS, determined using the 
consensus guidelines of the ISCL, the USCLC and the cutaneous lymphoma task force of the 
EORTC [25, 66, 70] – see Box 5 
 Skin response was determined by clearance of lesions, with complete response being 100% 
clearance and partial response being 50% to 99% clearance and no new tumours [72]  
 Overall response based on GRS was confirmed by sustained skin response per mSWAT 
assessment at the subsequent treatment cycle [66] – see Box 6 
 ORR4 was also assessed by INV  
EORTC=European Organisation for Research and Treatment of Cancer; GRS=global response score; INV=Investigator; 
IRF=Independent Review Facility; ISCL=International Society for Cutaneous Lymphomas; USCLC=US Cutaneous Lymphoma 
Consortium; mSWAT=Modified Severity Weighted Assessment Tool; ORR4=objective global response lasting ≥4 months 
Source: CS, p67 
Box 5 Global response score (GRS) 
 GRS is a composite assessment of total tumour burden:  
o Skin based on the mSWAT per INV - see Box 6 
o Nodal and visceral radiographic assessment per IRF 
o Sézary cell count (patients with mycosis fungoides only) per IRF 
INV=Investigator; IRF=Independent Review Facility; mSWAT=Modified Severity Weighted Assessment Tool 
Source: CS, p67 
Box 6 The modified severity weighted assessment tool (mSWAT) 
 mSWAT is a method widely used to assess skin response to treatment in MF and SS: 
o The body is divided into 12 regions with pre-assigned percentages of total BSA 
o The extent of skin disease is assessed for each region and weighted for more severe lesions 
(patch=1; plaque=2; tumour=4) 
o The products (BSA x weighting) of each region total a sum 0–400 [66]  
 St. John’s Institute of Dermatology in London has developed the CL-App (Cutaneous Lymphoma 
Resource Tools) to assist healthcare professionals managing patients with cutaneous lymphoma. 
In addition to management guidelines and prognostic scoring, the tool provides a visual and user-
friendly mSWAT calculator which allows clinicians to easily determine the mSWAT score used to 
assess response 
BSA=body surface area; MF= mycosis fungoides; mSWAT= Modified Severity Weighted Assessment Tool; SS=Sézary syndrome 
Source: CS, p30 
3.5 Economic analysis 
As specified in the final scope issued by NICE [65], the cost effectiveness of treatments was 
expressed in terms of the incremental cost per quality adjusted life year (QALY) gained. 
Outcomes were assessed over a 45 year time period (equivalent to a lifetime horizon) and 
costs were considered from an NHS perspective. 
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3.6 Other considerations 
As noted in Section 2.1.1, CTCL is a heterogeneous disease. Only patients with the MF or 
pcALCL CTCL subtypes were included in the ALCANZA trial [66]. Exploratory pre-specified 
and post-hoc subgroup analyses from the trial are presented in the CS (Figure 15) by histology 
(MF or pcALCL) and other factors (see Section 4.5 of this ERG report for further information). 
During the clarification process the ERG requested similar analyses for patients with advanced 
stage CTCL, which the company provided (company response to clarification question A7; 
see Section 4.6.1 for the presentation of these results). 
Within the final scope issued by NICE [65], it is stated that ‘If the evidence allows, the economic 
analysis should model stem-cell transplantation further down the treatment pathway’. As noted 
in Section 3.3, the company model includes alloSCT, following treatment with BV and 
comparator treatments, as a treatment for some patients (depending on their response to 
systemic therapy). However, the ERG considers that there is a lack of robust evidence relating 
to alloSCT effectiveness, outcomes following alloSCT in patients with advanced stage CTCL 
who have received prior treatment with BV, and the place of alloSCT in the treatment pathway. 
See Section 2.3.3 and Section 5.3.4 for further information relating to these two issues. 
As noted in Section 2.4, a PAS has been agreed with the Department of Health and BV is 
available at a confidential, discounted price. There are no PAS agreements in place for any 
Category A or Category B therapies. 
The company states (CS summary document, p6; CS, p47) that there are no equality 
considerations in relation to using BV to treat CTCL.  
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4 CLINICAL EFFECTIVENESS 
4.1 Systematic review methods 
Details of the company’s process and methods used to identify and select the clinical evidence 
relevant to the technology being appraised are presented in the CS, Section B.2.1 and 
Appendix D.  
The ERG considered whether the review was conducted in accordance with key good practice 
processes (see Table 3). Further information about the review methods is provided in Sections 
4.1.1 to 4.1.4 of this ERG report.  
Table 3 ERG appraisal of systematic review methods 
Review process ERG response Note 
Was the review question clearly defined 
in terms of population, interventions, 
comparators, outcomes and study 
designs? 
Yes  
Were appropriate sources searched? Yes The company also ran a rapid literature 
search “based on the strategy outlined in 
Appendix D” of the CS. Further information on 
the sources searched or search terms used is 
not provided 
Was the timespan of the searches 
appropriate? 
Yes Initial searches were run in January 2017 and 
updated searches were run in January 2018. 
It appears from the CS (p91) that the rapid 
literature search was conducted subsequent 
to January 2018 although the date of the 
searches is not specified 
Were appropriate search terms used? Yes  
Were the eligibility criteria appropriate to 
the decision problem? 
Partially The company excluded studies of fewer than 
20 patients (CS, p91, Appendix D.1.3 [Table 
1]). Particularly for rare diseases such as 
CTCL, this may result in the exclusion of 
potentially useful studies 
Was study selection applied by two or 
more reviewers independently? 
Yes  
Was data extracted by two or more 
reviewers independently? 
Not stated  
Were appropriate criteria used to assess 
the risk of bias and/or quality of the 
primary studies? 
Yes  
Was the quality assessment conducted 
by two or more reviewers independently? 
Not stated  
Were appropriate methods used for data 
synthesis? 
Yes  
CS=company submission; CTCL=cutaneous T-cell lymphoma; ERG=Evidence Review Group 
Source: LRiG Checklist 2018 
 
Overall, the ERG considers the process and methods used to conduct the company’s 
systematic review of clinical effectiveness evidence to be satisfactory. As a result, studies 
identified by the review are relevant to the decision problem and the results from the studies 
identified by the review should not be prone to bias.   
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4.1.1 Literature search  
The company’s searches were designed to identify efficacy and/or safety studies of BV and/or 
current therapies. Embase, MEDLINE and the Cochrane Library were all searched using 
predefined search strategies. Initial searches were run in January 2017 and updated searches 
were run in January 2018. While updating the search, proceedings from 12 appropriate 
dermatology and oncology conference websites were searched on 18 February 2018 to 
identify any recent studies for which there were currently no full-text publications. These 
searches were appropriately limited to the last 3 years (2014 to 2018, where available) as it 
was assumed that good quality studies published in abstract form prior to this date would have 
been published in full by the time of the searches. 
The company’s searches were designed to exclude studies published prior to 2007. The 
company states (CS, p90) that, “It was subsequently noted that earlier data on IFN may be of 
interest to the decision problem.” Thus, a rapid literature search was conducted to identify 
studies of IFN-α published prior to 2007. It is unclear when the rapid search was conducted or 
whether all the same data sources were searched. However, it is stated (CS, p91) that this 
search was “…based on the strategy outlined in Appendix D” of the CS. The ERG, therefore, 
has assumed that Embase, MEDLINE and the Cochrane Library were searched using the 
same search terms as the January 2018 search. 
4.1.2 Eligibility criteria 
As the company’s searches were designed to identify efficacy and/or safety studies of BV 
and/or current therapies, a wide range of therapies were considered to be eligible for inclusion, 
as specified in the appendices to the CS (Appendix D.1.1.3, Table 2). The ERG notes that the 
company states that they excluded studies with fewer than 20 patients (p91). For rare diseases 
such as CTCL, this could result in the exclusion of potentially useful studies, particularly where 
it is possible to include studies in a meta-analysis. However, in Appendix D.1.1.3 of the CS 
(Table 2), the company presents the criteria used to identify evidence relevant to the final 
scope issued by NICE [65]. Notably, the exclusion of studies of patients with fewer than 20 
patients is not specified as an exclusion criterion. It is, therefore, unclear if this criterion only 
applied to the original 2017 search (CS, Appendix D.1.1.3 [Table 1]). 
4.1.3 Data extraction 
The ERG notes that the optimal approach to data extraction is dual data extraction. It is unclear 
if this approach was used in the systematic review of clinical effectiveness provided in the CS. 
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4.1.4 Quality assessment methods 
The company’s approach to risk of bias assessment followed the method recommended by 
NICE [73, 74]. It is, however, unclear to the ERG whether this assessment was completed by 
one reviewer, or independently by two reviewers. The latter method is considered to be the 
preferred method. 
4.2 Identified trials 
4.2.1 Studies of BV  
The ALCANZA trial [66] was the only randomised controlled trial (RCT) of BV identified by the 
company. The ERG is not aware of any other RCTs of BV. 
Except where stated, all information in the remainder of this ERG report that relates to 
the ALCANZA trial has been taken from the CS. 
In addition, the company identified three non-randomised single-arm studies of BV [66, 75, 
76]: two phase II single-arm observational studies (Duvic et al 2015 [18] and Kim et al 2015 
[76]) and another study by Mathieu et al 2016 that was conducted retrospectively [75]. 
The ERG conducted its own electronic searches of the literature (Embase, MEDLINE and the 
Cochrane Library) on 31 July 2018. The purpose of the ERG’s searches was to determine if 
any additional studies of BV or any RCTs of comparator treatments could be found. No 
additional RCTs were found by the ERG. 
4.2.2 Studies of comparator treatments  
The comparator specified in the final scope issued by NICE [65] and the company’s decision 
problem is established clinical management without BV. As described in Section 2.3 and 
Section 3.3 of this ERG report, the company considered established clinical management for 
advanced stage CTCL to usually be a Category A therapy. Since the ALCANZA trial [66] 
included a comparator arm of PC, which constituted either MTX or BEX, the company also 
searched for studies of other potential comparators, in particular IFN-α.  
In total, the company identified 32 publications [43-50, 53, 54, 56-58, 77-95] from its 
systematic review of studies of interventions, other than of BV, that they considered were 
potentially relevant to the final scope issued by NICE [65]. These included studies of MTX [78, 
79], BEX [43-50, 86, 94] and IFN-α [53, 78, 79, 93]. However, MTX and IFN-α were only 
studied as combination therapies, as were most of the studies of BEX [46, 48-50, 86, 94]; only 
four BEX studies evaluated the effectiveness of BEX monotherapy [43, 44, 46, 47]. 
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Other studies that the company considered to be potentially relevant also included studies of 
TSEB [83, 84, 87, 89, 92], acitretin (which, like BEX, is a retinoid) [80], Category B therapies 
[54, 56-58, 86, 94] (including in combination with BEX [86] or prior to treatment with BEX [94]) 
and alloSCT [77, 81, 82, 85, 88, 90, 91, 95]. The ERG notes that one of the included BEX 
studies [46] was published in 2001 and thus did not meet the company’s stated eligibility 
criteria. However, this was one of only two RCTs [46, 79] identified by the company’s 
systematic review searches, the other RCT compared IFN-α in combination with MTX versus 
IFN-α in combination with retinoids [79]. The company’s rapid literature search identified an 
additional 19 studies of IFN-α [96-114], none of which were RCTs.  
The company concluded it was not feasible to include any of the studies in an indirect 
comparison. The ERG concurs with the company (See Section 4.10 of this ERG report for 
details). 
4.2.3 Studies not identified by the company’s searches 
The ERG did not identify any other relevant studies of BV or RCTs of comparator treatments 
from its own searches. However, the ERG did identify a retrospective analysis of 12 patients 
with LyP [115], of which nine patients had been included in the study by Duvic et al 2015 [18]. 
In addition, the ERG notes that three additional non-randomised studies of BV are referred to 
in the EPAR for BV [30]. These were not identified by the ERG’s searches or included in the 
CS (Table 4). In the EPAR for BV [30], two of the studies are described as being investigator 
sponsored trials and the other is described as being authored by Wieser 2016. The ERG 
subsequently identified this as a published retrospective study [116] with the aim of evaluating 
characteristics, risk factors, associated malignancies, long-term outcome and treatment of LyP 
in a single-centre cohort of 180 patients. In this study, 21 (11.6%) patients had received 
treatment with BV. 
Regarding treatments other than BV, a systematic review was published in 2012 that includes 
RCT evidence for the treatment of MF [117]. This Cochrane review includes RCTs of Category 
A therapies. However, all but one of the RCTs of Category A therapies included in this review 
are either only dose finding studies of BEX [46, 118] or RCTs of Category A therapies for early 
stage MF (IFN-α versus placebo [119, 120], IFN-α in combination with PUVA [121, 122], or 
ECP in combination with PUVA [123]). A further RCT which compared IFN-α in combination 
with acitretin versus IFN-α in combination with PUVA and which was published 20 years ago 
only included 8 (10%) patients with advanced stage CTCL  [105]. The ERG is only aware of 
one RCT of a Category A therapy published since this review, an RCT comparing two types 
of IFN-α combination therapy regimens [79] which was identified by the company’s rapid 
review searches.
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Table 4 Additional publications of brentuximab vedotin not identified by the company’s 
searches 
Author Description 
Lewis et al 2017 
[115] 
This brief report is a subset analysis of nine patients with LyP enrolled in Duvic et al 2015 
[18], a study identified by the company and included as part of the evidence base 
presented in the CS, plus three other patients with LyP not enrolled into the Duvec et al 
2015 study 
IST-001 This is described as investigator sponsored trial in the EPAR for BV [30]. The ERG did 
not identify this study from its searches and nor was the ERG able to identify this study 
from subsequent searches of the Internet. Efficacy data are reported for 72 patients from 
this study in the EPAR for BV [30] 
IST-002 This is described as investigator sponsored trial in the EPAR for BV [30]. The ERG did 
not identify this study from its searches and nor was the ERG able to identify this study 
from subsequent searches of the Internet. Efficacy data are reported for 36 patients from 
this study in the EPAR for BV [30] 
Wieser 2016 
[116] 
This is described as a retrospective single centre study in the EPAR for BV [30]. It is 
reported that 21 patients with LyP or LyP mixed histology received BV. The ERG has 
identified that this sample of patients is taken from a larger cohort of 180 patients with 
early and advanced stage CTCL and who received various types of treatment 
BV=brentuximab vedotin; EPAR=European public assessment report; IFN=interferon; LyP=lymphomatoid papulosis; 
MF=mycosis fungoides; RCT=randomised controlled trial 
4.3 Characteristics of the included studies of brentuximab vedotin 
Aside from the different study designs, the most obvious differences in the clinical studies of 
BV were the patient populations, specifically in terms of the CTCL subtypes included. Most, if 
not all, patients in all studies had previously received at least one prior systemic therapy. 
Where available [18, 66, 75, 76], a brief summary of patient characteristics in terms of 
demographics, CTCL subtypes and stage of disease is presented by the ERG in Table 5. 
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Table 5 Characteristics of patient populations in studies of BV 
Characteristic ALCANZA trial  Duvic et al 
2015  
Kim et al 
2015 
Mathieu et 
al 2016 All patients BV only 
Number of patients at baseline  128 64 54 32 32 
Age, median (range) 60 (48 to 69) 62 (51 to 70) 60 (31 to 77) 62 (20 to 87) 66 
Sex: Male, n (%) 70 (55) 33 (52) 27 (50) 19 (59) 20 (62) 
Race: White, n (%) 109 (85) 56 (88) 31 (57)  — [69]a — 
CD30 expression ≥10%, n (%)b 97/97 (100)  48/48 (100) 18/28 (64) 18/32 (56)  —c 
Type of CTCL, n (%)      
MF 97 (76) 48 (75) 31 (57) 29 (91) 19 (60) 
SS 0 0 0 3 (9) 10 (31) 
pcALCL 31 (24) 16 (25) 3 (6) 0 0c 
LyP only 0 0 10 (19) 0 0c 
Other 0 0 10 (19)d 0 3 (9)c 
Stage of CTCL      
Early stage CTCL, n (%) 33 (34) 15 (31) — 4 (13) 3 (9) 
Advanced stage CTCL, n (%) 95 (74) 49 (75) — 28 (88) 27 (90) 
Not specified, n (%) 0 0 58 (100) 0 2 (6) 
Type of advanced stage CTCL, 
n (% of advanced stage CTCL) 
  
   
IIB 38 (40) 19 (39) — 18 (64) 9 (33) 
IIIA-IIIB 6 (6) 4 (8) — 0 5 (19) 
IVA1 1 (1) 0 — Stage IV:  
MF: 7 (25) 
SS: 3 (11) 
5 (19) 
IVA2 10 (11) 2 (4) — 4 (14) 
IVB 7 (7) 7 (14) — 4 (14) 
Othere 1 (1) 1 (1) — 0 0 
Advanced stage pcALCL 31 (33) 16 (33) — n/a n/ac 
Patients included in analyses ITT: 128 
Safety: 128 





 ‘—‘=not reported; BV=brentuximab vedotin; CTCL=cutaneous T-cell lymphoma; ITT=intention-to-treat; LyP=lymphomatoid 
papulosis; MF=mycosis fungoides; n/a=not applicable; pcALCL=primary cutaneous anaplastic large cell lymphoma; SS=Sézary 
syndrome  
a Data on race are reported for 36 patients at a later data-cut on the ClinicalTrials.gov website for race: White=25 (69%) [124]. 
As the published paper [76] contains more detailed information and in order to ensure consistency with the CS, the ERG has 
reported data from the published paper [76] throughout this report, except for the data reported here for race 
b In Duvic et al 2015 [18] and Kim et al 2015 [76], CD30 expression was graded as percentage of the entire lymphocytic infiltrate 
seen in the tissue (low: <10%; medium: ≥10% to ≤50%; high: ≥50%) whereas in the ALCANZA trial, all patients were described 
as being CD30+ if one or more biopsy samples had ≥10% CD30+ malignant cells or lymphoid infiltrate (by central review); in the 
CS, all patients with MF in Duvic et al 2015 [18] are described by the company as being CD30+ (CS, p81) 
c It is unclear if pcALCL or LyP patients are included in this trial (and therefore classified under ‘other’); it is stated in this study 
that “cutaneous lymphocytic infiltrate expressed CD30 in most cases” 
d All ‘other’ patients had CD30+ lymphoproliferative disorders (CD30+ LPDs), i.e. LyP and MF (n=8) or LyP, MF and anaplastic 
large cell lymphoma (n=2) 
e Two patients with unknown disease stage were classified as having advanced stage CTCL because, given the balance of the 
trial population favouring advanced stage disease, there was a higher probability that they had advanced stage CTCL rather than 
early stage (CS, p83) 
Source: ALCANZA trial data taken from CS, (Table 10 and p79), clarification response to question A2 (Table1)  and CSR, p84 
and Table 11.d), observational study data taken from primary published papers [18, 76]  and abstract [75] 
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Most patients included in the studies were white and had advanced stage MF, although there 
was variability in the proportions of patients with these characteristics across studies. Between 
50% [18] and 62% [75] of patients in the studies were male. The study by Duvic et al 2015 [18] 
was the only study to include patients with LyP (LyP only, n=10; LyP plus a concurrent 
diagnosis, n=10). Kim et al 2015 [76] was the only study to include patients with SS (n=3).  
4.3.1 The ERG notes that clinical advice to the ERG is that approximately 60% of patients 
with MF and 20% of patients with pcALCL seen in clinical practice have advanced stage 
CTCL, whereas much higher proportions of patients in all of the published studies had 
advanced stage MF or pcALCL. However, the population that the company has focussed on 
in this appraisal is patients with advanced stage CTCL, since these are the patients who are 
expected to be candidates for treatment with BV in UK clinical practice. 
*********************************************************************************************************
********************************* Therefore, the greater proportion of patients with advanced 
stage CTCL included in these studies can be seen as a strength of the evidence base, rather 
than as a weakness. Except where stated, the focus of the evidence in the remainder of this 
ERG report is also on patients with advanced stage CTCL in order to be consistent with the 
CS.ALCANZA trial design 
The ALCANZA trial was an international, open-label, randomised, phase III, multi-centre trial 
of BV versus PC (MTX or BEX) in patients with CD30+ CTCL. Patients were deemed to have 
CD30+ CTCL if one or more biopsy samples had 10% or more CD30+ malignant cells or 
lymphoid infiltrate by central review [66]. Advice to the ERG is that this is the same definition 
used in NHS clinical practice (personal communication with Geetha Menon, 13 August 2018). 
Only patients with the MF or pcALCL subtypes of CTCL were eligible for inclusion. Patients 
with a concurrent diagnosis of sALCL, SS and other nHL (except for LyP) were excluded. 
Patients must also have been assessed to have Eastern Cooperative Oncology Group 
Performance Status (ECOG PS) 0 to 2 and to have received at least one prior systemic 
therapy (MF and pcALCL) or radiotherapy (pcALCL only).  
A total of 131 patients were enrolled between 13 August 2012 and 31 July 2015 and randomly 
assigned (1:1) centrally by an interactive voice and web response system to receive BV (n=66) 
or PC (n=65). Randomisation was stratified by baseline disease diagnosis (CS, Table 8) but 
not by disease stage (CS, p83). In total, patients were recruited from 34 centres across 11 
countries, including the UK (24 patients from four centres) (CS, Table 8).  
BV was administered intravenously at a dose of 1.8mg/kg once every 3 weeks, for a maximum 
of 48 weeks (i.e., 16 x 3-weekly cycles). In the PC arm, patients received oral MTX 5mg to 
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50mg once per week or oral BEX 300mg/m² once per day. It is also stated that patients 
received either PC treatment for up to 48 weeks (CS, Table 8). The ERG notes that, in clinical 
practice, patients are usually treated with either MTX or BEX until disease progression or x 
It is reported in the EPAR for BV [30] that nearly all patients received concomitant medication 
during the study (e.g. hydroxyzine, statins, folic acid, fenofibrate, levothyroxine). As noted in 
Section 2.3.2 of this ERG report, in clinical practice, patients continue to use topical 
moisturisers, steroids and topical radiotherapy alongside systemic therapy, as required. In the 
ALCANZA trial, concomitant medications that might have influenced outcomes were 
prohibited as per protocol and patients were not permitted to receive these within 3 weeks of 
first dose of study treatments. Radiotherapy was not explicitly listed as an excluded 
concomitant therapy but the ERG notes that a major protocol deviation listed in the EPAR for 
BV [30] relates to a patient who received radiotherapy without informing the subinvestigator. 
Another major protocol deviation was related to concomitant use of topical methylprednisolone 
0.1% and betamethasone 0.05% (see Section 4.4). 
The first analysis of the data took place after a median follow-up of 22.9 months. A clinical 
study report (CSR) [125] was produced for this data-cut and made available to the ERG during 
the clarification process. A second data-cut occurred after a median of 33.9 months. There is 
no CSR available for this data-cut.   
At both data-cuts, the following efficacy outcomes relevant to the final scope issued by NICE 
[65] and company’s decision problem were analysed: ORR4 (primary outcome), ORR, PFS 
and OS. In addition, outcomes relating to safety (AEs) and HRQoL were also analysed.  
While the trial enrolled 131 patients (BV=66; PC=65), all analyses included 128 patients:  
 Efficacy and HRQoL outcomes were analysed for the intention-to-treat population 
(ITT). Three patients were excluded from the ITT analysis as they had been found not 
to have CD30+ CTCL (BV=2; PC=1). Thus, the ITT population included 64 patients in 
each arm.  
 The three patients excluded from the ITT analysis were, however, included in the 
safety analysis but a different three patients were excluded from the safety analysis 
(all in the PC arm) because they had not received at least one dose of study drug. Two 
patients withdrew themselves prior to treatment and one other patient was withdrawn 
by the physician. Thus, in the safety analysis, there were 66 patients in the BV arm 
and 62 patients in the PC arm. 
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Results from analyses of data from the first data-cut have been published in a peer reviewed 
paper by Prince et al 2017 [66]. As previously highlighted, the focus of the CS is on 
patients with advanced stage CTCL, a subgroup of the overall ALCANZA trial 
population (n=95). Results from data analyses for this subgroup have been presented in the 
CS after a median follow-up of 33.9 months (CS summary document Section A.7.2; CS section 
B2). This subgroup includes a proportion of patients from the UK (n=19 [20%], clarification 
response to A3, Table 3). 
4.3.2 Baseline characteristics of advanced stage patients enrolled in the 
ALCANZA trial 
The baseline characteristics of ALCANZA trial patients with advanced stage CTCL were 
provided by the company during the clarification process (response to A2, Table 1). This 
included patients with MF stage IIB or above and all pcALCL patients. In the EPAR for BV 
[30], it is noted that the majority of patients with pcALCL had skin only lesions, 9 (56%) and 
11 (73%) patients who were treated with BV and PC respectively. The remainder (7 [44%] 
treated with BV and 4 [17%] treated with PC) were described as having extracutaneous 
disease. 
As the ALCANZA trial was stratified by baseline disease diagnosis (CS, Table 8) but not by 
disease stage (CS, p83), the subgroup of patients with advanced stage CTCL is not, techically, 
a randomised patient population. Stratified randomisation ensures that patient characteristics 
are balanced within each strata, i.e. within the subgroup of patients with MF and within the 
subgroup of patients with pcALCL for the ALCANZA trial. However, since randomisation was 
not stratified by disease stage, the randomisation procedure used in the ALCANZA trial did 
not ensure that patient characteristics were balanced within the subgroup of patients with 
advanced stage CTCL. However, the proportions of patients with MF and pcALCL in the 
subgroup of patients with advanced stage CTCL was similar in both treatment arms 
(clarification response to A2, Table 1); approximately two-thirds of patients had MF (BV=33; 
PC=31) and approximately a third had pcALCL (BV=16; PC=15). 
The company considered that patient characteristics were generally well balanced between 
treatment arms for the subgroup of patients with advanced stage CTCL, although it noted that 
patients in the BV arm were generally older than patients in the PC arm (CS, p83). Additional 
differences were observed by the ERG from the data presented in the clarification response 
to A2, Table 1. Median time since initial diagnosis was greater in the BV arm than in the PC 
arm. The BV arm also included more patients with stage IVB MF and pcALCL patients with T3 
and/or M1 involvement than the PC arm. Median lines of total prior therapy were also greater 
in the BV arm than in the PC arm, although for previous SDT and systemic therapies, the 
Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 49 of 172 
proportions were similar. There were fewer UK patients in the BV arm (n=7 [14% of all patients 
treated with BV in the subgroup of patients with advanced stage CTCL]) than in the PC arm 
(n=12 [26% of all patients treated with PC in the subgroup of patients with advanced stage 
CTCL]). Given the small numbers of patients in the trial, such imbalances are not unexpected. 
The ERG considers that if any of these differences led to bias, this bias would most likely 
favour the PC arm rather than the BV arm.   
For the subgroup of patients with advanced stage CTCL, patients in both trial arms had 
received a median of one prior SDT (clarification response to A3, Table 1). The range of prior 
SDTs was 0 to 6 in the BV arm and 0 to 7 in the PC arm (clarification response to A3, Table 
1). Patients in both trial arms in the subgroup of patients with advanced stage CTCL had 
received a median of two prior systemic therapies (CS, Table 17). The range of prior systemic 
therapies was large in both arms, 0 to 11 in the BV arm and 2 to 8 in the PC arm (CS, Table 
17). Most patients (62%) had received one (42%) or two (20%) prior systemic therapies and 
25% had received four or more prior systemic therapies. 
The mean number of prior SDTs was similar for UK patients to that of non-UK patients in both 
arms of the trial. For UK patients, the mean (standard deviation [SD]) was 1.4 (0.98) in the BV 
arm and 1.8 (1.14) in the PC arm whereas for non-UK patients, the mean (SD) was 1.7 (1.55) 
and 1.6 (1.84), respectively (clarification response to A3, Table 3). However, patients in the 
UK typically received fewer lines of systemic therapy than those outside of the UK (Table 6). 
The ERG urges caution in drawing conclusions from these results given the small numbers of 
UK patients, particularly in the BV arm. 
Table 6 Number of prior systemic therapy received by patients with advanced stage CTCL in 
the ALCANZA trial, UK versus non-UK 
Number of prior 
systemic therapies 
UK Non-UK 
BV (n=7) PC (n=12) All (n=19) BV (n=42) PC (n=34) All (n=76) 
0 0 0 0 1 (2) 0 1 (1) 
1 3 (43) 6 (50) 9 (47) 16 (38) 15 (44) 31 (41) 
2 2 (29) 4 (33) 6 (32) 6 (14) 7 (21) 13 (17) 
≥3 2 (29) 2 (17) 4 (21) 19 (45) 12 (35) 31 (41) 
Mean (SD) 2.0 (1.15) 1.7 (0.78) - 3.6 (3.17) 2.4 (1.78) - 
CTCL=cutaneous T-cell lymphoma; SD=standard deviation; UK=United Kingdom 
Source: clarification response to A3, adapted from Table 3 
 
There were also some differences in the type of therapy previously received between UK and 
non-UK patients (Table 7). Most notably, MTX was a prior treatment for a greater proportion 
of non-UK patients than UK patients. However, as noted in Section 2.3.2, MTX is commonly 
used for first- or second-line treatment of CTCL in NHS clinical practice. The lower proportion 
of patients treated with MTX in UK patients may therefore be reflective of the fewer lines of 
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prior systemic therapies that UK patients had generally received in comparison to non-UK 
patients. Overall, the ERG considers that the previous treatments received by patients with 
advanced stage CTCL appear to be broadly in line with NHS clinical practice in England. 
Table 7 Types of prior systemic therapy received by patients with advanced stage CTCL in 
the ALCANZA trial, UK versus non-UK 
Type of prior systemic 
therapies 
UK Non-UK 
BV (n=7) PC (n=12) All (n=19) BV (n=42) PC (n=34) All (n=76) 
IFN-α  4 (57) 7 (58) 11 (58) 21 (51) 15 (44) 36 (47) 
IFN-α-2a 0 0 0 3 (7) 2 (6) 5 (7) 
MTX 1 (14) 1 (8) 2 (11) 19 (46) 16 (47) 35 (46) 
BEX 3 (43) 5 (42) 8 (42) 16 (39) 10 (29) 26 (34) 
Chemotherapy, not MTX 4 (57) 6 (50) 10 (53) 21 (51) 15 (44) 36 (47) 
Alemtuzumab 0 0 0 2 (5) 2 (6) 4 (5) 
Mogamulizumab 0 0 0 1 (2) 0 1 (1) 
HDACi 0 0 0 9 (22) 7 (21) 16 (21) 
Other 2 (29) 2 (17) 4 (21) 13 (32) 8 (24) 21 (28) 
Unknown 0 0 0 8 (20) 2 (6) 10 (13) 
BEX=bexarotene; CTCL=cutaneous T-cell lymphoma; HDACi=histone deacetylase inhibitor; IFN-α=interferon alpha; 
MTX=methotrexate; UK=United Kingdom 
Source: clarification response to A3, adapted from Table 3 
4.4 Quality assessment  
The company assessed the risk of bias in the ALCANZA trial using the minimum criteria set 
out in the NICE STA: User guide for company evidence submission template [74], adapted 
from the Centre for Reviews and Dissemination’s guidance for undertaking reviews in health 
care [126]. The ERG considers that the ALCANZA trial was generally well designed and well 
conducted and the ERG agrees with the company’s conclusion that the trial has a low risk of 
bias for most domains (see Appendix 3, Section 9.3, Table 41). While the open-label design 
provides the opportunity for subjective results and investigator-assessed outcomes to be 
biased, the primary outcome of ORR4 plus the secondary outcome of PFS were assessed by 
an Independent Review Facility (IRF), conducted in a blinded manner. The other key trial 
outcome is OS, and this an objective outcome that should not be prone to bias.   
In addition to assessing the quality of the ALCANZA trial, the company also conducted quality 
assessments of the two prospective observational studies, Duvic et al 2015 [18] and Kim et al 
2015 [76], using criteria developed by the Effective Public Health Practice Project National 
Collaborating Centre for Methods and Tools [127]. The findings from these quality 
assessments are reported in Appendix D.1.5 of the CS (Table 25). The company concluded 
that the overall global ratings for both studies were weak. The ERG concurs with the 
company’s conclusion.    
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4.5 Statistical approach adopted for the ALCANZA trial 
Information relevant to the statistical approach taken by the company has been extracted from 
the clinical study report (CSR) [125], the trial statistical analysis plan (TSAP) [128], the trial 
protocol [129], and from the CS.  
A summary of checks made by the ERG to assess the statistical approach used to analyse 
data from the ALCANZA trial is provided in Table 8. 
Table 8 ERG assessment of statistical approach used to analyse data from the ALCANZA 
trial 
Review process ERG comment 
Was an appropriate 
sample size calculation 
specified in the trial 
protocol/TSAP?  
Yes (TSAP, p12) 
Were all primary and 
secondary outcomes 
presented in the CS pre-
specified? 
The primary outcome and some secondary outcomes were pre-specified in the 
TSAP (TSAP, pp16-17, p19). Time to subsequent anticancer therapy and 
maximum change in mSWAT score were presented in the CS (CS, pp73-77) but 
were not pre-specified in the TSAP.  
The company states that OS was not a pre-specified outcome of the ALCANZA 
trial since evaluation of OS is not feasible in most clinical trials of patients with 
CTCL because expected survival of patients exceeds the duration of the study 
(CS, p29). However, the ERG notes that OS data were collected and presented 
in the CS (CS, pp77-78); the ERG considers the company’s approach to be 
appropriate 
Were definitions for all 
relevant outcomes 
provided? 
Definitions for all pre-specified outcomes were provided in the TSAP (pp16-17, 
p19). Time to subsequent anticancer therapy was defined in the CSR (p116). 
No clear definition was provided for maximum change in mSWAT score  
Were all relevant outcomes 
defined and analysed 
appropriately? 
PFS was assessed using two criteria: 
1) pre-specified criterion that counted all events despite ≥2 missed visits or 
starting of subsequent anticancer therapy (EMA criteria) 
2) sensitivity analysis criterion that censored patients at last assessment before 
the missed visit or starting of subsequent anticancer therapy (FDA criteria)  
The ERG notes that PFS and time to subsequent anticancer therapy were 
analysed using the Cox PH method. The company confirmed in their clarification 
response to question A9 that the PH assumption was assessed by visually 
assessing log cumulative hazard plots and concluded that the assumption of PH 
for both outcomes is subject to uncertainty (see text below table for more 
information).  
Key secondary endpoints (CR per IRF, PFS per IRF, and symptom Skindex-29) 
were analysed using a fixed sequential testing procedure (weighted Holm 
procedure). The analyses for CR per IRF, PFS per IRF, and the changes in 
symptom domain of the Skindex-29 were assigned weights (0.7, 0.2, and 0.1, 
respectively) (EPAR, p33) 
Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 52 of 172 
Review process ERG comment 
Were all subgroup 
analyses and sensitivity 
analyses presented in the 
CS pre-specified? 
For the ITT population of the ALCANZA trial, the company presented results of 
subgroup analyses for the primary outcome, ORR4 (CS, p69), for several 
patient characteristics that were pre-specified in the TSAP (TSAP, pp18-19). 
Additional subgroup analyses for the primary outcome were also presented that 
were not explicitly pre-specified in the TSAP (skin involvement and baseline skin 
tumour score), although it is stated in the TSAP that subgroup analyses would 
not be limited to the list of pre-specified characteristics. The ERG is not 
concerned about the reporting of these additional subgroup analyses. 
The company presents data for various efficacy, safety and HRQoL outcomes 
for the subgroup of patients with advanced stage. The ERG notes that this is a 
post-hoc analysis; all data presented for the population relevant to the 
company’s decision problem are based on this post-hoc subgroup analysis. 
As part of the company’s response to the ERG clarification letter, the company 
provided the results of subgroup analyses for a range of patient characteristics 
for the outcome of ORR4 in the advanced stage CTCL patient population. 
These subgroup analyses were performed for the same set of patient 
characteristics as for the subgroup analyses of ORR4 in the ITT population.  
No sensitivity analyses for the efficacy outcomes of the ALCANZA trial were 
presented in the CS.  
Were all protocol 
amendments carried out 
prior to analysis? 
The conduct of the study was modified by five amendments to the original 
protocol. Protocol amendments and rationale for these amendments are 
provided in the CSR (CSR, pp71-76). The ERG is satisfied with the rationale for 
the amendments and notes that all amendments were made before the data 
cut-off date for the primary analysis (31st May 2016), so amendments were not 
driven by the results of the trial. 
Was a suitable approach 
employed for handling 
missing data? 
The company’s approach for handling missing data was pre-specified in the 
TSAP (TSAP, p18, pp20-23, p25). The ERG considers the company’s approach 
to be suitable. 
CR=complete response; CSR=clinical study report; CTCL=cutaneous T cell lymphoma; EMA=European Medicines Agency; 
EPAR=European public assessment report; FDA=Food and Drug Administration; HRQoL=health-related quality of life; 
IRF=independent review facility; ITT=intention-to-treat; mSWAT=modified severity weighted assessment tool; ORR4=objective 
global response lasting ≥4 months; OS=overall survival; PFS=progression-free survival; PH=proportional hazards; TSAP=trial 
statistical analysis plan 
Source: CS, CSR, company response to the ERG clarification letter, TSAP 
Generally, the ERG is of the opinion that the company’s statistical approach for the analysis 
of data from the ALCANZA trial was appropriate. The ERG notes that the Cox proportional 
hazards (PH) method was used to estimate the hazard ratios (HRs) for the outcomes of PFS 
and time to subsequent anticancer therapy. The validity of this method relies on the event 
hazards associated with the intervention and comparator data being proportional over time 
[130]. Since the company focuses on patients with advanced stage CTCL in their submission, 
the ERG assessed the validity of the PH assumption for PFS and time to subsequent 
anticancer therapy for this subgroup. The results reported for patients with advanced stage 
CTCL are from the updated analysis of the ALCANZA trial (33.9 month median follow-up), with 
disease progression determined by IRF assessment.  
From examining the Kaplan Meier (K-M) data provided by the company in their response to 
the ERG clarification letter, the ERG considers that the PH assumption may be violated for 
IRF-assessed PFS data from patients with advanced stage CTCL. The ERG notes that the 
company also assessed the PH assumption for PFS data for patients with advanced stage 
CTCL by visual examination of the log-cumulative hazard plot and quantile-quantile plot. The 
Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 53 of 172 
company also concludes that the PH assumption may not be appropriately justified. To 
investigate the PH assumption for the outcome of time to subsequent anticancer therapy, the 
ERG digitised the K-M graph provided in the CS (CS, Figure 35). The ERG also considers that 
the PH assumption may be violated for time to subsequent anticancer therapy data for patients 
with advanced stage CTCL.  
Consequently, the ERG considers that the reported HRs for IRF-assessed PFS and time to 
subsequent anticancer therapy in the subgroup of patients with advanced stage CTCL should 
be interpreted with caution as HRs are not an appropriate summary of treatment effect when 
the PH assumption does not hold. It is not possible to know whether the reported HRs would 
overestimate or underestimate the effect of BV versus PC. See Appendix 4, Section 9.4 for 
further details on the ERG assessment of PH for IRF-assessed PFS and time to subsequent 
anticancer therapy for patients with advanced stage CTCL. 
4.6 Efficacy results from the ALCANZA trial 
As the company focuses on patients with advanced stage CTCL, except where stated, only 
efficacy results for these patients are presented in this section. All results for this patient 
subgroup are from the updated analysis of the ALCANZA trial (median 33.9 months follow-
up). Although labelled as being investigator assessed in the CS, the company has clarified 
that all objective response and disease progression data were actually determined by IRF 
assessment. 
A summary of efficacy results for patients with advanced stage CTCL is provided in Table 9. 
Further information is provided in Sections 4.6.1 to 4.6.5 of this ERG report. The company 
also provided K-M data for the outcomes of PFS, time to subsequent anticancer therapy, and 
OS (CS summary document, Figure 5; CS, Figure 33, Figure 35 and Figure 36). 
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Table 9 Efficacy results for the ALCANZA trial, subgroup of patients with advanced stage 
CTCL, (33.9 month follow-up) 
Outcome BV (n=49) PC (n=46) 
ORR4 
n  
% (95% CI) 
29 
59.2 (45.4 to 72.9) 
4 
8.7 (2.4 to 20.8) 
% difference (95% CI) 
p-valuea 
50.5 (31.6 to 66.4) 
p<0.001 
PFS 
Median, months (95% CI) 16.5 (15.5 to 27.5) 3.5 (2.4 to 4.9) 





% (95% CI) 
34 
69.4 (56.5 to 82.3) 
8 
17.4 (6.4 to 28.3) 
% difference (95% CI) 
p-valuea 
52.0 (35.1 to 68.9) 
p<0.001 
Complete response n  
% (95% CI) 
10 
20.4 (9.1 to 31.7) 
1 
2.2 (0.1 to 11.5) 
% difference (95% CI) 
p-valuea 
18.2 (-2.0 to 37.6) 
p=0.005 
Partial response n (%) 24 (49.0) 7 (15.2) 
Stable disease n (%) 8 (16.3) 12 (26.1) 
Progressive disease n (%) 3 (6.1) 16 (34.8) 
Not evaluable n (%) 4 (8.2) 10 (21.7) 
Time to subsequent anticancer therapy 
Median, months (95% CI) 14.2 (12.2 to 20.4) 5.5 (3.4 to 9.5) 
HR (95% CI) 0.31 (0.19 to 0.51) 
OS 
Median, months (95% CI) 43.6 (41.0 to NA) 41.6 (21.1 to NA) 
aP-value calculated using a CMH test stratified by baseline disease diagnosis (pcALCL and MF)  
BV=brentuximab vedotin; CI=confidence interval; CMH=Cochran-Mantel-Haenszel; CTCL=cutaneous T cell lymphoma; 
HR=hazard ratio; MF=mycosis fungoides; NA=not available; ORR=objective response rate; ORR4=objective global response 
lasting ≥4 months; OS=overall survival; PC=physician’s choice; pcALCL=primary cutaneous anaplastic large cell lymphoma; 
PFS=progression-free survival 
Source: CS, pp85-86, 89-90; company response to the ERG clarification letter, question A6, question A8, question A10 
4.6.1 Objective response lasting at least 4 months 
In the subgroup of patients with advanced stage CTCL, a statistically significantly greater 
proportion of patients in the BV arm had an objective response lasting at least 4 months than 
patients in the PC arm (percentage difference=50.5, 95% CI: 31.6 to 66.4). As previously 
mentioned, for the analysis of ORR4 in the subgroup of patients with advanced stage CTCL, 
objective response was determined by IRF assessment. The company did not provide results 
for ORR4 by investigator assessment. However, the ERG notes that, in the ITT population, at 
the time of the primary analysis (22.9 months follow-up), the results for ORR4 by investigator 
assessment (BV versus PC: 59.4% versus 7.8%) were broadly comparable to those for ORR4 
by IRF assessment (BV versus PC: 56.3% versus 12.5%). 
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As part of the ERG’s clarification letter to the company, the ERG asked the company to 
perform subgroup analyses for the outcome of ORR4 in the subgroup of patients with 
advanced stage CTCL in the ALCANZA trial. The ERG asked for these subgroup analyses to 
be carried out using the same set of patient characteristics as were used for the subgroup 
analysis of ORR4 in the ITT population. The company provided the results of these subgroup 
analyses in Figure 2 of their response to the ERG clarification letter (replicated in Figure 15 of 
this ERG report). Point estimates of efficacy were in favour of BV across all patient subgroups, 
including whether patients had MF or pcALCL, or whether patients were treated with MTX or 
BEX in the PC arm. Apart from baseline ECOG PS ≥1 and a baseline skin tumour score of 0, 
which included a small number of patients (≤30 in both arms) and events (≤7 in both arms), 
the results were all statistically significantly different. 
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Figure 1 Subgroup analyses of ORR4 per IRF; advanced stage CTCL patient population (33.9 month follow-up) 
CI=confidence interval; CTCL=cutaneous T cell lymphoma; MF=mycosis fungoides; IRF=Independent Review Facility; ORR4=objective global response lasting ≥4 months; pcALCL=primary cutaneous 
anaplastic large cell lymphoma 
Source: Company response to the ERG clarification letter, question A7 (Figure 2) 
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4.6.2 Response rates 
Response rates favoured treatment BV over PC in the subgroup of patients with advanced 
stage CTCL, with a greater proportion of patients experiencing an objective response 
(complete response [CR] or PR) in the BV arm in comparison to the PC arm (69.4% versus 
17.4%, respectively). The proportion of patients experiencing a CR was also higher in the BV 
arm than in the PC arm (10% versus 1%, respectively). Although the company did not provide 
results for ORR or CR by investigator assessment, the ERG notes that, in the ITT population, 
results for CR by investigator assessment (BV versus PC: *************) were broadly 
comparable to those for CR by IRF assessment at the time of the primary analysis (BV versus 
PC: 16% versus 2%).  
The ERG notes that these ORRs for patients in the PC arm are lower than have been 
previously reported in the literature, albeit they are typically from single-arm observational 
studies (Section 2.3.2). Reasons for this are unknown. 
4.6.3 Progression-free survival 
The BV arm median PFS was considerably longer than PC arm median PFS (16.5 months 
versus 3.5 months, respectively). The company also reported a statistically significant HR for 
this comparison. However, due to concerns about the validity of the PH assumption (see 
Section 4.5 of this ERG report), the ERG considers that this HR should be interpreted with 
caution.  
On examination of the K-M data for IRF-assessed PFS in the subgroup of patients with 
advanced stage CTCL (Figure 2), the ERG noted that there is a short period of time when a 
large number of PFS events occur in the BV arm; between approximately 64 weeks (14.7 
months) and 77 weeks (17.7 months), 11 PFS events occur. The TSAP for the ALCANZA trial 
states that all patients randomised to the BV arm were allowed to receive a maximum of 16 
cycles of treatment (a treatment duration of approximately 48 weeks), and also that patients 
were to be followed for survival every 12 weeks for a minimum of 24 months after the end of 
treatment (EOT) visit (TSAP, p6). The K-M data combined with these details from the TSAP 
suggest that a number of patients in the BV arm who finished treatment at 48 weeks without 
having progressed would not have been followed up until 12 weeks after their EOT visit. 
Therefore, patients who progressed between their EOT visit and the assessment 12 weeks 
later would all have been recorded as having progressed at the 12-week assessment point 
(approximately 60 weeks after starting treatment). The ERG considers that this is the most 
likely explanation for the sudden drop in PFS between 64 weeks (14.7 months) and 77 weeks 
(17.7 months) of follow-up. The ERG also notes that median PFS is reached within this period 
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(at approximately 71 weeks [16.5 months]). Since the recording of progression events 
between the EOT visit and the follow-up assessment 12 weeks later may well have been 
delayed for some patients, the ERG considers that median PFS may have been overestimated 
in the BV arm.  
 
Figure 2 K-M graph for IRF-assessed PFS in the advanced stage CTCL patient subgroup of 
the ALCANZA trial (33.9 month follow-up) 
BV=brentuximab vedotin; CTCL=cutaneous T cell lymphoma; KM=Kaplan-Meier; IRF=Independent Review Facility; 
PFS=progression-free survival; TPC=treatment by physician’s choice 
Note: Time measured in days 
Source: CS, Figure 31 
As part of the company’s response to the ERG clarification letter, the company provided K-M 
data for PFS by investigator assessment for the subgroup of patients with advanced stage 
subgroup CTCL after a median of 33.9 months. The ERG considers that the results for PFS 
by investigator assessment are similar to those for PFS by IRF assessment, as shown by the 
K-M curves presented in Figure 3. 
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Figure 3 K-M curves for IRF-assessed PFS and investigator-assessed PFS for the subgroup 
of patients with advanced stage CTCL 
BV=brentuximab vedotin; CTCL=cutaneous T cell lymphoma; INV=investigator; IRF=Independent Review facility; K-M=Kaplan-
Meier; PFS=progression-free survival; TPC=treatment by physician’s choice 
Note: Time measured in days 
Source: Additional response to clarification question B1 
Subgroup analyses of PFS were not presented in the CS. They were, however, presented in 
the published paper [66] but only after 22.9 months and only for all patients enrolled into the 
trial, i.e., including those with early stage disease. Point estimates of efficacy were in favour 
of BV across all patient subgroups, including whether patients had MF or pcALCL, or whether 
patients were treated with MTX or BEX in the PC arm. Apart from baseline ECOG PS ≥1 and 
patients aged ≥65 years, which showed no statistically significant difference between arms, 
the results were all statistically significantly different in favour of BV. 
4.6.4 Time to subsequent anticancer therapy 
The BV arm median time to subsequent anticancer therapy was considerably longer than that 
for the PC arm (14.2 months versus 5.5 months, respectively). The company also reported a 
statistically significant HR for this comparison, although due to the concerns about the validity 
of the PH assumption (see Section 4.5 of this ERG report), the ERG considers that this HR 
should be interpreted with caution.  
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The ERG notes that the median time to subsequent anticancer therapy was lower than median 
PFS in the BV arm but higher than median PFS in the PC arm. As suggested by the ERG in 
Section 4.6.3, this may support the ERG consideration that median PFS appears to be 
overestimated in the BV arm due to the timing of assessments. 
As part of the company’s response to the ERG clarification letter, the company provided a 
breakdown of subsequent anticancer therapies for patients with advanced stage CTCL in the 
ALCANZA trial. The table provided by the company is replicated in this ERG report in Table 
10.  
Table 10 Subsequent anticancer therapies for patients with advanced stage CTCL 
Subsequent systemic therapy BV (n=49) PC (n=46) 
≥1 subsequent anticancer therapy, n (%)a 27 (55.1) 29 (63.0) 
Skin-directed therapy, n (%)b 
Phototherapy 5 (18.5) 5 (17.2) 
Radiotherapy 6 (22.2) 10 (34.5) 
Topical chemotherapy 0 1 (3.5) 
Topical steroids 0 1 (3.5) 
Systemic therapy, n (%) 
BV 8 (29.6) 21 (71.4) 
MTX 7 (25.9) 7 (24.1) 
BEX 6 (22.2) 4 (13.8) 
Chemotherapy other than MTX 18 (66.7) 16 (55.2) 
Denileukin diftitox 1 (3.7) 0 
HDACi 4 (14.8) 4 (13.8) 
Immunotherapy 6 (22.2) 1 (3.5) 
Other 7 (25.9) 4 (13.8) 
BEX=bexarotene; BV=brentuximab vedotin; CTCL=cutaneous T-cell lymphoma; HDACi=histone deacetylase inhibitor; 
MTX=methotrexate; PC=physician’s choice 
aPercentages are reported based on the number of patients in each arm 
bPercentages are reported based on the number of patients who received ≥1 subsequent anticancer therapy 
Source: company response to the ERG clarification letter, question A4 
Most patients in both arms received subsequent anticancer therapy. For patients in both arms 
of the trial, this was often chemotherapy, a Category B therapy. In both arms of the trial, a 
quarter of patients who received subsequent anticancer therapy also received MTX, a 
Category A therapy. Approximately a quarter of patients in the BV arm received 
immunotherapy, which is likely to have included IFN-α, another Category A therapy. However, 
the most common therapy received in the PC arm was BV. As noted in the CS (p89), 46% of 
patients crossed over from the PC arm to receive BV as a subsequent anticancer therapy (of 
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whom 30% received it as their first subsequent anticancer therapy). Nearly a third of patients 
receiving subsequent anticancer therapy in the BV arm also received additional BV. This was, 
however, only eight patients which highlights the difficulty in interpreting the data from such a 
small sample of patients. 
As part of their response to the ERG clarification letter (question A5), the company also 
provided details about how many patients in each arm of the ALCANZA trial received an 
alloSCT. This information appears to be provided for all patients enrolled into the trial, not just 
for patients with advanced stage CTCL. In total, seven patients in the ALCANZA trial received 
an alloSCT; five patients received an alloSCT before the time of the primary data analysis 
(median follow-up 22.9 months) and an additional two received an alloSCT before the time of 
the updated data analysis (median follow-up 33.9 months). Of the seven patients that received 
an alloSCT, five were in the BV arm and two were in the PC arm (both received MTX). Both 
PC arm patients who received an alloSCT had crossed over to the BV arm and had received 
additional subsequent systemic therapies prior to the alloSCT. Of the five patients in the BV 
arm who received an alloSCT, two patients received the alloSCT directly after their study 
treatment; the remaining three patients received additional subsequent systemic therapies 
prior to their alloSCT. Of the seven patients who received an alloSCT, four were based in the 
UK; this equates to 17% of UK patients enrolled in the ALCANZA trial subsequently receiving 
an alloSCT. 
4.6.5 Overall survival 
While OS was not a pre-specified endpoint in the ALCANZA trial, OS data were collected and 
are presented in the CS (pp89-90). The company reported that there appears to be a trend 
towards longer OS observed in the BV arm versus PC (median OS [95% CI]: 43.6 months 
[41.0 months to not estimable] versus 41.6 months [21.1 months to not estimable], 
respectively). However, as noted by the company, OS data are “extremely immature at 33.9 
months of follow-up” (p89) and confounded by subsequent anticancer therapy and crossover. 
Furthermore, the company states that interpreting results from this analysis involves high 
uncertainty, as illustrated by the single figure difference in the number of observed events. 
The ERG concurs this result should be interpreted with caution due to confounding, the small 
number of patients included in the analysis and the small number of events that had occurred 
by the 33.9 month follow-up date (16 events [33%] in the BV arm and 18 events [39%] in the 
PC arm [CS, Table 27]).  
The company explored various methods of adjusting for treatment switching, as suggested by 
the NICE Decision Support Unit guidance [131]. However, none of these methods were 
particularly well suited to the data given the small number of patients and events and the lack 
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Superseded – see erratum
 
of a secondary common baseline at the time data were collected on time-dependent 
covariates (a prerequisite for the two-stage method of crossover adjustment). The ERG agrees 
with the company that none of the available methods of crossover adjustment are suitable for 
the ALCANZA trial and considers that it is not possible to obtain robust estimates of clinical 
effectiveness for BV in comparison to PC for the outcome of OS.  
4.7 Efficacy results from non-randomised studies 
The company presents results from Duvic et al 2015 [18] and Kim et al 2015 [76] as supporting 
evidence for the efficacy of BV, these studies include other subtypes of CTCL i.e., not MF and 
pcALCL. The ERG has summarised the findings, reported in the CS, for these two studies, for 
the retrospective study by Mathieu et al 2016 [75], and the findings from the studies (the 
unpublished IST-001 and IST-002 studies and Weiner 2016 [116]) reported in the EPAR for 
BV [30] in Table 11 and Table 12. The ERG urges caution in interpreting these findings, 
particularly in comparing results across studies, given likely differences in the patient 
populations. The findings are, however, illustrative of the effects of BV treatment across these 
different patient populations. 
Baseline characteristics for the studies included in the CS [18, 75, 76] have been previously 
summarised in Section 4.3 (Table 5) of this ERG report. Two of these studies [75, 76] included 
mostly (≥88%) patients with advanced stage CTCL. The stage of disease of patients included 
in the study by Duvic et al 2015 [18] is not reported. However, the median (range) number of 
previous systemic therapies in the Duvic et al 2015 study [18] was 2 (1 to 10) for patients with 
MF and 1 (0 to 5) for patients with CD30+ LPDs, similar to the patterns in the ALCANZA trial. 
The types of previous therapies are not reported [18]. The median (range) number of previous 
systemic therapies in the Kim et al 2015 study [76] was 3 (1 to 13) for all patients. In this study 
[76] most patients had received prior treatment with cytotoxic agents and one patient had had 
an alloSCT. The number of previous lines of therapies in Mathieu et al 2016 was reported to 
be between 2 and 14 [75]. There are no data available regarding the patient characteristics of 
patients treated with BV for the three studies (IST-001, IST-002 and Weiner 2016 [116])  which 
were reported in the EPAR for BV [30]. It is, therefore, unknown how many patients in these 
studies had advanced stage CTCL or how many previous lines of therapy patients in these 
studies had received.  
The numbers of patients with CTCL subtypes other than MF included in all of the studies are 
small. The CTCL subtype was known for patients in all but the Wieser 2016 study. Of the 218 
patients in these studies, 147 (67%) had MF, 19 (9%) had SS, 5 (2%) had pcALCL, 22 (10%) 
had LyP only, 22 (10%) had mixed subtypes (most commonly LyP and MF, n=18 [8%]) and 3 
(1%) had other CTCL subtypes. 
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Only in the IST-002 study were findings for ORR4 reported. The findings (reported in Table 
11) for patients with MF (50%) and MF with CD30 expression ≥10% (67%) were broadly similar 
to ORR4 findings for patients treated with BV in the subgroup of patients with advanced stage 
CTCL (59.2%) and the ITT population (60.9%) of the ALCANZA trial after a median of 33.9 
months follow-up. The ORR4 findings for patients with SS (25%) were notably lower (but, 
nonetheless, much higher than reported for patients in the PC arm of the ALCANZA trial [7.8% 
in the subgroup of patients with advanced stage CTCL, 8.7% in all patients, after a median 
follow-up of 33.9 months]). 
Table 11 ORR4 results for patients treated with brentuximab vedotin in IST-002 
CTCL subtype Number of patients ORR4  
All patients 36 50% 
MF  32 53% 
MF, CD30 expression <10% 17 41% 
MF, CD30 expression ≥10%  15 67% 
SS  4 25% 
CD30=cluster of differentiation; CD30-=cluster of differentiation-negative (CD30 expression <10%) CD30+=cluster of 
differentiation -positive (CD30 expression ≥10%); CTCL=cutaneous T-cell lymphoma; CD30=cluster of differentiation; 
MF=mycosis fungoides; ORR4=objective global response lasting ≥4 months; SS=Sézary syndrome 
Source: EPAR, adapted from Table 30 
 
All studies reported findings for ORR and most also report findings for PFS (Table 12). The 
data (albeit from small numbers of patients) show that findings for ORR and median PFS 
observed in the non-randomised studies for different subtypes of CTCL are generally 
consistent across studies and are also in line with the findings reported in the ALCANZA trial. 
However, median PFS reported in the IST-002 study (25.0 months) was longer for patients 
with MF than was reported for all patients in the Duvic et al 2015 study [18] (13.2 months), or 
in the subgroup of patients with advanced stage CTCL or for all patients in the ALCANZA trial 
(16.5 months and 15.8 months, respectively, after a median follow-up of 33.9 months).  
Results from the IST-001 and IST-002 studies showed that median PFS for patients with SS 
(≤7.8 months) tended to be lower than those for patients with other CTCL subtypes (≥13.2 
months). Study IST-001 presents the duration of PFS for each individual patient with SS and 
it is noticeable that the shortest duration (4.2 months) is nonetheless longer than the median 
PFS reported for patients in the PC arm of the ALCANZA trial (3.5 months in the subgroup of 
patients with advanced stage CTCL and 3.6 months in all patients, after a median of 33.9 
months follow-up). Extreme caution must be taken when interpreting these findings for patients 
with SS as the studies only included a total of six patients with SS.   
It is reported by Duvic et al 2015 [18] that patients with LyP and pc-ALCL lesions responded 
more rapidly than patients with MF lesions, but that responses were of shorter duration. 
Regarding the association between CD30 expression and response, the company describes 
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all patients in this study as having CD30+ CTCL (CS, p81), however, the authors of the study 
[18] state that CD30 expression was graded as percentage of the entire lymphocytic infiltrate 
seen in the tissue (low, <10%; medium, ≥10% to ≤50%; or high, >50%). The authors found 
that CD30 in baseline MF skin lesion biopsies did not seem to correlate with response to 
brentuximab vedotin [18]. 
The ERG found, from its searches, that an additional subset analysis of nine patients enrolled 
in Duvic et al 2015 [18] plus three patients not enrolled in that study had been conducted by 
Lewis et al 2017 [115]. All patients were 18 years or older, had a diagnosis of LyP and were 
required to have scarring, more than 10 lesions, or active lesions on the face, hands, or feet. 
As also reported by Duvic et al 2015 [18], ORR was 100% in this study [115].   
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Table 12 ORR and PFS results of non-randomised studies of brentuximab vedotin 
CTCL 
subtype 
Duvic et al 2015 [18] Kim et al 2015 [76] Mathieu et al 2016 [75] IST-001 [30] IST-002 [30] Wieser 2016 [116]  
n ORR n ORR n ORR n ORR n ORR n ORR 
All patients 48 73% 30 70%† 32 50% 72 67% 36 50% 21 67%* 
MF  28 54% 27 -- 19 -- 41 54% 32 53% -- -- 
CD30- MF --* --a n/a n/a -- -- 20 55% 17 41% -- -- 
CD30+ MF --a --a n/a n/a -- -- 20 55% 15 67% -- -- 
SS  n/a n/a 3 -- 10 -- 2 50% 4 25% -- -- 
pcALCL  n/a n/a n/a n/a -- -- 3 67% n/a n/a -- -- 
Lyp only 9 100% n/a n/a -- -- 13 92% n/a n/a -- -- 
Lyp/MF  7 100% n/a n/a -- -- 11 82% n/a n/a -- -- 
Mixed 9b 100% n/a n/a  -- 13c 85% n/a n/a -- -- 
Other -- -- -- -- 3 -- -- -- -- -- -- -- 
PFS n Median n Median n Median n Median n Median n Median 
All patients 48 13.2 mos§ 30 NR 32 NR 72 10.0 mos 36 25.0 mos -- -- 
MF  28 -- 27 -- 19 -- 41 10.0 mos 32 25.0 mos -- -- 
CD30- MFa --a --a n/a n/a -- -- 20 7.2 mos 17 -- -- -- 
CD30+ MF --a --a n/a n/a -- -- 20 10.8 mos 15 25.0 mos -- -- 
SS  n/a n/a 3 -- 10 -- 2 5.5 mos¥ 
4.8 mos¥ 
4 7.8 mos -- -- 
pcALCL  2 n/a n/a n/a -- -- 3 10.0 mos n/a n/a -- -- 
Lyp only 9 -- n/a n/a -- -- 13 11.7 mos n/a n/a -- -- 
Mixed 9b -- n/a n/a  -- 13b 6.9 mos n/a n/a -- -- 
Other -- -- -- -- 3 -- -- -- -- -- -- -- 
 ‘—‘=not reported; CD30=cluster of differentiation; CD30-negative (CD30 expression <10%) CD30+=CD30-positive (CD30 expression ≥10%); CI=confidence interval; CTCL=cutaneous T-cell 
lymphoma; LyP=lymphomatoid papulosis; MF=mycosis fungoides; n/a=not applicable; mos=months; NR=not reached; ORR=objective response rate; pcALCL=primary cutaneous anaplastic large cell 
lymphoma; PFS=progression-free survival; SS=Sézary syndrome  
aThe company describes all patients in Duvic et al 2015 [18] as being CD30+ (CS, p81), however Duvic et al 2015 [18] report some patients did have CD30 expression <10% (number not reported)  
b Mixed histology subtypes: Lyp/MF (n=7), pcALCL/Lyp (n=1) and pcALCL/MF (n=1) 
c Mixed histology subtypes reported to be Lyp/MF (n=11), pcALCL/Lyp (n=1) and pcALCL/MF (n=1) 
† 95% confidence interval (CI): 53% to 83% 
§ 95% CI: 10.8 mos to 16.8 mos 
¥ Individual patient PFS duration, not medians 
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4.8 Safety 
Safety data for the ALCANZA trial are presented for all patients after a median follow-up of 
22.9 months or 33.9 months in the CS (Section B.2.10.1). Some data for patients with 
advanced stage CTCL are also presented in the CS (pp96-97), and additional data for this 
subgroup were provided by the company during the clarification process. All data for patients 
with advanced stage CTCL relate to analyses undertaken after a median follow-up of 33.9 
months. Safety data from the two prospective non-randomised studies [18, 76] are also 
reported in the CS (Section B.2.10.2 and Section B.2.10.3). In addition, the ERG has extracted 
the limited safety data from the abstract of the retrospective study [75]. These three studies 
also include some patients with subtypes of CTCL other than MF and pcALCL (see Section 
4.3 of this ERG report). 
Following consideration of the safety data presented below (Section 4.8.1 to Section 4.8.5 and 
Appendix 5, Section 9.5) the ERG concurs with the company that the results from the 
ALCANZA trial and single-arm observational studies [18, 75, 76] indicate that treatment with 
BV has not been associated with new, or unexpected, toxicities. The majority of reported AEs 
were grade 1 or grade 2 in severity, and the ERG notes that, compared to studies of BV for 
other indications (HL and sALCL) reported in the EPAR for BV [30], grade 3 TEAEs were 
reported less frequently in the ALCANZA trial. As noted by the company, and supported by 
clinical advice to the ERG, peripheral neuropathy appears to be the most clinically important 
AE associated with BV. 
The ERG also notes the conclusions reached by the EMA (pp99-100 of the EPAR for BV [30]). 
In particular, the EMA states that toxicity from BV was “substantial” in the ALCANZA trial, but 
largely consistent with earlier studies of BV. The EMA also considered the lack of safety data 
for patients with other subtypes of CTCL and, whilst they concluded that the safety data from 
the ALCANZA trial could be extrapolated to patients with other subtypes of CTCL, they 
considered that safety in the CTCL subtypes other than MF and pcALCL should be monitored 
post-marketing. 
4.8.1 Exposure to study treatment  
Median duration of treatment with BV reported in the studies of BV is summarised in Table 13. 
It is noticeable that in the overall ALCANZA trial population, patients in the BV arm were on 
treatment for longer than patients in the PC arm. Duration of BV treatment in the ALCANZA 
trial was also longer than that for patients with CTCL who were enrolled in the single-arm 
observational studies [18, 75, 76]. 
Confidential until published 
 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 67 of 172 
 
Superseded – see erratum
 
Table 13 Duration of treatment reported in the studies of BV 
Study, treatment (number of patients) 3-weekly cycles, median (range)  Days, median 
ALCANZA trial, median 22.9 months follow-up   
BV (n=66) 12 (5 to 16) 269 
MTX (n=25) 3 (2 to 6) 77 
BEX (n=37) 5.5 (3 to 11) 114 
Duvic et al 2015 
BV for MF (n=28) / BV for LyP/pcALCL (n=20) 
 
7 (2 to 9) / 7.5 (2 to 16) 
 
Not reported 
Kim et al 2015 
BV (n=30) 
 
6 (1 to 16) 
 
Not reported 






BEX=bexarotene; BV=brentuximab vedotin; LyP=lymphomatoid papulosis; MF=mycosis fungoides; MTX=methotrexate; 
pcALCL=primary cutaneous anaplastic large cell lymphoma 
Source: CS, data extracted from p93 and p97 and data extracted from Mathieu et al 2016 [75] 
After median follow-up of 22.9 months, the median relative dose intensity for the ALCANZA 
trial overall population was 99.6% (inter-quartile range [IQR] 92.7% to 100.0%) for BV and 
94.3% (IQR 73.6% to 100.0%) for BEX (CS, p93). The median dose of MTX was 21.7 mg/week 
(IQR 16.7mg to 30.6mg). Three patients remained on treatment (all in the BV arm) at this data-
cut. 
After a median of 33.9 months follow-up, mean duration of exposure to BV for patients with 
advanced stage CTCL was 237 days, and mean duration of exposure to PC was 130 days 
(CS, p96). As only mean duration for this subgroup is reported, these data cannot be 
compared with the data in Table 13. 
4.8.2 Safety profile in the ALCANZA trial  
A summary overview of all AEs and deaths, for all patients, after a median of 22.9 months 
follow-up in the the ALCANZA trial is presented in Table 19 of the CS. During the clarification 
process, the ERG requested the same data for the subgroup of patients with advanced stage 
CTCL after a median of 33.9 months follow-up and these data are presented in Table 14 of 
this ERG report. The ERG observes that the results for the overall trial population after a 
median of 22.9 months follow-up and in the subgroup of patients with advanced stage CTCL 
after a median of 33.9 months follow-up are very similar. 
Confidential until published 
 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 68 of 172 
 
Table 14 Summary of ALCANZA trial AEs 
Type of adverse event, n (%) Overall trial population, median 
22.9 months follow-up  
Subgroup of patients with 
advanced stage CTCL, median 









Any TEAE 63 (95) 56 (90) 46 (94) 40 (91)
Grade 3 TEAE 27 (41) 29 (47) 19 (39) 24 (55)
Any TRAE 57 (86) 44 (71) 41 (84) 31 (70)
Grade 3 TRAE 19 (29) 18 (29) 14 (29) 15 (34)
Any SAE 19 (29) 18 (29) 13 (27) 16 (36)
Any TRSAE 9 (14) 3 (5) 7 (14) 3 (7)
AE leading to discontinuation 16 (24) 5 (8) 12 (24) 4 (9)
On-treatment deaths 4 (6) 0 3 (6) 0
AE=adverse event; BV=brentuximab vedotin; PC=physician’s choice SAE=serious adverse event; TEAE=treatment-emergent 
adverse event; TRAE=treatment-related adverse event; TRSAE=treatment related serious adverse event 
On-treatment deaths were defined as deaths occurred within 30 days after the last dose of study drug. 
Source: CS, adapted from Table 19, subsequent clarification response to A12 
As presented in Table 14, the vast majority of patients in both the BV and PC arms of the 
ALCANZA trial reported at least one any-grade treatment-emergent adverse event (TEAE). 
Nausea, fatigue and pyrexia were common AEs associated with all three therapies (Appendix 
5, Section 9.5, of this ERG report). Peripheral neuropathy was reported to be the most 
common reason for premature discontinuation of treatment with BV (CS, p49); after a median 
follow-up of 22.9 months, 9 (56%) discontinuations in the BV arm were attributable to 
peripheral neuropathy (CSR, p176). As highlighted on p89 of the EPAR for BV [30], other AEs 
that led to study drug discontinuation were experienced by no more than one patient in either 
treatment group. 
It is reported on p89 of the EPAR for BV [30] that within the PC arm of the ALCANZA trial, 
after a median follow-up of 22.9 months, more treatment-related adverse events (TRAEs) and 
grade ≥3 TRAEs were experienced by patients treated with BEX than by patients treated with 
MTX. Conversely, serious adverse events (SAEs), including treatment-related SAEs, were 
experienced more frequently by patients treated with MTX than by patients treated with BEX.  
4.8.3 Common types of severe (grade ≥3) adverse events  
The ERG highlights that the grade ≥3 TRAEs included in the company model are those that 
occurred in ≥5% of patients in the ALCANZA trial (either arm) with advanced stage CTCL (CS 
summary document, Section A.11.4). Therefore, within this section, the ERG has focused only 
on grade ≥3 AEs. Further information on any-grade AEs is presented in Appendix 5, Section 
9.5 of this ERG report. However, the ERG notes that grade ≥3 AE data reported in the 
published paper [66] for the overall trial population and company clarification response for 
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patients with advanced stage CTCL (response to A12, Table 9) are presented for grade ≥3 
TEAEs, not grade ≥3 TRAEs. 
Few grade ≥3 TEAEs were experienced by two or more patients treated with either BV or BEX 
in either the overall ALCANZA trial population after a median of 22.9 months follow-up 
(published paper, Table 3 [66]) or in the subgroup of patients with advanced stage CTCL after 
a median of 33.9 months follow-up (company clarification response to A12, Table 9). No grade 
≥3 TEAE occurred at all in two or more patients treated with MTX in either the overall trial 
population or in the subgroup of patients with advanced stage CTCL.  
In the subgroup of patients with advanced stage CTCL, the grade ≥3 TEAEs occurring in two 
or more patients in the BV arm were peripheral sensory neuropathy (8%), neutropenia (6%) 
and peripheral motor neuropathy (4%); grade ≥3 fatigue (5%), diarrhoea (2%) and skin 
infection (2%) were also reported by at least two patients in the overall trial population. In the 
subgroup of patients with advanced stage CTCL treated with BEX, grade ≥3 
hypertriglyceridemia (25%), neutropenia (8%) and anaemia (8%) occurred in two or more 
patients; grade ≥3 pruritus occurred in two patients treated with BEX in the overall trial 
population (5%). 
In the CS, the grade ≥3 AEs experienced by patients with advanced stage CTCL are grouped 
into system classes (CS, Table 22 and Table 33). The most common AEs in the BV arm were 
peripheral neuropathy (14%), gastrointestinal disorders (14%) and blood and lymphatic 
system disorders (anaemia, neutropenia and thrombocytopenia) (12%). In the PC arm, the 
most common AEs were hypertriglyceridemia (20%) and investigations (alanine 
aminotransferase, aspartate aminotransferase or blood triglycerides increased, lymphocyte 
count decreased, raised triglycerides) (14%). The data for the PC arm were not presented for 
MTX and BEX separately. The ERG notes that there appear to be more AEs of blood and 
lymphatic system disorders in the BV arm and hypertriglyceridemia in the PC arm included in 
the system classes (n=6 and n=9, respectively) than were reported in the company’s 
clarification response (n=4 and n=7, respectively). It is unclear if this is because the former 
relates to occurrences of the AE (in which case, an event experienced by a patient more than 
once is counted more than once) whereas the latter relates to the number of patients 
experiencing a specific AE (in which case an event experienced by a patient more than once 
is counted only once). 
As per the ALCANZA trial, few grade ≥3 TRAEs were experienced by two or more patients 
with BV in the prospective observational studies; grade ≥3 data are not presented in the 
abstract of the retrospective study [75]. In Duvic et al 2015 [18], the most common grade ≥3 
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TRAE was neutropenia (6%) followed by nausea (4%), unstable angina or myocardial 
infarction (4%), arthralgia (4%) and infection (4%). Neutropenia (13%) and skin eruption (9%) 
were the only grade ≥3 TRAEs reported by two or more patients in the study by Kim et al 2015 
[76]. The only other grade ≥3 TRAE reported in this study was peripheral neuropathy, which 
was reported to have been experienced at grade 4 severity by one patient (3%). It is reported 
that this patient died of pneumonia as a complication of the neuropathy [76]. 
4.8.4 Adverse events of special interest (patients with early stage and 
advanced stage CTCL) 
Peripheral neuropathy, haematological toxicities including neutropenia, and infusion-related 
reactions (IRRs) are described as AEs of special interest (AESI) in the EPAR for BV [30]. The 
company has focussed on peripheral neuropathy in the CS (pp94-96), which the company has 
described as a “known toxicity” of treatment with BV. 
Peripheral neuropathy  
After a median follow-up of 22.9 months in the ALCANZA trial, 44 (67%) patients in the BV 
arm had peripheral neuropathy. This was the most common any-grade and grade ≥3 TEAE 
for all patients treated with BV observed in this trial. The company states (CS, p94) that 82% 
of patients with peripheral neuropathy had either improvement (≥1 grade) or resolution of 
peripheral neuropathy after discontinuation, dose reduction, dose delay, or completion of 
treatment and that most patients did not need to delay treatment. The ERG observes that after 
a median follow-up of 22.9 months, 16 (36%) patients required at least one delay (p79 of the 
EPAR for BV [30]) and 9 (20%) patients with peripheral neuropathy discontinued treatment 
with BV (CSR, Table 12.r). These data are not mutually exclusive (i.e., patients requiring a 
dose delay may also have subsequently discontinued treatment). Data reported in the EPAR 
for BV [30] also show that the median time to any peripheral neuropathy was 12 weeks (range 
0 weeks to 48 weeks) in the BV arm and 2.5 weeks (range 0 weeks to 10 weeks) in the PC 
arm (p79).  
Data, from the updated analysis (33.9 months) of all patients in the ALCANZA trial reported in 
the CS (Table 21), indicate that there were no new cases of peripheral neuropathy between 
22.9 months and 33.9 months. Furthermore, peripheral neuropathy had now improved in 86% 
of patients: 59% had had a complete resolution (median time to resolution: 30 weeks) and 
27% had 1 severity grade improvement (median time to improvement: 13 weeks). 
Nonetheless, the ERG notes that, at the time of this more recent data-cut, 41% of patients in 
the BV arm still had ongoing peripheral neuropathy: 34% of grade 1 severity and 7% of grade 
2 severity (CS, Table 21). Median time to resolution was shorter for the four patients with 
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peripheral neuropathy in the PC arm (10.5 weeks) than the 44 patients in the BV arm (30.0 
weeks) (CS, Table 21). 
As per the ALCANZA trial, peripheral neuropathy was often reported to be reversible in the 
prospective observational studies [18, 76]: 45% of patients with peripheral neuropathy in the 
study by Duvic et al 2015 [18] had complete resolution and 59% of patients with peripheral 
neuropathy in the study by Kim et al 2015 [76] had improvement or resolution by 12 months. 
Median time to resolution or improvement was reported to be longer in these studies [18, 76] 
than in the ALCANZA trial (CS, pp97-98 and Table 21). Furthermore, data from the 
observational studies also show that peripheral neuropathy often deteriorates before it 
improves. It is reported by Duvic et al 2015 [18] that, of 31 patients with peripheral neuropathy, 
30 patients had grade 1 events, of whom 21 (70%) progressed to grade 2 severity. Kim et al 
2015 [76] report the median time to any peripheral neuropathy was 13 weeks (range 3 weeks 
to 89 weeks) and the median time to grade 2 peripheral neuropathies was 20.8 weeks (range 
15 weeks to 46 weeks).  
Neutropenia 
As reported on p81 of the EPAR for BV [30], neutropenia or decreased neutrophil count TEAEs 
were reported for 9% of patients in the BV arm and 6% of patients in the PC arm. From data 
reported in Table 36 of the EPAR for BV [30], grade ≥3 neutropenia was reported at a much 
lower incidence for patients treated with BV in the ALCANZA trial after a median of 22.9 
months (3%) than in previous studies for sACLC or HL (20% to 22%). However, grade ≥3 
neutropenia was also reported in the ALCANZA trial at a lower frequency than in the 
prospective observational studies of CTCL (6% to 13%) (Section 4.8.3 of this ERG report). It 
is reported on p81 of the EPAR for BV [30] that neutropenia TEAEs required ≥1 dose delay 
for four patients in the BV arm but did not require dose reductions, holds, or permanent 
discontinuations. No events of febrile neutropenia were reported in either arm. 
Infusion-related reactions 
As reported on pp81-82 of the EPAR for BV [30], IRRs occurred in nine patients (14%) treated 
with BV; all events occurred during cycle 2 or cycle 3. Two patients experienced a grade 3 
IRR (urticaria and drug hypersensitivity). None of the IRRs were considered SAEs, and no 
grade 4 IRRs or anaphylaxis TEAEs were reported. One patient discontinued treatment with 
BV as a result of a grade 3 urticaria. 
4.8.5 Treatment-related deaths  
As reported in in the CS (p94), after a median follow-up of 22.9 months, in the overall trial 
population of the ALCANZA trial, 24% of patients in the BV arm and 23% in the PC arm had 
Confidential until published 
 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 72 of 172 
 
died. Four (6%) patients in the BV arm experienced on-treatment deaths (defined as deaths 
that occurred within 30 days of their last dose of study drug). In patients with advanced stage 
CTCL, after a median of 33.9 months follow-up, there were three (6%) on-treatment deaths in 
the BV arm (subsequent clarification response to A12). There were no on-treatment deaths in 
the PC arm. 
There was only one treatment-related death. The treatment-related death occurred in a patient 
with pcALCL within 30 days of their last dose of BV. Their cause of death was attributed to 
multiple organ dysfunction syndrome. This was attributed by the investigator to tumour lysis 
caused by BV on sites of visceral lymphoma involvement. Although not reported in the CS, 
the ERG observes from the EPAR for BV [30] (p78) that this patient did not meet the trial 
eligibility criteria as they had elevated liver function test results at baseline and their enrolment, 
therefore, constituted a major protocol violation. 
As highlighted above, one patient (3%) with treatment-related grade 4 peripheral neuropathy 
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4.9 Health-related quality of life  
HRQoL results are reported in the CS, a published paper [66] and the EPAR for BV [30] for all 
patients in the ALCANZA trial. The CS also includes an analysis for patients with advanced 
stage CTCL. HRQoL was measured using three different instruments: 
 The Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire 
[132], a 27-item general cancer HRQoL instrument with four primary subscales: 
physical well-being, social/family well-being, emotional well-being, and functional well-
being. 
 The Skindex-29 [133], a 30-item, dermatology-specific, self-reported questionnaire 
designed to assess 3 domains: symptoms (pre-specified as a key secondary endpoint 
in the ALCANZA trial), emotions, and function. 
 The European Quality of Life 5-Dimension 3 Level (EQ-5D-3L) questionnaire and EQ-
5D Visual Analogue Scale (VAS) [134], generic instruments for collecting patient-
reported HRQoL; EQ-5D-3L is a 5-item questionnaire which assesses the dimensions 
of mobility, self-care, usual activities, pain/discomfort and anxiety/depression, whilst 
the VAS was used to record self-rated health on a 20-cm vertical line ranging from 0 
(worst imaginable health state) to 100 (best imaginable health state). 
 
All HRQoL questionnaires were completed by patients still on treatment on day 1 of cycles 1, 
2, 4, 6, 8, 10, 12, 14, and 16 (before any other study procedures were performed).  Patients 
who were progression-free and no longer on study treatment completed HRQoL 
questionnaires within 30 days +/- 2 days of EOT. Progression-free patients then had their 
HRQoL measured every 12 weeks (± 2 weeks) after EOT for at least 24 months, and then 
every 6 months (± 1 month) until progression or the end of the study. Patients whose disease 
had progressed were followed-up every 12 weeks after EOT for up to 24 months and then 
every 6 months until withdrawal, death or the end of the study. For patients not required to 
return to clinic for post-treatment follow-up, questionnaires were completed by phone or by 
mail. Results are presented in the CS up to EOT. 
The ERG notes that the FACT-G questionnaire is an instrument that has been validated for 
use for many different types of oncology, including nHL [135]. The company highlights that 
Skindex-29 has been extensively studied and validated in different patient populations with 
skin diseases, including CTCL [13, 14, 136]. However, the company questions the 
appropriateness of the EQ-5D-3L for patients with CTCL. Company results show a poor 
correlation between the symptom domain of Skindex-29 and the EQ-5D-3L results for patients 
with advanced stage CTCL. Results presented in the CS (p30 and Section B.2.7.4, Figure 33) 
from the Skinindex-29 questionnaire classified these patients as severely symptomatic but 
results from the EQ-5D-3L questionnaire suggested that patients were close to perfect health 
(i.e., an average score of close to 1.0). A large proportion of patients with relatively high EQ-
5D-3L scores (≥0.7) also had a Skindex-29 symptom score of >52 (CS, p99). The company 
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notes (p87) that symptom scores >52 are classified as having a severe negative impact on 
HRQoL (scores of 42 to 51 are classified as moderate and scores of 39 to 41 are classified as 
mild) [137]. 
HRQoL data for patients with advanced stage CTCL are only included in the CS (pp86-88). 
The data reported are from an analysis of the symptom domain of Skindex-29 (which relates 
to skin problems) and EQ-5D-3L. The company reports (CS, p86) that patients with advanced 
stage CTCL treated with BV had a greater symptom reduction compared with those treated 
with PC (change from baseline to EOT, mean [SD]: –16.31 [28.98] versus –2.41 [21.04], 
respectively). The difference was described as being clinically meaningful. No statistically 
significant difference in EQ-5D-3L values was found between arms (CS, p88). 
Similar findings to those reported for the subgroup of patients with advanced stage CTCL after 
a median follow-up of 33.9 months were reported for the Skindex-29 and EQ-5D-3L scores in 
the ITT population after a median follow-up of 22.9 months and after a median follow-up of 
33.9 months. For other measures of HRQoL in the ITT population, no differences between 
arms in scores obtained by FACT-G or EQ-5D VAS were reported. It is also reported in the 
published paper (p560) that “No substantial difference in Skindex-29 emotional or functioning 
domains was seen over time” [66]. For more information about HRQoL findings in the ITT 
population, see Appendix 6, Section 9.6 of this ERG report.  
When interpreting all of the HRQoL results, it is important to consider the number of patients 
who completed the questionnaires. Whilst compliance was reported to be high over time from 
baseline to EOT (i.e., most of those eligible to complete questionnaires did so), the number of 
eligible patients at each point in time the data were collected decreased, reflecting the higher 
number of patients who had disease progression over time. This decrease was more 
pronounced in the PC arm than in the BV arm and was particularly noticeable from cycle 4 
onwards, when the number of patients in the PC arm had halved from baseline, and from cycle 
8 onwards when the number of patients in the PC arm was <10 (Table 15). As patients who 
remain on treatment in either arm are those who are benefitting from treatment (i.e., 
progression-free and/or no serious or severe AEs), it is perhaps unsurprising that there are no 
statistically significant differences in many of the aspects of HRQoL captured by the FACT-G, 
EQ-5D-3L or EQ-5D VAS questionnaires. The ERG, therefore, concurs with the view 
expressed by the EMA in the EPAR for BV [30] that, in relation to the impact of BV on HRQoL, 
“no firm conclusions can be drawn” (p64).  
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Table 15 Number of patients with advanced stage CTCL in the ALCANZA trial completing 
Skindex-29 questionnaire at each cycle 
Cycle BV (n=49) PC (n=46) 
n % of baseline n % of baseline 
1 48 98 43 93 
2 43 88 35 76 
4 40 82 22 48 
6 33 67 17 37 
8 32 65 8 17 
10 30 61 8 17 
12 26 53 7 15 
14 23 47 4 9 
16 20 41 3 7 
EOT 34 69 26 57 
BV=brentuximab vedotin; CTCL=cutaneous T cell lymphoma; EOT=end of treatment; PC=physician’s choice 
Source: CS, adapted from Figure 32 
4.10 ERG critique of the indirect evidence 
As the ALCANZA trial did not include IFN-α as a treatment option in the PC arm, the company 
assessed the feasibility of performing indirect comparisons to obtain estimates of 
effectiveness for treatment with BV versus IFN-α (CS summary document Section A.8.2.1; 
CS, Section B.2.9.1). As the ALCANZA trial did not include patients with CTCL other than MF 
or pcALCL, the company also considered the feasibility of treatment with BV versus standard 
of care for patients with SS/LyP (CS summary document Section A.8.2.2; CS, Section 
B.2.9.2).  
4.10.1 Feasibility of comparing brentuximab vedotin with interferon-
alpha 
The company’s feasibility assessment of indirectly comparing treatment with BV and IFN-α 
focused on the relevant patient population, patients with advanced stage CTCL. The company 
states that only studies that reported PFS and/or OS data were considered for inclusion in the 
indirect comparison, as these outcomes are the key inputs for the economic model. The ERG 
notes that as well as studies of IFN-α, the company also considered studies of other IFN 
preparations such as IFN-gamma [112] for inclusion. 
In total, the company identified 23 publications relevant to IFN in CTCL [53, 78, 79, 93, 96-
114]. The company assessed the viability of each publication as a data source for the indirect 
comparison (Appendix D to the CS, Table 18). The company determined that none of the 
identified studies could be used as a data source for the indirect comparison for various 
reasons. The company therefore concluded that it was not feasible to conduct an indirect 
comparison of treatment with BV versus IFN-α. While reasons for excluding studies from a 
systematic review or indirect comparison are sometimes arrived at in a hierarchical manner, 
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the company has not employed such an approach. Therefore, in some instances, studies have 
been excluded for multiple reasons and the number of reasons for exclusion therefore exceeds 
the numbers of studies that were excluded. The reasons cited by the company for exclusion 
were as follows:  
 IFN-α used as combination therapy rather than monotherapy (12 studies) 
 lack of relevant outcomes reported (8 studies) 
 patient population not consistent with that of the ALCANZA trial or relevant to the 
decision problem (2 studies) 
 IFN preparation was not consistent with UK clinical practice (3 studies). 
 
The ERG agrees with the company’s assessment that there is insufficient evidence to perform 
an indirect comparison.  
4.10.2 Feasibility of comparing brentuximab vedotin with standard of 
care for patients with SS/LyP 
The company’s search for evidence of the clinical effectiveness of treatment with BV in 
patients with SS/LyP identified only two phase II studies of BV [18, 76] (see Section 4.2.1 and 
Section 4.3) for an overview of these studies). Kim et al 2015 [76] only included three patients 
with SS whereas Duvic et al 2015 [18] only included 10 patients with LyP. Neither study 
reported OS or PFS results for patients with SS or LyP. Furthermore, both trials were single-
arm studies and any indirect comparison would have required the use of population 
adjustment methods (such as matching-adjusted indirect comparison and simulated treatment 
comparison). Both these approaches involve fitting regression models including multiple 
covariates. This was not considered feasible given the small sample sizes available. 
Furthermore, even if the use of these methods was feasible, the company did not identify any 
data sources for of standard care for patients with SS or LyP to form a comparator dataset. 
The company determined that it was not possible to conduct an indirect comparison for 
treatment with BV versus standard of care for patients with SS/LyP for the reasons discussed. 
The ERG agrees with the company’s conclusion.  
4.11 Summary of findings for the overall ALCANZA trial population  
In addition to subgroup evidence for patients with advanced stage CTCL, the company also 
presents evidence for the overall trial population of the ALCANZA trial after a median follow-
up of 22.9 months and 33.9 months. In all trial patients, results were consistent at both data-
cuts. The key efficacy findings from the subgroup of patients with advanced stage CTCL are 
consistent with those for the overall trial population (after a median follow-up of 33.9 months) 
(see Table 16). Safety and HRQoL findings for the subgroup of patients with advanced stage 
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CTCL are also similar to, and consistent with, those for the overall trial population (See 
Sections 4.8 and 4.9 of this ERG report).  
Table 16 Summary of key efficacy findings from the ALCANZA trial after median follow-up of 
33.9 months 
Outcome, population Summary of results 
ORR4 
ITT population Favours BV (n=64) versus PC (n=64): 60.9% versus 7.8%  
Advanced stage subgroup Favours BV (n=49) versus PC (n=46): 59.2% versus 8.7% 
PFS 
ITT population Favours BV (n=64) versus PC (n=64): 15.8 months versus 3.6 months 
Advanced stage subgroup Favours BV (n=49) versus PC (n=46): 16.5 months versus 3.5 months  
OS 
ITT population “no difference” between treatment arms 
Advanced stage subgroup “not possible to claim a difference” between treatment arms 
BV=brentuximab vedotin; ITT=intention-to-treat; ORR4=objective global response lasting ≥4 months; OS=overall survival; 
PC=physician’s choice; PFS=progression-free survival 
Note: ORR4 and PFS outcomes are per Independent Review Facility (note: data at 33.9 months were wrongly labelled as per 
investigator in the CS) 
Source: CS summary document, adapted from p13 and p16; CS, adapted from p68, p70, p78, p85 and pp89-90 
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4.12 Conclusions of the clinical effectiveness section 
The majority of the evidence is derived from the ALCANZA trial, an international, open-label, 
randomised, phase III, multicentre trial of treatment with BV versus PC (MTX or BEX) in 
patients with CD30+ CTCL (n=131). The ALCANZA trial is a well-designed and good quality 
trial. The company’s statistical approach to the analysis of data from the ALCANZA trial was 
appropriate, with the exception that the PH assumption required for the appropriate use of the 
Cox PH model is subject to uncertainty for PFS and time to subsequent anticancer therapy. 
Therefore, it is not possible to know whether the reported HRs overestimate or underestimate 
the effect of treatment with BV versus PC. 
The focus of the company’s decision problem is patients with advanced stage CTCL (n=95) 
as these are the patients considered by the company that would be candidates for treatment 
with BV in NHS clinical practice. The ERG concurs with this viewpoint. Moreover, the ERG 
notes that the results from the subgroup of patients with advanced stage CTCL in the 
ALCANZA trial are consistent with results from the overall ALCANZA trial population. 
The ERG considers that the patient characteristics for patients with advanced stage CTCL in 
the ALCANZA trial are reasonably similar to the characteristics of patients who would be seen 
in NHS clinical practice in England. Thus, the results from the ALCANZA trial are likely to be 
generalisable to patients in NHS clinical practice.  
The comparators (MTX and BEX) in the PC arm of the trial are two of the most commonly 
used therapies for NHS patients with MF who have had a median of two previous lines of 
systemic therapy, as was the case in the ALCANZA trial.  Clinical advice to the ERG is that (i) 
Category A therapies are the most relevant comparators to BV for patients with MF and (ii) 
Category B therapies would normally be preferred to Category A therapies for patients with 
advanced stages of pcALCL who have received at least one prior systemic therapy and are fit 
enough to tolerate the drugs. However, clinical advice is that MTX and BEX are likely to be 
appropriate comparators to BV for the patients included in the ALCANZA trial with 
pcALCL who were not fit for Category B drugs. As the ALCANZA trial did not include IFN-α as 
a treatment option in the PC arm, the company assessed the feasibility of indirectly comparing 
BV with IFN-α but concluded that this was not possible due to a lack of relevant data. Since 
IFN-α is commonly used before or after MTX or BEX in NHS clinical practice and since MTX, 
BEX and IFN-α are generally considered to have equal clinical efficacy, the lack of evidence 
to compare treatment with BV to IFN-α is not considered be a major limitation.  
The ALCANZA trial has shown that compared with PC, for patients with advanced stage 
CTCL, BV results in increased ORR4 and improved PFS; reflecting these improvements, 
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patients were treated with BV for longer than with MTX of BEX. However, median PFS may 
be overestimated in the BV arm due to the timing of assessments following EOT. The OS data 
from the ALCANZA trial are immature and confounded by subsequent anticancer therapy and 
crossover and so the relative effect of treatment on OS is unclear. ORRs for patients in the 
PC arm are also lower than have been previously reported in the literature, albeit they are 
typically from single-arm observational studies. The reasons for this discrepancy are unclear. 
The safety data from the ALCANZA trial show that for patients with advanced stage CTCL, 
treatment with BV was not associated with new or unexpected toxicities, the majority of 
reported AEs being grade 1 or grade 2 in severity. However, compared with patients treated 
with PC, more patients treated with BV reported any-grade TRAEs, TRSAEs and 
discontinuation due to AEs. Peripheral neuropathy is the most common AE associated with 
treatment with BV and is the most clinically significant. There were four on-treatment deaths 
in patients with advanced stage CTCL, all in the BV arm. However only one death was 
considered to be treatment related. The patient who died did not meet the trial eligibility criteria 
as the patient had elevated liver function test results at baseline and their enrolment, therefore, 
constituted a major protocol violation. 
Regarding HRQoL, patients with advanced stage CTCL treated with BV had a greater skin 
symptom reduction compared with those treated with PC, as measured by the Skindex-29 
questionnaire. This improvement is reported by the company to be clinically meaningful. 
However, there were no statistically significant or clinically meaningful differences in HRQoL 
reported from scores obtained by EQ-5D-3L or EQ-5D VAS.  
The relative efficacy of treatment with BV compared to PC for patients with subtypes of CTCL 
other than MF and pcALCL is uncertain as all patients in the subgroup of patients with 
advanced CTCL in the ALCANZA trial either had MF (n=64) or pcALCL (n=31). Evidence for 
other subtypes is limited to single-arm studies only. Given the rarity of CTCL, particularly for 
subtypes other than MF, obtaining evidence for the relative efficacy of patients with other 
CTCL subtypes is difficult. Consequently, cost effectiveness evidence is only available for 
patients with MF and pcALCL (see Section 5 of this ERG report). 
A final uncertainty with the evidence from the ALCANZA trial relates to the possible impact 
that prior treatment may have on efficacy, safety and HRQoL. While most patients (62%) in 
the subgroup of patients with advanced stage CTCL had received one (42%) or two (20%) 
prior systemic therapies, a quarter had received four or more prior systemic therapies. The 
maximum number of prior systemic therapies that patients had received was 11. 
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5 COST EFFECTIVENESS 
This section provides a summary and structured critique of the economic evidence submitted 
by the company in support of the use of BV. The two key components of the economic 
evidence presented in the CS are (i) a systematic review of relevant literature and (ii) a report 
of the company’s de novo economic evaluation. The company has also provided an electronic 
copy of their economic model, which was developed in Microsoft (MS) Excel. 
5.1.1 Objective of the company’s systematic review 
The company performed a systematic search of the literature to identify studies that evaluated 
the cost effectiveness of treatment, or provided costs and resource use estimates, for people 
with CD30+ CTCL who had received at least one previous treatment.  
5.1.2 Company searches 
The company initially searched the databases listed in The search strategies used are shown 
in Appendix G and are used to identify cost effectiveness studies and cost and resource use 
estimates. 
Table 17 in December 2017. These searches were updated on 23rd February 2018. The 
search strategies used are shown in Appendix G and are used to identify cost effectiveness 
studies and cost and resource use estimates. 
Table 17 Details of the databases searched for economic evidence 
Database Interface 
Excerpta Medica Database (Embase®)  Embase.com 
Medical Literature Analysis and Retrieval System Online (MEDLINE®)  Embase.com 
Cochrane Library (including the databases: HTA, NHS EED, DARE, CENTRAL and the 
Cochrane Database of Systematic Reviews Wiley.com 
EconLit® Ebsco.com 
CENTRAL=Cochrane Central Register of Controlled Trials; DARE=Database of Abstracts of Reviews of Effects; HTA=Health 
Technology Assessment; NHS EED=NHS Economic Evaluation Database;  
Source: CS, Appendix G 
The company also carried out electronic searches to identify relevant proceedings from 13 
conferences relating to haematology, oncology and dermatology which took place between 
2016 and 2018.  
Additionally, the company searched HTA websites (NICE, the Scottish Medicines Consortium 
[SMC], Haute Autorité de santé [HAS], Canadian Agency for Drugs and Technologies in 
Health [CADTH] and Pharmaceutical Benefits Advisory Committee [PBAC]) for relevant 
information contained within submissions to those organisations.   
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5.1.3 Eligibility criteria used in study selection 
The main inclusion and exclusion criteria used by the company to select studies are shown in 
Table 18 and Table 19. 
Table 18 Economic evaluation review inclusion and exclusion criteria 
Characteristic Inclusion Exclusion 
Population Patients with relapsed and/or 
refractory CTCL (defined according to 
the 2008 WHO classification) 
In vitro studies, animal studies 
Healthy volunteers 
Animal studies 
Intervention/comparators Not restricted by intervention - 
Outcomes Main outcomes:  
ICER: cost per QALY  
ICER: cost per DALY  
ICER: cost per event avoided  
 
Additional outcomes:  
Range of ICERs as per sensitivity 
analyses  
Assumptions underpinning model 
structures  
Key costs drivers  
Sources of clinical, cost and quality of 
life inputs  
Discounting of costs and health 
outcomes  
Model summary and structure 
Studies with no outcomes of interest 
Study types Economic models: 
Cost utility analyses  
Cost effectiveness analyses 
Cost benefit analyses 
Cost minimisation analyses 
Interventional or observational study 
designs (registry, chart review, 
administrative claims) 
Systematic literature reviews 
CTCL=cutaneous t-cell lymphoma; DALY=disability adjusted life years; ICER=incremental cost effectiveness ratio; QALY=quality 
adjusted life years; WHO=World Health Organisation.  
Source: CS, Appendix G, Table 28 
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Table 19: Resource use and cost review inclusion and exclusion criteria 
Characteristic Inclusion Exclusion 
Population Adult CD30+ CTCL in patients who 
have received at least one previous 
treatment (defined according to the 
2008 WHO classification [138]; 
updated in 2016 [139]) 
Studies reporting children, in vitro 
Not CD30+ CTCL in patients who 
have received at least one 
previous treatment 
Interventions/Comparators Not restricted by 
intervention/comparator 
NA 
Outcomes Direct costs 
Direct medical and pharmacy 
healthcare costs per patient per year 
(interventions, concomitant 
medications, treatment of AEs/co-
morbidities) 
Method of valuation  
Indirect costs 
Productivity loss costs 
Presenteeism: at work productivity 
level (also from patients’ viewpoint) 
Short- and long-term sick leave 
(absenteeism) 
Withdrawal from labour force 
Method of valuation (Human capital or 
friction cost approach or contingent 
valuation) 
Patient and family/caregiver costs 
Travel, co-payments 
Annual loss of income 
Formal and informal care 
Caregiver burden 
No cost or recourse information 
Study design Objectives of the study must include 
an assessment of costs of illness or an 
assessment of interventions in 
management of CTCL 
Studies reporting predictors of costs 
were considered for inclusion 
Studies that do not provide cost 
or resource use for the 
concerned population 
Not original studies  
AE=adverse events; CTCL=cutaneous t-cell lymphoma; WHO=World Health Organisation. 
Source: CS, Appendix I, Table 45 
 
5.1.4 Included and excluded studies 
The company search identified 4,312 unique citations, of which 37 remained after title and 
abstract screening. Details of the screening process and the reasons for study exclusions are 
presented in the CS (Section B.3.1 and Appendix G). 
For the review of economic evaluations at full-text stage, the majority (20/37) of abstracts are 
excluded as they did not contain any of the outcomes listed in Table 18. All but one of these 
are excluded based on a review of the full texts. One abstract is identified from the search of 
conference proceedings and 3 further publications are obtained from hand searching of HTA 
websites. This resulted in 5 publications included at full-text review (1/37 plus 4 from additional 
searches). Only one of these 5 articles, a submission to the SMC [140]. reported results for a 
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UK population with CTCL, This study is an evaluation of ECP which, as mentioned in Section 
2.3.2, is only recommended for use in patients with SS.  
The 37 full-text articles obtained from the literature search were reviewed for cost and resource 
use information relevant to the company economic model. All but two of these studies are 
excluded. An additional two papers were found through hand searching of the grey literature. 
None of the four articles reported resource use and cost information for people with CD30+ 
CTCL who have received at least one previous treatment in the UK, however one paper 
reported medical costs for people with MF in Italy and three papers contained information 
about resource use and costs relevant to people with CD30+ CTCL in the US.  
5.1.5 Findings from cost effectiveness review 
Economic evaluations 
The SMC guidance paper [140], includes a report of the evaluation that was undertaken to 
assess the cost effectiveness of ECP for people with CTCL compared with current standard 
treatment (ST). It is reported in the SMC paper that the results generated by an economic 
model with a 3-year time horizon suggest that ECP dominates ST, and the authors 
demonstrate that this finding is robust to sensitivity analyses (cost of treatment, survival and 
utility estimates). Total costs for ECP are £39,580 and £94,452 for ST and total quality 
adjusted life years (QALYs) are 3.40 for ECP and 1.63 for ST. The company presents results 
in the CS (Tables 23 and Table 24) but states there are not enough details of the methods or 
parameters used reported in the paper to be enable to use in their economic model  
Resource use and costs 
The company describe the information contained in four the papers providing resource use 
and costs information (CS, Appendix I, Table 46). However, as none of the studies include UK 
resource use or costs information, and therefore lack relevance to the NHS, the company do 
not use any of these estimates in their model. 
5.1.6 ERG critique of the company’s review of cost effectiveness 
evidence 
Summary details of the ERG’s appraisal of the company’s cost effective systematic review 
methods are provided in Table 19. 
The ERG considers the databases searched and the search terms used by the company are 
reasonable. The inclusion criteria, with respect to the population of interest, differ between the 
economic evaluation review and the review that was carried out to source resource use and 
cost information to inform the economic model. The ERG considers this approach is 
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appropriate as the economic evaluation review is designed to locate economic evaluations of 
relevance to the population defined in the final scope issued by NICE, whereas the resource 
use and cost information review is specific to the narrower, advanced stage CTCL population, 
that the company describes in the CS.  
The ERG considers that although the SMC guidance paper [140] met the review inclusion 
criteria specified by the company it is not relevant to this appraisal. This is because ECP is 
not listed as a comparator to BV in the final scope issued by NICE, and because the focus of 
the company model is people with MF and, to a lesser extent, pcALCL, and ECP is used to 
treat people with SS.  
Table 20 ERG appraisal of systematic review methods (cost effectiveness) 
Review process ERG response 
Was the review question clearly defined in terms of population, 
interventions, comparators, outcomes and study designs? 
Unclear. The search terms 
appear reasonable however the 
economic search filter is 
complicated and not cited so the 
ERG is unclear whether this filter 
has been tested. 
Were appropriate sources searched? Yes 
Was the timespan of the searches appropriate? Yes – ran in December 2017 and 
then updated in February 2018 
Were appropriate search terms used? Yes 
Were the eligibility criteria appropriate to the decision problem? Yes 
Was study selection applied, independently, by two or more 
reviewers? 
Yes 
Were data extracted, independently, by two or more reviewers? Yes  
Were appropriate criteria used to assess the quality of the primary 
studies? 
Yes 
Was the quality assessment conducted, independently, by two or 
more reviewers? 
Unclear – whether data 
extraction was conducted by two 
or more reviewers 
Were any relevant studies identified? One study was identified, 
although the ERG consider it 
lacks relevance to the decision 
problem.  
Source: LRiG Checklist 2017 
 
5.2 ERG summary of the company’s submitted economic evaluation 
The company developed a de novo economic model to compare the cost effectiveness of 
treatment with BV versus treatment with PC (MTX or BEX) in adults with advanced stage 
CTCL who had had at least one previous treatment. 
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5.2.1 Model structure 
The company developed a partition survival model in MS Excel. The model structure 
comprises five mutually exclusive health states (see Figure 4). It includes two different 
pathways which are only differentiated by the inclusion of alloSCT in one of the pathways.  
At baseline, the whole model population is in the pre-progression health state and is in receipt 
of BV or PC. Patient eligibility for an alloSCT is based on response to treatment in the pre-
progression health state. All eligible patients move to the Allogeneic stem-cell transplant (SCT) 
health state at 18 weeks. On disease progression patients transition to the Non-SCT post-
progression or Allogenic SCT relapse states. The resource use and costs in these two post-
progression states are assumed to be the same, with the exception of the use of TSEB as a 
subsequent anticancer therapy, which is excluded from the Allogenic SCT relapse state as 
the patients receiving an alloSCT are assumed to have had TSEB therapy as part of their pre-
alloSCT conditioning regimen. 
Patients in the post-progression health states (Non-SCT post-progression and Allogenic SCT 
relapse) receive subsequent therapies for a defined period of time and then progress to end 
stage symptom management, where they remain until death.  
 
Figure 4 Health state structure of the company model 
Source: CS summary document, Section A.10 (Figure 6); CS, Section B.3.2.3 (Figure 38)  
 
5.2.2 Population 
The company model population is patients with advanced stage CTCL (MF Stage IIB or 
greater, and patients with pcALCL) previously treated with at least one systemic therapy. The 
focus on patients with advanced stage CTCL disease is narrower than the population 
described in the final scope issued by NICE. At baseline, the mean age of the cohort (57.1 
years), the percentage of females (47.83%) and other baseline characteristics reflect the 
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characteristics of the subgroup of patients in the ALCANZA trial with advanced stage CTCL 
(approximately 75% of the overall trial population). 
5.2.3 Interventions and comparators 
Intervention 
The EMA [63] licensed dosing regimen for BV is 1.8mg/kg IV infusion administered every 3 
weeks for up to a maximum of 16 cycles (48 weeks). The use of BV is estimated in the 
company model using data from the ALCANZA trial, a method of moments calculation to 
account for wastage and a relative dose intensity of 95%. In the ALCANZA trial, if patients’ 
disease progressed before 48 weeks then treatment was stopped on disease progression. 
Time-on-treatment (ToT) data from the ALCANZA trial are used directly in the model. 
Comparators 
In the final scope issued by NICE, it is stated that the comparator should be established clinical 
management without BV. The company uses data from the PC arm (MTX or BEX) of the 
ALCANZA trial to populate their model. MTX is administered in tablet form once a week. The 
licensed prescribed dose ranges from 5-50mg and the company model uses the mean dose 
in the ALCANZA trial of 23.44mg once a week. BEX is also administered in tablet form with a 
recommended dose of 300mg/m2 and tablets taken once a day. The dose in the company 
model is based on a method of moments calculation of the drug usage in the ALCANZA trial 
and a dose intensity of 90%. ToT data from the ALCANZA trial are used directly in the model. 
The company states that IFN-α is commonly used in NHS practice and, therefore, is a relevant 
comparator. However, the company was unable to locate any (direct or indirect) evidence 
comparing treatment with IFN-α versus BV for the population of interest and, therefore, 
treatment with IFN-α is not included in the company’s economic model. 
Upon progression patients are treated in the economic model with active therapies which 
include chemotherapy and TSEB. 
5.2.4 Perspective, time horizon and discounting 
The company states that the economic evaluation is undertaken from the NHS perspective. 
The cycle length is 1-week and the model time horizon is set at 45 years. Both costs and 
outcomes are discounted at 3.5% per annum, in line with the NICE Reference Case [73], and, 
due to the short cycle length, a half-cycle correction is not used. 
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5.2.5 Treatment effectiveness and extrapolation in the base case 
The company model is populated with clinical effectiveness data from the ALCANZA trial (33.9 
months median follow-up). The ALCANZA trial did not contain any data that could be used to 
inform the clinical pathway of people undergoing an alloSCT, nor provide alloSCT outcomes. 
The company, therefore, used evidence from the supra-regional centre based in London [37] 
to generate estimates for these parameters. 
Progression-free survival 
In the company economic model reflects disease progression, as established by the 
ALCANZA trial IRF. 
The company report that the log-cumulative hazard plot and the quantile-quantile plot suggest 
that the PH assumption is not valid for IRF assessed PFS. Six standard parametric models 
were fitted to each arm of the ALCANZA trial K-M data (see Figure 5). Goodness of fit was 
assessed visually and also using the Akaike Information Criterion (AIC) and Bayesian 
Information Criterion (BIC), with the final specification based on clinical advice. In the base 
case, separate Weibull parametric curves are used to estimate PFS for both the BV and PC 
model arms.  
 
Figure 5: ALCANZA trial PFS K-M data and fitted parametric survival curves 
BV=brentuximab vedotin; KM=Kaplan-Meier; PFS=progression-free survival; PC=physician’s choice 
Source: CS, figure 40 
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Overall survival 
The OS data from the ALCANZA trial are immature and are considered unreliable due to both 
the small number of events and the high proportion of patient crossover. The company 
attempted to adjust OS estimates for crossover; however, none of the methods used produced 
clinically plausible results. The company then assume that, in the model, unadjusted OS data 
for patients in the PC arm of the trial could be used to represent OS for all patients. The clinical 
experts consulted by the company supported this assumption as trial results showed that, 
compared with PC, treatment with BV delivered no definitive OS benefit. 
The company fitted six parametric models to OS data from each am of the ALCANZA trial. 
The AIC and BIC goodness-of-fit values were used initially to identify the survival model with 
the best statistical fit to the trial data. The company’s preferred model is, however, chosen 
based on clinical plausibility and on how closely the parametric curves aligned with historical 
data collected from UK patients with advanced stage MF and SS [8, 26]. The log-logistic 
parametric model is considered to have the best fit and is used in the company’s base case 
analysis. The OS extrapolations and one of the validation datasets [26] are shown in Figure 
6.  
 
Figure 6 OS ALCANZA trial K-M data, extrapolations and published data [26] 
BV=brentuximab vedotin; K-M=Kaplan-Meier; OS=overall survival; PC=physician’s choice; PSM=parametric survival model 
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Time on treatment  
Patients could only receive BV or PC for a maximum of 48 weeks. Extrapolation of ToT is not 
required as the ToT data are complete. However, adjustments are made to the data to enable 
it to fit within the model 1-week cycle framework, i.e., transitions were modelled to occur at the 
end of each weekly cycle rather than on the actual day on which they occurred. The company 
states that the impact of this adjustment is negligible. 
AlloSCT outcomes 
The company states that alloSCT is an option for people with refractory CTCL but eligibility for 
the procedure primarily depends on the fitness of the individual. Level of fitness encompasses 
age, health issues and how well the individual has responded to CTCL treatment. Data from 
people attending the London supra-regional centre for CTCL [37] to receive an alloSCTs are 
used to estimate alloSCT outcomes in the company model. The company assumes that all 
patients who receive a transplant do so at 18 weeks, this assumption is based on advice to 
the company from clinical experts. 
Patients eligible for alloSCT  
The ORR results from the ALCANZA trial show that 68.8% and 17.8% for patients treated with 
BV and PC respectively, achieved a partial or complete response to treatment. In the company 
base case it is assumed, based on clinical advice, that 40% of patients showing at least a 
partial response to treatment, as measured by the ORR, are eligible for an alloSCT. As a 
consequence, in the company base case, 27.5% of patients treated with BV and 7.11% of 
people treated with PC are modelled to have an alloSCT.  
Post-alloSCT disease-free survival 
The company digitised K-M disease-free survival (DFS) data, from the London supra-regional 
centre [37], for patients who had had minimal intensity alloSCT (following the Stanford Protocol 
for bridging therapy) and fitted six parametric models to these data. The goodness of fit of the 
curves is determined using the AIC and BIC statistics, visual examination and an assessment 
of clinical plausibility. The company states that the K-M data suggest that there is a decreasing 
probability of relapse for approximately the first 12 months and that beyond 12 months no 
relapses occur. Clinical advice to the company supported this view and the company, 
therefore, used the Gompertz model, which follows this specification, in their model (see 
Figure 7).  
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Figure 7 Post-alloSCT disease-free survival curves 
DFS=disease-free survival; alloSCT=allogeneic stem-cell transplant; PSM=parametric survival model 
Source: Company model 
 
Post-alloSCT overall survival 
The company estimated survival after an alloSCT using digitised post-alloSCT OS data from 
the London supra-regional centre [37]. Six parametric curves (exponential, Weibull, Gompertz, 
generalised gamma, log-normal and log-logistic) were fitted to the data, and goodness of fit 
was assessed using the AIC and BIC statistics, visually and clinical opinion. The company 
states that the OS data demonstrate a long-term remission plateau for disease-free patients, 
as shown in the DFS data, but also that worse outcomes are expected for those people who 
have relapsed. The company chose a log-normal model to represent post-alloSCT survival as 
it considered that it most appropriately captured the available DFS K-M data. 
In the company model, the DFS and OS curves converge at 12.8 years, which implies that all 
patients who had relapsed had died by this point. This is much shorter than survival in the 
progressed health state without an alloSCT, which can be up to 25 years; however, clinical 
advice provided to the company was that this was the most clinically plausible of the estimated 
parametric curves presented to them by the company. Figure 8 depicts the estimates used in 
the company economic model. 
DFS 
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Figure 8 Modelled post-alloSCT DFS and OS 
alloSCT=allogenic stem-cell transplant; BV=brentuximab vedotin; DFS=disease-free survival; OS=overall survival;  
Source: CS, Section B.3.3.4.3 Figure 51 
 
5.2.6 Health-related quality of life 
The EQ-5D-3L, the Skindex-29 symptom domain and the FACT-G were used, in the 
ALCANZA trial, to collect data HRQoL data and the company conducted a literature searches 
to identify HRQoL studies. However, they were unable to find any studies that evaluated 
HRQoL using either the EQ-5D-3L or EQ-5D-5L tool in populations of people with CD-30+ 
CTCL. 
Utility values, estimated from a longitudinal mixed-effects regression model are used in the 
company base case, with the EQ-5D-3L tariff values for the advanced stage CTCL population 
as the dependent variable. A stepwise selection process was used to derive the best model 
specification which included progression status and Skindex-29 symptom domain score as 
the explanatory variables. Goodness of fit was assessed using the AIC and BIC statistics, the 
clinical plausibility of the estimates and by comparing the predicted results to the utility values 
collected during the ALCANZA trial. In the company base case the PFS utility values differ by 
treatment.  
The company use a published estimate [141] to reflect the HRQoL of people in the end-stage 
management state. Due to the absence of evidence, general post-alloSCT utility values are 
used in the company model. Post-progression HRQoL is assumed to be the same for all 
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patients regardless of transplant status. A summary of the utility values used in the company 
model is provided in Table 21.  
Table 21 Summary of utility values used in the company model 
State Utility value: 
mean (standard 
error) 
95% CI Source Justification 
PFS – BV  0.68 0.62 to 0.76 ALCANZA trial Utility regression based 
on phase III trial 
PFS - PC 0.64 0.57 to 0.72 ALCANZA trial Utility regression based 
on phase III trial 
SCT  
(0-14 days) 
0.42 0.38 to 0.46 Van Agthoven et al 
2001 [142] 
No CTCL source; 
selected source is well-
recognised for alloSCT 
HRQoL 
SCT  
(14 days – 3 
months) 
0.60 0.54 to 0.65 Van Agthoven et al 
2001 [142] 
No CTCL source; 
selected source is well-




0.77 0.69 to 0.84 Van Agthoven et al 
2001 [142] 
No CTCL source; 
selected source is well-
recognised for alloSCT 
HRQoL 
PD 0.61 0.52 to 0.70 ALCANZA trial Utility regression based 





0.38 0.33 to 0.44 Swinburn et al 2015 
[141] 
No CTCL source; 
Swinburn is based on 
closest related 
lymphoma  
alloSCT=allogenic stem-cell transplant; CI=confidence interval; CTCL= cutaneous t-cell lymphoma; HRQoL= health-related 
quality of life; PD=progressive disease; PFS=progression-free survival;  
Source: CS, Section B.3.4.6. Table 41 
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5.2.7 Adverse events 
Treatment related grade 3 or 4 AEs experienced by at least 5% of the total ALCANZA trial 
population are included in the company model. In addition, following clinical advice to the 
company, all treatment related incidences of septicaemia and peripheral neuropathy are also 
included in the model.  
Experiencing an AE is assumed to result in a decrement to HRQoL. The company has linked 
each AE with a utility decrement selected from a targeted review of NICE appraisals of 
treatments for lymphoma indications. In the absence of an estimate for a specific AE, the 
disutility estimate from a comparable AE is applied. The incidence of each AE is sourced from 
the ALCANZA trial and used to calculate a weekly rate of occurrence. Information on the 
duration of each AE is taken by pooling duration of each of the adverse events across 
treatment arms from the ALCANZA trial. A per cycle rate for each AE is calculated using the 
pooled durations and, separately for BV and PC, the total time on treatment. This AE rate is 
then used to calculated AE costs and AE associated utility decrements.  
Table 22 shows the adverse event rates and the disutility values used in the company model.
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Table 22 Summary of adverse event utility decrements used in the company economic model 
Adverse event Number of 
events 
Duration (days) Disutility Assumptions Source of disutility 
value 
BV PC  Mean SD 
Blood and lymphatic 
system disorders 
6 4 15.5 16.6 -0.10 Reported for anaemia Beusterien et al 2010 
[143] 
Gastrointestinal disorders 7 0 10.7 8.7 -0.103 Reported for diarrhoea Lloyd et al 2006 [144] 
General disorders and 
administration site 
conditions 
4 0 81.8 135.8 -0.07 Assumed equivalent to fatigue Nafees et al 2008 
[145] 
Multiorgan failure 1 0 1.0 1.0 -0.20 No decrement available assumed equivalent to grade III/IV 
pneumonia and associated with significant decrement 
Beusterien et al 2010 
[143] 
Infections and infestations 3 0 26.0 17.7 -0.14 Reported as severe skin condition Brown et al 2001 [146] 
Septicaemia 0 1 20.0 20.0 -0.20 No decrement available assumed equivalent to grade III/IV 
pneumonia and associated with significant decrement 
Beusterien et al 2010 
[143] 
Peripheral neuropathy 7 0 258.0 301.1 -0.11 Assumed to be grade 1/2 peripheral sensory neuropathy Swinburn et al 2015 
[141] 
Skin and subcutaneous 
tissue disorders 
0 0 0.0 0.0 -0.03 Equivalent to rash Nafees et al 2008 
[145] 
Investigations 0 6 18.2 5.2 0 Assumed 0 NA 
Hypertriglyceridemia 0 9 50.9 81.7 0 Assumed 0 NA 
BV=brentuximab vedotin; PC=physician’s choice; SD=standard deviation; NA=not applicable 
Source: CS, adapted from, Tables 33 and 40 
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Clinical opinion was used by the company to estimate the proportion of each of the AEs 
requiring treatment, and the setting in which that treatment took place. The assumptions used 
in the company model are shown in Table 23.  
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************************************** **** *** *** *** *** 
************** *** ** ** **** ** 
******************** **** ** ** **** ** 
Source: company model 
The unit costs as detailed in Table 24, are sourced from NHS Reference Costs (2016/2017) 
[147]. Unit costs are applied to cycle event probabilities from the ALCANZA trial to produce 
AE cycle costs of £4.97 and £5.99 for patients treated with BV and PC respectively. 
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Table 24 Adverse event unit costs assumptions in the company model 
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Source: Company model 
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5.2.8 Resources and costs 
Pre-progression health state  
Drug costs 
Estimates of the quantity of BV, MTX and BEX used per patient, per week, and the split 
between the proportions of patient receiving MTX and BEX are estimated using ALCANZA 
trial data. Resource use estimates for these drugs took account of adherence. The resource 
use estimates for BV took account of patient weight and the estimates for BEX took account 
of body surface area. Vial sharing is not assumed to occur.  
When generating results, a confidential PAS discount (CS summary document, Table 1; CS, 
Table 2) is applied to the list price of BV. The cost of MTX is taken from the drugs and 
pharmaceutical electronic market information tool (eMIT) [149]. A cost for BEX is not available 
from eMIT and, therefore, it is taken from the monthly index of medical specialties (MIMs) 
[150, 151]. 
MTX and BEX are taken orally. The cost, used in the company model, to reflect the cost of 
administering these treatments is the NHS Reference Outpatient Cost ‘Delivery of exclusively 
oral chemotherapy’, (£163.82 per week) [147]. 
BV is administered via IV infusion and the cost, used in the company model, to reflect the 
treatment administration cost is the NHS Reference cost ‘Delivery of simple chemotherapy, 
£173.99 per dose [147]. 
Company model drug cost details are presented in Table 42 of the CS and reproduced in 
Table 25 
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Table 25 Drug formulation, dose, administration, proportion of doses received and total drug 


















BV *************** ******c **** **** *** ********* 
MTX *************** ***** ** **d* ******************** ***** 
BEX ******************* ******* *** **** *** ******* 
BEX=bexarotene; BV=brentuximab vetodin; MTX= methotrexate; IV=intravenous; Q3W=once every 3 weeks; Q1W=once a week  
a Based on data from the ALCANZA trial 
b Although costs in the table are provided by week, the model costs BV per administration, i.e. a single cost is applied every 3 
weeks  
c PAS price 
d Based on mean dose in ALCANZA trial of 23.44mg 
Source: CS, adapted from, Table 42 and economic model 
Resource use 
The resource use estimates for people in the pre-progression health state are derived from 
treatment protocols from the London Cancer Alliance (LCA) skin systemic anticancer therapy 
(SACT) database [152] and expert opinion. In the company model, a cost of £388.63 per 
weekly cycle per patient is applied in the pre-progression health state. Details of the individual 
resource use elements that are used to calculate the total pre-progression health state cost 
per cycle are provided in Table 26.  
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Table 26 Resource use in the pre-progression health state 








Hospital outpatient   
Clinical nurse 
specialist 
100.00% 0.19 N/A N/A £16.39 NHS Ref Costs 2016/17 [147] WF01A:370 Total outpatient attendances, Non-consultant 
led,  Medical oncology 
Oncologist 
outpatient visit 





100.00% 0.19 £33.05 NHS Ref Costs 2016/17 [147] WF01A:370 - Total outpatient attendances, Consultant led,  
Medical oncology 
Home visit   
District nurse 100.00% 2.60 N/A N/A £96.01 NHS Ref Costs 2016/17 [147] - N02AF Total Other Currencies, District Nurse, Adult, Face 
to face 
Investigations and tests   
Complete 
blood count 
100.00% 0.25 N/A N/A £0.77 NHS Ref Costs 2016/17 [147] - DAPS05 Haematology 
Liver function 
test 
100.00% 0.25 £3.15 NHS Ref Costs 2016/17 [147] - DAPS09 Other - 5 tests required  
U&Es 100.00% 0.25 £0.28 NHS Ref Costs 2016/17 [147] - DAPS04 Clinical Biochemistry 
CT scan 50.00% 0.08 £5.10 NHS Ref Costs 2016/17 [147] - RD26Z, Total HRGs, CT Scan of Three Areas, with 
Contrast 
Imaging - PET 50.00% 0.08 £19.94 NHS Ref Costs 2016/17 [147] -RN07A -Positron Emission Tomography (PET), 19 years+ 
Dressings   
Full body 
coverage 
0.00% 0 0 Dressings £0.00 The use of various sizes of allevyn, mepitel and mepilex dressings are assumed along with 
elasticated vest and leggings garments. The costs are all sourced from the BNF. 
Localised 
coverage 
60.00% 7 7 Dressings £183.75 
PET=positron emission tomography; U&Es= urea and electrolytes test; CT=computed tomography, NHS Ref Costs= NHS Reference Costs            
Source: CS, adapted from Section B.3.5.2 Table 45 and company model 
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AlloSCT resource use and costs 
The company states that an accurate estimate of the cost of an alloSCT is difficult to obtain. 
They use an estimate from a French study by Debals et al 2018 [153] which includes 
procedural costs and the cost of follow-up for 2 years. The estimate of £96,956 used in the 
company model is derived by converting the published cost into pound sterling and uplifting 
the cost to current prices using the PSSRU hospital and community health service (HCHS) 
inflation index [148].  
Post-progression health state 
In the company model, the post-progression health state is split into two phases. During the 
first phase, patients receive subsequent active therapy for CTCL; the second phase starts 
when all active therapeutic options have been exhausted.  
Data from the ALCANZA trial are used to estimate the total time spent in the post-progression 
health state and then a payoff approach is used to split this time into two phases. Mean costs 
and QALYs for active subsequent therapy and end-stage care are multiplied by the time spent 
in those phases and then summed to give mean costs and QALYs for the whole post-
progression state. The company state that the payoff approach prevents the need for tunnel 
states whilst enabling time-dependent transitions from the subsequent active therapy phase 
to the end-stage care phase of the post-progression health state. 
For people ineligible for an alloSCT, time spent in the post-progression health state is 
estimated as the area between the PFS and OS curves. The first phase is fixed at 1.86 years 
for people who have not had an alloSCT and the resource use in this time period includes the 
costs of chemotherapy and TSEB treatments, as well as costs associated with hospital visits, 
district nurse home visits, investigations and tests, and other drug treatments (for example, for 
pain relief). The resource use that is in addition to the subsequent active drug therapy is 
assumed to be the same for everyone regardless of whether they had an alloSCT. The details 
of the resource use and cost assumptions are shown in Appendix 7, Section 9.7, Table 43 
For people who had undergone an alloSCT, the area between OS post-alloSCT and alloSCT 
DFS curves are used to estimate the time spent in the post-progression health state. The first 
phase in post-progression for this group is treatment with chemotherapy and excludes TSEB 
treatment as it is assumed that these patients would have received TSEB as part of their 
alloSCT. This time period for the subsequent active therapy phase of the post-progression 
health state is set at 0.94 years for post-alloSCT patients. During this time resource use that
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 is in addition to chemotherapy and its delivery is also included, as shown in Appendix 7, 
Section 9.7, Table 43. 
Although the first phase in post-progression differs in duration according to whether or not the 
patients received an alloSCT, the resource use and costs estimates following this first phase 
are the same for both groups. End-stage care forms the second phase of the post-progression 
health state and includes the resource use and costs of hospital visits, home visits, 
investigations and tests and drug treatments for pain relief or depression for example. The 
details of the company’s End stage care phase resource use assumptions are shown in 
Appendix 7, Section 9.7, Table 44. 
Post-progression active therapy phase: resource use and costs 
The active therapies used as a third-line and subsequent treatments for people with CTCL are 
estimated from an international registry of data collected from people with CTCL, the 
Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study [61]. 
Durations of treatment and response are sourced from the London Cancer Alliance (LCA) skin 
systemic anticancer therapy (SACT) protocols [152]. Table 27 shows the resource use and 
cost estimates for third line and subsequent active therapies. The dosing regimen and costs 
for ‘other mono chemotherapy’ are assumed, ********************************************* to be 
for treatment with ************************************************ Patients may receive treatments 
more than once and hence total proportions exceed 100%. The cost of the drugs used as third 
and subsequent lines of therapy are taken from eMit [149], where available and, if not 
available, are taken from MIMs [154-159].
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Table 27 Drug formulation, dose, administration, proportion of doses received and total drug 



























IV D1, D8, 
D15 in q28 
days 
   £54.63 *** 16.00 £655.55 
£2.97 200mg 2.00     
£7.75 1000mg 0.53     
£26.12 2000mg 2.40     
CHOP IV; D1, D8, 
D15 
   £21.69 *** 9.00 £54.66 
Cyclophosphamide 750 mg/m2 £139.00 50mg/100 28.68 £13.29    
Hydroxydaunorubicin 50 mg/m2 £1.34 10mg/5 1.78 £2.76    
£3.63 50mg/5 1.62    
Oncovin 
 
1.4ml/ m2 £15.64 1ml/5 0.83 £2.89    
£26.59 2ml/5 1.14    
Prednisolone 
 
100mg £23.15 25mg/56 4 £2.76    





£360.23 20mg 2  ***a   
Chlorambucil Oral, daily, 
0.2mg/kg 
£42.87 2mg/25 7  ***a   







    









£3,475.95 N/A 8 £72.67 **** 47.83b £3,475.95 
CHOP=Cyclophosphamide, Hydroxydaunorubicin, Oncovin & Prednisolone; D=day; DOR=duration of response; IV=intravenous; 
N/A=not applicable;; Q2W=once every 2 weeks;  
 a*******************************************************************************  
b=includes the assumption of 11 months duration of response 
Source: CS, adapted from, Tables 46 and 47  
The resource use estimates for people receiving active therapy in the post-progression health 
state are summarised in Table 43 (Appendix 7, Section 9.7). The company generated these 
estimates based on information from the LCA SACT [152] protocols and expert opinion. The 
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duration of post-progression active therapy is estimated as almost 97 weeks. The weekly cost 
in the model for resource use during the post-progression active therapy phase is **************. 
Post-progression End-stage management phase:  
In the absence of published or trial estimates of the resource use for people with CTCL in the 
End-stage management phase, the company conducted semi-structured interviews with 
clinicians who are responsible for the end-stage management of patients in the seven supra-
regional centres for treating CTCL in England, and the Welsh centre in Cardiff. The purpose 
of the interviews was to obtain estimates of levels of resource use that arise as a consequence 
of pain, anxiety and depression, itch relief, skin care and wound management. Further details 
of this exe cise can be found in the CS, Appendix L. Details of the resource use and cost 
estimates for end-stage CTCL management used in the model (£2,095 per weekly cycle per 
patient) are provided in Table 44 (in Appendix 7, Section 9.7). These costs include hospital 
outpatient appointments, tests and scans, care giver visits to the patients’ home (for example, 
as Macmillan nurses and social care), as well as specialist dressings (for example, mepilex 
and allevyn) for wound care, and medications.  
Cost of death 
In addition to the end-stage resource use, the company model also includes the cost of generic 
oncology end-of-life care (£286 per week) applied to patients while in the end stage phase of 
the post-progression health state [160]. 
5.2.9 Cost effectiveness results 
Base case results from the company’s model, Table 28, show that treatment with BV 
generates an additional *** QALYs at a cost saving of ******** compared with treatment with 
PC. This makes BV the dominant treatment. 
Table 28 Base case fully incremental cost effectiveness results (PAS price for BV) 






Incremental  Incremental cost 
per QALY gained 
Cost  LYG QALYs 
PC ******** 7.23 **** 
BV ******** 8.43 **** ********* 1.20 **** BV dominates 
LYG=life year gained; PAS= Patient access scheme; PC=physician’s choice; QALY=quality adjusted life year 
Source: CS, adapted from summary document, Section A.13 Table 7; CS, Section B.3.7.1 Table 51 
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5.2.10 Sensitivity analyses 
Deterministic sensitivity analysis 
The company performed one-way sensitivity analysis (OWSA) on many of the variables 
included in the economic model. The parameter values are varied according to the 95% CIs 
of the distributions. Where Cis were not available ±10% of the mean value are used to set the 
bounds of the range. The company’s OWSA results show that the cost of CTCL end-stage 
care, the utility value assigned to patients 3 months post alloSCT, the cost of medium allevyn 
dressings and the choice of utility associated with the end stage care phase of the post-
progression health state have the greatest impact on the size of the ICER per QALY gained 
for the comparison of treatment with BV versus PC (see Figure 9).  
Figure 9 Tornado diagram showing OWSA results for BV versus PC including PAS 
CTCL=cutaneous T-cell lymphoma; HSUV=health state utility values; ICER=incremental cost-effectiveness ratio; SCT=stem-
cell transplant; 
Source: Company economic model 
 
Probabilistic sensitivity analysis 
Most of the input parameters are varied in the company probabilistic sensitivity analysis. The 
largest group of parameters not varied are the proportions of patients treated in each setting 
for AEs, e.g., general practice or as an inpatient. Figure 10 shows the uncertainty around the 
estimated mean cost per QALY difference between treatment with BV versus treatment with 
PC. The mean probabilistic ICER per QALY gained demonstrated that treatment with BV 
dominated treatment with PC. However, although the mean incremental QALYs generated by 
the PSA are similar to the deterministic results, there is a difference of almost **********
-£160,000 -£140,000 -£120,000 -£100,000 -£80,000
Post-progression - CTCL specific end stage care
HSUV - SCT (beyond 3 months)
Medium Allevyn dressings
Post progression utility (Swinburn et al. 2015)
Treatment as two groups BV/PC: Mean Skindex pre progression BV
Round et al. 2015
Palliative care support team
Cost of SCT
Mepilex large sheet dressings
Pre-progression
Lower bound Upper bound
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between the mean incremental costs generated by the two analyses 
*************************************************************************).  
 
Figure 10 Scatter plot showing cost effectiveness of treatment with BV versus PC (5,000 
iterations) 
Source CS, Section B.3.8.1 Figure 56 
QALY=quality adjusted life years 
Figure 11 shows the probability of treatment with BV being the most cost effective treatment 
option at a willingness-to-pay threshold of £30,000 per QALY is 91.38%. 
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Figure 11 Cost effectiveness acceptability curve of treatment with BV vs PC 
Source: CS Figure 57 
5.2.11 Scenario analyses 
The company presents the results of a number of scenario analyses, grouped by key areas 
(CS, Tables 54-58). In all of the scenarios treatment with BV dominates PC. 
5.2.12 Model validation and face validity check 
The company states that input from clinical experts was sought during model development to 
ensure that the model was built to reflect clinical reality. Additionally, a checklist designed to 
highlight modelling errors and assess assumptions was used and an economist not involved 
in building the model checked for coding errors and validated the model.
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5.3 ERG detailed critique of company economic model 
5.3.1 NICE Reference Case checklist 
Table 29 NICE Reference Case checklist completed by the ERG 
Attribute Reference case 
Does the de novo economic evaluation 
match the reference case? 
Defining the decision 
problem 
The scope developed by NICE Partial. The population considered in the 
economic model submitted by the 
company is a subgroup of the population 
(patients with advanced stage CTCL) 
described in the final scope issued by 
NICE. 
Comparator(s) As listed in the scope developed by NICE Partial. The company presents 
comparator (MTX or BEX) evidence from 
the PC arm of the ALCANZA trial. IFN-α 
is also used in UK clinical practice to treat 
patients with advanced stage CTCL after 
one previous treatment. The company 
conducted a literature search to identify 




All direct health effects, whether for 
patients or, when relevant, carers 
Yes 
Perspective on costs NHS and PSS NHS perspective taken, unclear if all PSS 
costs are considered. 
Type of economic 
evaluation 
Cost utility analysis with fully incremental 
analysis 
Yes 
Time horizon Long enough to reflect all important 
differences in costs or outcomes between 
the technologies being compared 
Yes 
Synthesis of 
evidence on health 
effects 
Based on a systematic review N/A  
Measuring and 
valuing health effects 
Health effects should be expressed in 
QALYs. The EQ-5D is the preferred 
measure of HRQoL in adults. 
Yes 
Source of data for 
measurement of 
HRQoL 
Standardised and validated instrument. 
The EQ-5D is the preferred measure of 
HRQoL in adults 
Partial – EQ-5D-3L utility values obtained 
from the ALCANZA trial were adjusted to 
take into account the Skindex-29 
symptoms domain score and progression 
status of patients. 
Source of preference 
data for valuation of 
changes in HRQoL 
Reported directly by patients and/or carers Yes 
Equity 
considerations  
An additional QALY has the same weight 
regardless of the other characteristics of 
the individuals receiving the health benefit 
Yes
Evidence on 
resource use and 
costs 
Costs should relate to NHS and PSS 
resources and should be valued using the 
prices relevant to the NHS and PSS 
Yes 
Discounting The same annual rate for both costs and 
health effects (currently 3.5%) 
Yes  
BEX=bexarotene; BV=brentuximab vetodin; EQ-5D-3L=EuroQol-5 dimension-3 level; HRQoL=health-related quality of life; 
MTX=methotrexate; NMA=network meta-analysis; PC=physician’s choice; PSS=Personal Social Services; QALY=quality 
adjusted life year 
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5.3.2 Drummond checklist  





Was a well-defined question posed in 
answerable form? 
Yes  
Was a comprehensive description of the 
competing alternatives given? 
Yes  
Was the effectiveness of the programme 
or services established? 
Partial The evidence is based on a post-hoc analysis of a 
subgroup of patients with advanced stage CTCL in 
the ALCANZA trial; OS data from this patient 
subgroup are based on small numbers of patients 
and events, are immature, are confounded by 
treatment crossover and do not show a statistically 
significant OS difference in favour of BV compared 
to PC. However, the company states that 
improvement in survival was not the treatment goal 
for this group of patients. 
Were all the important and relevant costs 
and consequences for each alternative 
identified? 
Yes  
Were costs and consequences 
measured accurately in appropriate 
physical units? 
Yes  
Were the cost and consequences valued 
credibly? 
Partial QALYs in the company base case were estimated 
using utilities calculated from a regression model 
incorporating two HRQoL measures (EQ-5D-3L 
and Skindex-29 symptom domain). Incorporating 
two different measures in this way means that the 
QALYs generated are not comparable with the 
QALYs estimated in other appraisals using the 
EQ-5D-3L method only. 
Were costs and consequences adjusted 
for differential timing? 
Yes  
Was an incremental analysis of costs 
and consequences of alternatives 
performed? 
Yes  
Was allowance made for uncertainty in 
the estimates of costs and 
consequences? 
Yes  
Did the presentation and discussion of 
study results include all issues of 
concern to users? 
Yes  
BV=brentuximab vetodin; CD30+=CD30-positive; CTCL=cutaneous t-cell lymphoma; EQ-5D-3L=EuroQol-5 dimension-3 level; 
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5.3.3 Key issues in the company model 
The key issues in the company model that the ERG has been able to address relate to the 
inclusion of alloSCT in the treatment pathway, the use of a regression model to estimate utility 
values (PFS and post-progression survival), the application of extra AE utility decrements and 
the cost of oral chemotherapy. However, there remains substantial uncertainty in the results 
of the cost effectiveness model once these issues have been addressed. 
The model structure limits the ERG’s ability to investigate the impact of varying assumptions 
about survival; however, restructuring the model is not within the ERG’s remit. There are also 
parameter values relating to the post-progression health state that the ERG does not consider 
to be adequately supported by evidence or tested by extensive sensitivity analyses. 
The ERG’s preferred approach to estimating cost effectiveness is to remove alloSCT from the 
treatment pathway and to adjust several of the parameter values used in the company model. 
The ERG has then produced three scenarios to test the sensitivity of the model to alternative, 
plausible assumptions for which there is little evidence available. These assumptions are: 
changes to the post-progression pathway (Scenario 1); changes to resource use frequencies 
(Scenario 2); and the assumption of an OS gain for treatment with BV (Scenario 3). 
5.3.4 ERG’s preferred approach to estimating cost effectiveness 
Allogenic SCT as a treatment option 
The final scope issued by NICE suggests consideration of the use of alloSCT in the treatment 
pathway of patients with advanced stage CTCL if the evidence allows. The ERG does not 
consider there is sufficient evidence to allow alloSCT to be modelled robustly and so does not 
consider that alloSCT should be included in the model base case analysis. Uncertainties in 
the evidence are around i) outcomes after treatment with alloSCT, ii) outcomes following 
alloSCT in patients who have received prior treatment with BV, and iii) the position of alloSCT 
in the treatment pathway. 
Outcomes after treatment with alloSCT in patients with advanced stage CTCL 
The ERG considers that, although there is some published evidence [161] of outcomes 
following alloSCT in patients with advanced CTCL, data are lacking for the population included 
in the company model. 
The company presents the results of a meta-analysis [38] in Section B.1.3.3 of the CS. This 
study included 19 patients who received an alloSCT in the US, one of these patients had early 
stage disease (stage IB). The patients analysed were younger than patients with advanced 
stage CTCL in the ALCANZA trial (median age=42 years versus 60 years) and had received 
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more systemic therapies (median=4.5 versus 2.0). The company does not use the data from 
this study [38] in the model, as a recent change in practice (use of a less-intensive conditioning 
regime prior to alloSCT in patients with advanced stage CTCL) has led to the results of the 
meta-analysis being out of date. 
The data underpinning the post-alloSCT pathway in the company model are taken from a 
presentation made at a conference detailing the experiences of the UK’s leading supra-
regional centres for alloSCT [37]. The information included in the CS is not sufficient for the 
ERG to assess how representative the dataset used to inform the presentation are of the 
patients who receive alloSCT in the company model. Only 18/40 patients in the study [37] 
received the less-intensive conditioning regimen, which the company advocates as being best 
practice. The ERG considers that the small sample and the lack of clarity on the disease-stage 
of the population and/or number of prior treatments received generate too much uncertainty 
which leads to unreliable outcomes. Whilst the data presented by the company show that 
some outcomes may improve with alloSCT, the ERG considers that it is not possible to be 
certain which outcomes would improve, or how important they would be for patients with 
advanced stage CTCL who have received at least one previous treatment. 
The ERG considered alternative sources of evidence for alloSCT outcomes and identified a 
Cochrane review that was published in 2013 [161] that had searched for evidence on alloSCT 
in patients with advanced stage CTCL. The authors of the review found case series and 
retrospective evidence that suggest that alloSCT can lead to sustained remission in patients 
with advanced stage CTCL but that comparative RCT evidence did not exist. The review 
findings generally support the use of alloSCT in patients with advanced stage CTCL. However, 
evidence of outcomes in older patients, particularly people aged 60 and older is lacking and, 
historically, studies have included patients who have been more heavily pre-treated with 
systemic therapies than the patients in the ALCANZA trial.  
Outcomes following alloSCT in patients with advanced stage CTCL who have received prior 
treatment with BV 
The ERG is not aware of any evidence of outcomes for alloSCT post-treatment with BV. The 
use of alloSCT outcomes from patients with pre-treatments that are reflective of current 
practice, as in the company model, assumes BV does not alter the course of the disease in 
any way that may influence the success of alloSCT. The ERG considers this assumption to 
be untested and, given the influence of the intensity of the conditioning regimen used on 
alloSCT outcomes, it would be premature to speculate what the effect of treatment with BV 
might have on these outcomes. 
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The position of alloSCT in the treatment pathway 
Clinical advice to the ERG is that people with stage IIB and stage III disease often have periods 
during which the disease is well managed, and that the disease can remain stable for several 
years before progression occurs. In the company model, the proportion of patients (40%) 
achieving a PR or CR after treatment with BV or PC are eligible for alloSCT and receive their 
transplant at 18 weeks. The clinician advising the ERG noted that alloSCT carries a significant 
risk of complications such as infections and graft-versus-host disease, which can be fatal. It 
would therefore be unlikely for clinicians to offer the treatment to patients who are stable and 
feeling well and who have only thus far received a handful of treatments (and still have more 
treatment options available to them). It was also suggested that patients themselves would be 
unlikely to accept alloSCT at this point in the treatment pathway.  
The number of patients both eligible for and willing to have an alloSCT is dependent on factors 
such as the patient’s general health and comorbidities, the availability of matched donors and 
the capacity of the specialist centres performing the alloSCT treatments. Clinical advice to the 
ERG is that such factors would result in far fewer than 40% of complete or partial responders 
undergoing the procedure than has been assumed in the company model.  
At clarification, the company provided additional information on the patients that had received 
alloSCT during the ALCANZA trial. As alloSCT was neither a pre-specified nor exploratory trial 
end-point, very few data were collected on alloSCT other than whether the procedure was 
undertaken. Seven patients from the ITT population of the ALCANZA trial received an alloSCT 
[BV=5, PC=2]. Only two patients received alloSCT directly after the study treatment, which is 
the point at which alloSCT occurs in the company model, all others had subsequent systemic 
therapies pre-alloSCT. Both of the patients in the PC arm who had an alloSCT received 
treatment with BV as a subsequent anticancer therapy prior to alloSCT.  
The company states that, as four out of 24 UK based patients in the ITT population of the 
ALCANZA trial had an alloSCT, this demonstrates a 17% uptake. However, the ERG 
considers that as only two people who had an alloSCT in the trial did so directly after treatment, 
the proportion of patients that is more representative of patients having alloSCT, as modelled 
by the company, is 1.56% (2/128 ITT population); a similar estimate is not available for patients 
with advanced stage CTCL. The ERG considers that this approach demonstrates that the 
proportions of people eligible for alloSCT within the economic model are over-estimated and 
that this adds further weight to the argument that alloSCT is not part of standard care for 
patients with advanced stage CTCL in the NHS in England. 
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When alloSCT is removed from the treatment pathway, treatment with BV dominates 
treatment with PC. When compared to the company base case analysis results, incremental 
costs decrease by ******************* and incremental QALYs decrease by *************** 
Parameter values 
Utility values: PFS and post-progression survival 
The ERG acknowledges that utility values calculated using the direct results from the EQ-5D-
3L questionnaires completed during the ALCANZA trial may not capture all aspects of HRQoL 
in patients with advanced stage CTCL (see Section 4.9 of this ERG report); however, the ERG 
prefers to use the EQ-5D utilities in the model to retain adherence to the NICE Reference case 
[73] and to ensure comparability with the ICERs per QALY gained that inform other STAs. 
The ERG has investigated the impact on the ICER per QALY gained of using utility values for 
the progression-free health state and the post-progression (active therapy) health state 
calculated using the observed EQ-5D-3L values from the ALCANZA trial instead of those used 
by the company. Treatment with BV remains dominant when using observed EQ-5D-3L utility 
values. When compared to the company base case analysis results, incremental QALYs 
decrease by *************** for treatment with BV versus treatment with PC. 
The observed ALCANZA trial EQ-5D-3L PFS utility values included in the company model are 
higher for treatment with BV than with PC due to differences at baseline. The ERG does not 
consider it appropriate to use different baseline PFS utility values in the model. The ERG has 
investigated the impact of assuming that the PFS utility values calculated using the observed 
EQ-5D-3L values are the same for patients treated with BV and PC by using an average 
(0.689) of the observed EQ-5D-3L values from the BV and PC arms of the ALCANZA trial. 
Applying average observed EQ-5D-3L PFS utility values from the ALCANZA trial to the 
company’s base case analysis results in a reduction in incremental QALYs for treatment with 
BV versus PC of ****** from *************** Treatment with BV remains dominant over treatment 
with PC. 
Utility values: end-stage care 
The company uses a published utility value [141] for progressed disease in a population with 
relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma to 
represent HRQoL in end-stage care in the company model. The ERG considers there is 
considerable uncertainty about whether this utility value (0.38) is appropriate for use in this 
way. It is not clear how closely HRQoL in patients with advanced stage CTCL is correlated 
with HRQoL in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell 
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lymphoma in general. Nor is it clear how closely HRQoL in patients with relapsed/refractory 
Hodgkin lymphoma and systemic anaplastic large cell lymphoma who have experienced 
disease progression correlates with the HRQoL of patients with advanced stage CTCL who 
are in receipt of end-stage care. The ERG also notes that the mean age of patients in the 
published study [141] ranged between 32.5 and 43.4 years (depending on country), which is 
substantially younger than the mean age of the patients in the company model.   
The ERG has not amended the utility value for the end-stage care phase in the company 
model, as it is not aware of any published estimates of utility that are more appropriate for this 
state. However, it cautions that the validity of the utility values used in the model for the end-
stage care phase is subject to uncertainty. 
Utility values: adverse event decrements 
The company has included utility decrements for severe AEs in the base case analysis. The 
ERG considers that any changes in HRQoL that occur as a result of the AEs related to the 
study drugs would be captured in the mean EQ-5D-3L values from the ALCANZA trial; hence, 
the addition of a further utility decrement for severe AEs is likely to overestimate the impact of 
the study drugs on HRQoL. Removing the extra utility decrements for severe AEs from the 
company base case analysis increases incremental QALYs for treatment with BV versus PC 
by ****** from *************. Treatment with BV remains dominant over treatment with PC. 
Oral chemotherapy administration costs 
The company model includes an administration cost for exclusively oral chemotherapy using 
NHS Reference Costs 2016/17 [147] plus the cost of a pharmacist dispensing the medications. 
The company also includes the costs of additional blood tests, scans and outpatient visits in 
the resource use estimates for the progression-free state. The ERG considers that this 
approach represents double-counting of some of the aspects of the delivery of oral 
chemotherapy, particularly the pharmacy dispensing costs, but it is unclear if any of the other 
tests and hospital visits also form part of the NHS Reference Cost [147] for the delivery of 
exclusively oral chemotherapy. The ERG has removed the NHS Reference Cost [147] of 
£163.82 from the administration costs of oral chemotherapy. 
Treatment with BV remains dominant over treatment with PC when the costs of oral 
chemotherapy are reduced. Incremental costs are reduced by ****** from ********************** 
when compared to the company base case analysis results. 
The combined result of the ERG’s model amendments to the company base case is hereafter 
referred to as the ERG revised base case. 
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5.3.5 Areas of uncertainty 
Post-progression health state 
The ERG notes that mean time spent in the post-progression health state in the company 
model for patients who do not receive alloSCT is shorter for patients treated with BV than for 
patients treated with PC (Figure 12). This is due to the combined effect of three elements in 
the company model: mean PFS in the company model is longer for patients treated with BV 
than with PC; mean OS in the company model (for patients who do not receive alloSCT) is the 
same for both treatments; and mean post-progression survival is calculated as the difference 
between mean OS and mean PFS. This means that the risk of death after progression is 
modelled to be higher for treatment with BV than with PC.  
The assumption that treatment with BV is associated with patients spending a shorter time in 
the post-progression health state than patients treated with PC is critical to the model cost 
effectiveness results. The differential end-stage care costs accrued by patients treated with 
BV versus PC in the ERG’s revised base case are substantial **********).  
Clinical advice to the ERG is that it is unusual for patients to spend 3 to 4 years in a highly 
resource-intensive end-stage care phase. However, the ERG is unaware of any published 
evidence that robustly maps the post-progression phases experienced by patients with 
advanced stage CTCL. Given the impact of the costs accrued in the post-progression state in 
the company model, the lack of evidence for the assumptions made by the company about 
the post-progression pathway introduce substantial uncertainty into the model results. 
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Figure 12 Distribution of health states in company base case model without alloSCT and 
according to clinical advice 
BSC=best supportive care; BV=brentuximab vedotin; PC=physician’s choice; PF=progression-free 
Post-progression resource use 
Clinical advice to the ERG is that resource use for patients receiving end-stage care is over-
estimated by the company. Patients with advanced stage CTCL would not be sufficiently well 
to attend outpatient appointments at the frequency assumed by the company. It was also 
noted that the NHS and voluntary health care sector have neither the budget nor the capacity 
to enable several visits per week from district and Macmillan nurses. 
Assumption of equal OS resulting in zero OS gain 
The company has assumed in the base case analysis (for patients who do not receive 
alloSCT) that treatment with BV and treatment with PC are equally effective in terms of OS, 
since the results of the ALCANZA trial do not show a statistically significant OS difference for 
the comparison of treatment with BV compared with PC. The company argues that the 
limitations of the OS data from the ALCANZA trial (small numbers of patients and events, and 
high rates of crossover) prevent robust estimates of OS gain being generated. The ERG 
agrees that there is insufficient evidence from the ALCANZA trial to make robust claims about 
lifetime OS gain. Clinical advice to the ERG is that there is no robust evidence to either support 
or refute the assumption of zero OS gain as implemented in the company submitted model. 
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The ERG notes that the company’s assumption of equal OS resulting in zero OS gain may 
appear to be a conservative approach. However, modelling zero OS gain alongside a PFS 
gain for treatment with BV means that, after progression, patients treated with BV die more 
quickly than patients treated with PC. Consequently, patients treated with BV spend less time 
in the highly resource-intensive end-stage care phase than patients treated with PC. This 
means that the costs accruing to the BV arm are lower than the costs accruing to the PC arm. 
Populations and pathways in the company model  
The company states that the populations that are represented in the model are patients with 
advanced stage MF and patients with pcALCL. However, as noted in the joint submission to 
the National Institute for Health and Care Excellence (NICE) from the Royal College of 
Pathologists and the British Society for Haematology [39] as part of this appraisal, treatment 
decisions are made according to each patient’s needs and the expertise of the centre (p4). 
The relevance of the treatment pathways included in the model to the subgroup of patients 
with advanced stage MF and, in particular, patients with pcALCL is therefore unknown. 
5.3.6 Model inflexibility and structural issues 
Parts of the company model are inflexible or result in implausible outcomes due to structural 
issues in the model. These issues are not addressed by the ERG, since amending structural 
issues is outside the remit of the ERG. 
Payoff approach  
The company has used a payoff approach to model patient outcomes after progression. Mean 
costs and QALYs for active subsequent therapy and end-stage care are multiplied by the time 
spent in those phases and then summed to give mean costs and QALYs for the whole post-
progression state. The payoff approach imposes limitations on the flexibility of the company 
model and does not allow for specific parameters and/or assumptions to be investigated 
thoroughly. In particular, the ERG was unable to explore the sensitivity of the model results to 
the use of different parametric survival functions. The ERG acknowledges that the company 
base case model – including alloSCT – benefits from the simplification introduced by the payoff 
approach. The payoff approach is described in more detail in in Appendix 8 (Section 9.8) and 
in NICE DSU TSD19 [162]. 
Mean post-progression survival 
There is a zero risk of disease progression for patients treated with BV during the first 17 
cycles of the company model. This is the combined result of i) the company’s use of data from 
the PC arm of the ALCANZA trial to model OS for treatment with BV and PC, ii) the 
independent modelling of PFS for patients treated with BV and PC, and iii) a fix in the model  
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that stops PFS being greater than OS if the parametric curve estimates for PFS and OS 
overlap.  
The combination of these three elements leads to no patients experiencing disease 
progression during the first 17 cycles of the model. A zero risk of disease progression in the 
early part of the model for patients treated with BV means that, for these patients, mean post-
progression survival is underestimated by the company. However, comparison of the PFS and 
OS data from the ALCANZA trial, provided by the company at clarification, indicates that six 
patients treated with BV experienced disease progression during the first 17 cycles of 
treatment.  
Proportion of patients with disease progression in each model cycle 
The proportion of patients entering the post-progression health state in each cycle is estimated 
from the difference in PFS between cycles. For example, if PFS=90% in cycle 1 and PFS=80% 
in cycle 2, then 10% of patients would enter the post-progression health state in cycle 2. This 
method does not take into account the proportion of patients who die before experiencing 
disease progression. Not taking account of deaths in the progression-free state amounts to 
assuming a zero mortality risk before disease progression for treatment with BV and PC. A 
comparison of the PFS and OS K-M data from the ALCANZA trial indicates that five patients 
in the BV arm (16%) and six patients in the PC arm (18%) died before experiencing disease 
progression. The modelling of a zero risk of death before disease progression therefore does 
not reflect the trial evidence. 
The proportion of patients who experience disease progression in each cycle is over-estimated 
in the company base case analysis and so costs and QALYs for the post-progression state 
are also over-estimated.  
Probabilistic sensitivity analysis 
In the CS, the company presents mean PSA results that are substantially different 
(**************) compared with the deterministic results generated by the company model. The 
ERG is concerned that this difference may be the result of the non-standard methods used to 
implement some of the sensitivity analyses, but may also simply demonstrate the sensitivity 
of the model results to changes in parameter values.  
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5.3.7  
5.4 Impact on the ICER per QALY gained of additional clinical and 
economic analyses undertaken by the ERG 
The ERG has carried out the following revisions to the company base case ICERs per QALY 
gained for treatment with BV versus PC: 
 Removal of alloSCT [R1] 
 Utility estimates: observed EQ-5D-3L utility estimates from the ALCANZA trial [R2]  
 Utility estimates: PFS utility equal for treatment with BV and PC [R3] (includes R2) 
 Utility estimates: removal of AE decrements [R4] 
 Removal of extra oral chemotherapy costs [R5]  
Details of all Microsoft Excel revisions carried out by the ERG to the company’s model are 
presented in Appendix 9 (Section 9.9). 
A summary of the individual and combined effects of the ERG’s model amendments on the 
company’s base case cost effectiveness results for the comparison of treatment with BV 
versus PC is shown in Table 31.  
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Table 31 Cost effectiveness results for ERG revisions to the company base case (PAS price for BV) 
Revision 
BV PC Incremental ICER per QALY 
gained Cost QALYs LY Cost QALYs LY Cost QALYs LY 
Company original base case ******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
R1) Remove alloSCT ******** ***** 6.829 ******** ***** 6.829 ******** ***** 0.000 BV Dominates 
R2) Utility estimates: observed EQ-5D-
3L utility estimates from the ALCANZA 
trial 
******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
R3) Utility estimates: PFS utility equal for 
treatment with BV and treatment with PC 
(includes R2) 
******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
R4) Utility estimates: removal of AE 
decrements 
******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
R5) Remove extra oral chemotherapy 
costs 
******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
ERG revised base case ******** ***** 6.829 ******** ***** 6.829 ******** ***** 0.000 BV Dominates 
AE=adverse events; alloSCT=allogeneic stem-cell transplantation; BV=brentuximab vedotin; PC=physician’s choice; EQ-5D-3L=EuroQol 5 dimension-3 level; NHS=National Health Service; 
ICER=incremental cost effectiveness ratio; LY=life years; QALY=quality adjusted life year 
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5.5 ERG scenario analyses 
The ERG notes that there are major assumptions included in the model for which there is 
neither robust evidence nor extensive sensitivity analyses. The ERG has produced three 
scenarios to test the sensitivity of the model to alternative, plausible assumptions. These 
assumptions are: changes to the post-progression pathway (Scenario 1); changes to resource 
use frequencies (Scenario 2); and assuming an OS gain for treatment with BV (Scenario 3). 
The ERG cautions that the scenarios presented are intended to highlight the sensitivity of the 
model to plausible alternatives to the company assumptions that the ERG does not consider 
to be supported by robust evidence. The ERG also cautions that the results of the scenario 
analyses may not be meaningful, since the model is relatively inflexible and does not 
accommodate changes to certain parameters.  
The ERG accepts that, given the evidence from the ALCANZA trial (see Section 4.6.5 of this 
ERG report) and based on clinical advice to the ERG, the company is justified in investigating 
a scenario in which a single OS curve is used to model survival for both treatment with BV and 
PC. However, it is critical to note the implications of this approach for assumptions about the 
natural history of advanced stage CTCL (Section 5.5.1). 
Although there is insufficient evidence from the ALCANZA trial to model robustly any survival 
gain for treatment with BV, the ERG cautions that absence of evidence does not amount to 
evidence of absence and it remains plausible that there may be some survival gain attributable 
to treatment with BV without also modelling alloSCT as part of the treatment pathway. The 
ERG is concerned that modelling a small gain in OS without also modelling alloSCT may have 
a substantial impact on the size of the ICER per QALY gained as this approach reduces the 
difference in the time patients spend in the post-progression health state (Section 5.5.3). 
5.5.1 Scenario 1: Changes to the post-progression pathway (zero OS 
gain for patients not receiving alloSCT) 
Clinical advice to the ERG, regarding the patient pathway after progression in current NHS 
clinical practice, is that it is usual for patients to spend (i) almost 5 years receiving active 
subsequent treatments after disease progression, (ii) followed by 1 year receiving best 
supportive care (BSC) and (iii) then around 6 months receiving end-stage care (Figure 12). 
The ERG notes that this revised post-progression pathway (Scenario 1) represents one of 
possibly many plausible alternatives to the company’s original post-progression pathway. 
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ERG Scenario 1: 
 Active subsequent therapy includes treatment with chemotherapy or TSEB, some 
medical resource use including nurse visits and dressings, and patients have a 
moderate HRQoL. The mean length of this phase is variable between treatments and 
depends on the difference between PFS and OS. 
 BSC does not include active subsequent treatment but does include some medical 
resource use (assumed to the same as the medical resources used during active 
subsequent therapy), and patients have a HRQoL that is worse than the HRQoL of 
patients receiving active subsequent treatment but is better than the HRQoL of 
patients receiving end-stage care. The mean length of this phase is fixed at 1 year for 
both treatments. 
 End-stage care does not include active subsequent treatment, but does include 
substantial resource use (including palliative care visits several times per week and 
expensive wound management, as per the company base case analysis) and patients 
have a very low HRQoL. The mean length of this phase is fixed at 6 months for both 
treatments. 
 
Figure 13 ERG Scenario 1: Changes to the post-progression pathway: distribution of health 
states 
BSC=best supportive care; BV=brentuximab vedotin; PC=physician’s choice; PF=progression free 
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The ERG used cost and utility estimates from the company base case model for the active 
subsequent therapy and end-stage care phases of the post-progression health state. The ERG 
assumed that the costs of being in the BSC phase would be the same as the cost of being in 
the active subsequent therapy phase minus treatment-related costs. The ERG also assumed 
that the utility value associated with being in the BSC phase would be the midpoint between 
the utility values used in the company model for active subsequent therapy and end-stage 
care. 
Table 32 ERG Scenario 1: Changes to the post-progression pathway: cycle costs and 
utilities 
Post-progression state Weekly cycle cost Utility 
Active subsequent therapy £965 0.64 
BSC £904a 
Average of active therapy and 
end-stage=0.495 
End-stage care £2,381 0.38 
BSC=best supportive care 
a Equal to medical resource use and other costs (including hospital visits, home visits, tests and supportive drug therapies such 
as pain relief) in active therapy 
Source: Company model 
 
The ERG’s exploratory analysis of the sensitivity of the results to changes in the assumptions 
used in the post-progression health state means that treatment with PC dominates treatment 
with BV.  
5.5.2 Scenario 2: Changes to resource use frequencies (zero OS gain for 
patients not receiving alloSCT) 
The ERG has re-estimated several of the resource use estimates used in the company model 
based on clinical advice (Table 33). If changes made to resource use brought the frequency 
of resource use in the end-stage care phase to below that of the same resources used in the 
pre-progression state or in the active subsequent treatment phase, the same estimates of 
resource use would also be applied to the other modelled health states for logical consistency 
(Table 34). 
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Table 33 ERG Scenario 2: Amendments to end-stage care phase resource use parameter 
estimates 
 Company base case ERG scenario 2* 
 





visit /dose (if 
applicable) 










100 2.25  100 0.25  
Dermatologist 
visit 
100 0.17  50 0.17  




100 2.63  100 0.25  
Macmillan nurse 
/ Social services 
100 1 7 100 0.25 1 
Palliative care 
support team 




25 7 3 12.5 7 3 
Mepilex large 
sheet dressings 
25 7 2 12.5 7 2 
Mepilex small 
dressings 
25 7 3 12.5 7 3 
Mepilex heels 25 7 2 12.5 7 2 
Elasticated 
garments 
25 1 1 12.5 1 1 
Medium Allevyn 75 7 7 37.5 7 7 
a Changes to company base case in shaded cells; Source: company model; clinical advice to the ERG 
Table 34 ERG Scenario 2: Amendments to resource use parameter estimates in pre-
progression and post-progression (non end-stage care) states 
 Company base case ERG scenario 2a 
 





visit /dose (if 
applicable) 













60 7 7 37.5 7 7 
Post-progression (active subsequent therapy/BSC) 
Home visit 




60 7 7 
37.5 7 7 
a Changes to company base case in shaded cells; Source: company model; clinical advice to the ERG 
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Using the ERG revised base case, implementing these resource use changes yields an 
ICER per QALY gained of £26,331.  
Resource use unit costs 
Clinical advice to the ERG is that less expensive alternatives to Allevyn, Mepilex and Mepitel 
dressings (included in the company model) may be used in NHS clinical practice. The ERG 
has not re-costed the dressings used in the model due to uncertainty around what constitutes 
standard practice in the NHS for treating wounds in patients with advanced stage CTCL. The 
ERG notes that, when comparing treatment with BV and PC, if the total costs of the end-stage 
care phase are reduced (due to the use of cheaper dressings), then the ICER per QALY 
gained would increase.  
5.5.3 Scenario 3: Assuming an OS gain for treatment with BV versus PC 
The ERG has investigated the impact of modelling an OS gain for treatment with BV versus 
treatment with PC. The ERG considers it reasonable to assume that mean OS gain is equal 
to mean OS in the company base case analysis (1.2 years) i.e., when alloSCT is included in 
the treatment pathway. The ERG used the company’s base case log-logistic OS curve to 
represent survival for patients treated with PC. The ERG then adjusted the OS curve for 
treatm nt with PC using an acceleration factor (AF=0.779) to generate a 1.2 year mean OS 
gain for treatment with BV versus PC. The resulting OS curves are shown in Figure 14. 
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Figure 14 ERG scenario 3: OS gain (mean 1.2 years) 
Source: company model; ERG calculations 
The ERG cautions that this scenario has been included to highlight the sensitivity of the current 
model structure to the implementation of a potential survival gain for treatment with BV versus 
PC. The ERG is not suggesting that OS gain for treatment with BV is equal to 1.2 years or that 
the log-logistic curve is appropriate; only that this seems to be a reasonable assumption to 
test in a scenario. The ERG also cautions that the structure of the model is not flexible enough 
to allow a reliable result to be produced when changing the parametric curve used to estimate 
OS. 
Using the ERG revised base case, the ICER per QALY gained generated when applying a 
mean OS gain of 1.2 years for the comparison of treatment with BV versus PC is £95,491. 
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5.6 Impact on the ICER per QALY gained of additional scenario 
analyses undertaken by the ERG 
The ERG has carried implemented the following scenarios using the ERG revised base case: 
 Changes to post-progression pathway [S1]  
 Changes to resource use frequencies [S2] 
 Assuming an OS gain for treatment with BV equal to company base case (1.2 years) 
(when alloSCT is included in the treatment pathway) [S3]. 
A summary of the individual effects of the scenarios modelled by the ERG on the company’s 
base case cost effectiveness results for the comparison of treatment with BV versus PC is 
shown in Table 35.  
Details of all Microsoft Excel revisions carried out by the ERG to the company’s model are 
presented in Appendix 9 (Section 9.9). 
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Table 35 Cost effectiveness results for ERG scenarios (PAS price for BV)  
Revision 
BV PC Incremental ICER per QALY 
gained Cost QALYs LY Cost QALYs LY Cost QALYs LY 
Company original base case ******** ***** 8.432 ******** ***** 7.228 ********* ***** 1.204 BV Dominates 
ERG revised base case  ******** ***** 6.829 ******** ***** 6.829 ******** ***** 0.000 BV Dominates 
S1) Changes to post-progression pathway ******** ***** 6.829 ******** ***** 6.829 ******* ****** 0.000 BV Dominated 
S2) Changes to resource use frequencies ******** ***** 6.829 ******** ***** 6.829 ****** ***** 0.000 £26,331 
S3) Assuming an OS gain for treatment 
with BV equal to company base case (1.2 
years) 
******** ***** 8.029 ******** ***** 6.829 ******* ***** 1.201 £95,491 
AE=adverse events; BV=brentuximab vedotin; PC=physician’s choice; ICER=incremental cost effectiveness ratio; LY=life years; QALY=quality adjusted life y
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5.7 Conclusions of the cost effectiveness section 
The revisions and scenarios implemented by the ERG in the company model for the 
comparison of treatment with BV versus PC yield a mixture of effects. Incremental costs and 
incremental benefits both increase and decrease depending on the individual revision/ 
scenario or combination of revisions/scenarios.   
Each of the ERG revisions to the company base case results in ICERs per QALY gained 
where BV dominates PC. The incremental costs vary from ************** (revised utility estimates) 
to *********** (when alloSCT is removed). The incremental QALYs range from ******* (removal of 
AE decrements) to ******* (when alloSCT is removed). When all the ERG revisions are 
combined BV still dominates PC with incremental costs of ***************************************** 
**************************** 
The resulting ICERs per QALY gained from the individual ERG scenarios vary from £26,331 
(changes to resource use frequencies) to treatment with PC dominating treatment with BV 
(changes to post-progression pathway).  
The ERG’s analyses highlight the high level of uncertainty around the company base case 
cost effectiveness results. The ERG cautions that the ICERs per QALY gained for the 
comparison of treatment with BV and PC presented in this ERG report may not be reliable 
. 
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6 END-OF-LIFE CRITERIA 
The NICE end-of-life criteria are as follows: 
 The treatment is indicated for patients with a short life expectancy, normally less than 
24 months  
 There is sufficient evidence to indicate that the treatment offers an extension to life, 
normally of at least an additional 3 months, compared with current NHS treatment 
 
The company has not made a case for BV meeting the above criteria. 
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7 OVERALL CONCLUSIONS 
7.1 Clinical effectiveness 
The majority of the evidence is derived from the ALCANZA trial, an international, open-label, 
randomised, phase III, multicentre trial of BV versus PC in patients with CD30+ CTCL (n=131). 
The focus of the company’s decision problem is only patients with advanced stage CTCL 
(n=95) as these are the patients considered by the company to be those who would be eligible 
for BV in clinical practice. The ERG concurs. 
The PC arm of the ALCANZA trial consists of MTX or BEX. The ERG considers these are the 
most appropriate comparators for patients with MF. Clinical advice to the ERG is that (i) 
Category A therapies are the most relevant comparators to BV for patients with MF and (ii) 
Category B therapies would normally be preferred to Category A therapies for patients with 
advanced stages of pcALCL who have received at least one prior systemic therapy and are fit 
enough to tolerate the drugs. However, clinical advice is that MTX and BEX are likely to be 
appropriate comparators to BV for the patients included in the ALCANZA trial with 
pcALCL who might have had earlier stage disease or who were not fit for Category B drugs.  
Results from the ALCANZA trial show that, compared with PC, treatment with BV results in 
improved ORR4 and PFS; reflecting these improvements, patients were treated with BV for 
longer than with MTX of BEX. However, improvements in OS or HRQoL have not been 
conclusively demonstrated. Furthermore, peripheral neuropathy is a very common AE for 
patients treated with BV which, although mostly of only grade 1 or 2 in severity, can lead to 
treatment discontinuation for approximately 16% of patients.  
Overall, the ERG considers that the patients in the ALCANZA trial with advanced stage CTCL 
are similar to patients with advanced stage MF and pcALCL who would be seen in NHS clinical 
practice. The ERG highlights the lack of relative effectiveness evidence for other subtypes of 
CTCL. However, obtaining evidence for other subtypes is difficult given CTCL is an orphan 
disease and given other subtypes constitute less than half of all patients with CTCL.  
7.2 Cost effectiveness 
The ERG’s analyses highlight the high level of uncertainty around the company base case 
cost effectiveness results. The ERG cautions that the ICERs per QALY gained for the 
comparison of treatment with BV and PC presented in this ERG report may not be reliable.  
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9 APPENDICES  
9.1 Appendix 1: CTCL staging and prognosis 
9.1.1 MF/SS staging and prognosis 
As described in the CS (p24), CTCLs are classified using the tumour-node-metastasis (TNM) 
system, where ‘T’ represents tumour involvement (which for CTCL is patches or plaques), ‘N’ 
represents lymph node involvement and ‘M’ represents the presence of metastasis [23, 24, 
163]. The staging of MF/SS also includes an additional ‘B’ criterion (B0–B2), representing the 
degree of blood tumour burden (i.e., leukaemic blood involvement). ‘B’ staging is based on 
the presence/absence of Sézary cells in the blood, with B1 representing low- and B2 
representing high-blood tumour burden. The TNMB designations for MF/SS are used to group 
CTCL into early stage (stages IA to IIA) or advanced stage (stages IIB to IVB) disease (Figure 
15) [23, 164].  






































































IVA is separated into IVA1 (with blood involvement; B2) 










BSA=body surface area 
Note: Sézary syndrome only presents in advanced stage 
Figure 15 Classification and staging for mycosis fungoides and Sézary syndrome 
Source: CS, adapted from Figure 4 and Pinter-Brown et al 2014, adapted from Table 2 [164] 
Early stage MF (stages IA to IIA) usually presents with cutaneous patches and plaques [23]. 
Advanced MF (stages IIB to IVB) is characterised by skin tumours, erythroderma, and nodal 
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or visceral involvement. SS presents only in advanced stage disease with extreme pruritus, 
erythroderma, lymphadenopathy and circulating Sézary cells [21]. 
Median OS and 5-year survival rates by stage of disease from three studies of MF/SS [8, 26, 
27] are presented in the CS (p28) and reproduced by the ERG (with the inclusion of additional 
information) in Table 36. The data clearly show that prognosis for patients with advanced stage 
disease differs markedly to prognosis for patients with early stage disease. 




Early stage disease Advanced stage disease 
IA IB IIA IIB IIIA IIIB IVA1 IVA2 IVB 
Median OS (years) 
Kim et al 
2003 [26]a 
- 12.9 4.0 1.5 
Agar et al 
2010 [8]b 
35.5 21.5 15.8 4.7 4.7 3.4 3.8 4.7 4.7 
Scarisbrick 
et al 2015 
[27]c 
Not applicable - study only 
included patients with 
advanced stage disease 
5.7 - 5.2 4.4 2.4 2.8 
- 4.0 
5.2 
Five-year OS rates 
Kim et al 
2003 [26]a 
96% 75% 44% 27% 
Agar et al 
2010 [8]b 
94% 84% 78% 47% 47% 40% 37% 18% 18% 
Scarisbrick 
et al 2015 
[27]c 
Not applicable - study only 
included patients with 
advanced stage disease 




‘-‘ indicates median not reached 
a Single-centre retrospective study, n=525 (all patients from the United States) 
b Database analysis, n=1502 (all patients from the UK) 
c Multi-centre retrospective study (29 centres spanning five continents), n=1275 (UK patients, n=261)  
9.1.2 CD30+ LPDs staging and prognosis 
The ISCL and the cutaneous lymphoma task force of the EORTC have established a 
consensus proposal for a TNM classification system (i.e. tumour, node, metastasis) applicable 
for other subtypes of CTCL (Table 37) [24]. Due to the clinical and pathologic heterogeneity 
of CTCL, the authors highlight that the currently proposed system is meant to be primarily an 
anatomic documentation of disease extent and should not to be used as a prognostic guide 
[24].  
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Table 37 Proposed TNM classification of cutaneous lymphoma other than mycosis fungoides 
and Sézary syndromea 
Classification 
Tumour (T) 
T1: Solitary skin involvement 
T1a: a solitary lesion <5 cm diameter 
T1b: a solitary >5 cm diameter 
T2: Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions 
 T2a: all-disease-encompassing in a <15-cm-diameter circular area 
 T2b: all-disease-encompassing in a >15- and <30-cm-diameter circular area 
 T2c: all-disease-encompassing in a >30-cm-diameter circular area 
T3: Generalised skin involvement 
 T3a: multiple lesions involving 2 noncontiguous body regions 
 T3b: multiple lesions involving ≥3 body regions 
Lymph nodes (N) 
N0: No clinical or pathologic lymph node involvement 
N1: Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement 
N2: Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region that 
does not drain an area of current or prior skin involvement 
N3: Involvement of central lymph nodes 
Metastasis (M) 
M0: No evidence of extracutaneous non–lymph node disease 
M1: Extracutaneous non–lymph node disease present 
a Proposed by the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the 
European Organization for Research and Treatment of Cancer (EORTC) 
Source: Source: Kim et al 2007, adapted from Table 2 [24] 
The company states (CS, p26) that it is implicit in the definition of CD30+ LPD that 
extracutaneous disease is absent and, therefore, all patients are classified as N0 and M0 at 
presentation and remain so during early stage disease. While pcALCL and LyP share the 
expression of CD30 antigen as a common immunophenotypic hallmark, they differ in regard 
to their clinical presentation [25]. The company highlights that patients with pcALCL generally 
present with solitary or grouped, rapidly growing, and ulcerating large tumours or thick plaques 
(CS, p27); most patients with pcALCL, therefore, have localised disease [22, 25]. Patients with 
N1–N3 and M1 classifications are considered to have advanced stage disease, where the 
lymphoma is active beyond the skin (i.e., in the nodes or blood) and beyond the nodes 
(metastasised). Extracutaneous spread (i.e., metastasis) is uncommon for patients with 
CD30+ LPDs; it is reported to occur in 13% of patients with pcALCL [22, 25]. The ERG notes 
that LyP tends to be self-resolving, typically occurring in early adulthood and presenting with 
recurrent nodules and papules at distant sites which become necrotic before resolving to form 
an atrophic scar [21, 25]. 
While staging for CTCL other than MF/SS is intended to be an anatomic documentation of 
disease extent and not a prognostic guide [24], the company highlights that significant survival 
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decrements are observed when comparing the prospects of patients with advanced versus 
early clinical stages (CS, p29). Broadly speaking, patients with regional or generalised 
involvement have more advanced stage disease than those with localised disease. The 
company highlights that patients with pcALCL with regional lymph node involvement 
demonstrate an overall 5-year OS rate of 76% [3]; the ERG notes that Liu et al 2003 report 
disease-specific 5-year survival of 50% for generalised pcALCL (versus 91% for localised 
pcALCL) [22].  
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9.2 Appendix 2: Estimated number of patients eligible for treatment 
with BV 
Clinical advice to the ERG is that there may be 30 to 40 new cases of CTCL that are treated 
at the Liverpool centre each year. If replicated across all seven supra-regional centres in the 
UK, this equates to between 210 and 280 new cases in the UK each year. All these patients 
will have failed topical therapies and will be candidates for systemic therapies, but not all will 
have advanced stage CTCL. 
The company highlights (CS, p23) that 1659 people were recorded as being newly diagnosed 
with CTCL in England between 2009 and 2013 (PHE data) [10]. Assuming incidence has 
remained unchanged during each year of this period, this equates to 332 patients per year. 
Not all of these patients would have had advanced stage CTCL. Prevalence figures cited in 
the CS (p24) from the PROCLIPI observational study suggest that *** of patients in the UK 
have advanced stage CTCL. Thus, based on data from this study, approximately *** patients 
may be diagnosed with advanced stage CTCL in England each year.  
Clinical advice to the ERG is that a higher proportion of patients with MF have advanced stage 
disease than early stage disease, whereas the opposite is true for patients with pcALCL and 
LyP. The estimated proportions are summarised in Table 38. 
Table 38 Estimated proportions of new patients with early stage and advanced stage CTCL 
CTCL subtype Early stage, % Advanced stage, % 
MF 40 60 
SS 0 100 
pcALCL 80 20 
LyP 90 10 
CD30+ LPDs=primary cutaneous CD30-positive lymphoproliferative disorders; CTCL=cutaneous T-cell lymphoma; LyP= 
Lymphomatoid papulosis; MF= mycosis fungoides; pcALCL=primary cutaneous anaplastic large cell lymphoma; SS=Sézary 
syndrome 
Source: Clinical advice to the ERG 
Crudely applying these estimates to PHE data [10], means that approximately 140 patients 
may be diagnosed with advanced stage CTCL in England each year (Table 39). However, this 
estimate is highly uncertain as it relies on four key assumptions, none of which may be true. 
First, it has been assumed that incidence remained unchanged during each year of the period 
between 2009 and 2013 and that incidence has not changed since. Second, it has been 
assumed that the estimated proportions of patients with early stage and advanced stage CTCL 
presented by the ERG are correct for England. Third, PHE data do not categorise patients 
with CD30+ LPDs further by their subtypes of pcALCL and LyP and so it has been assumed 
by the ERG that 15% of these patients have advanced stage CTCL. Fourth, it has also been 
assumed by the ERG that 15% of patients with all other subtypes of CTCL also have advanced 
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stage disease. In addition, the estimate fails to take into consideration that only 23% of patients 
with MF/SS may have CD30+ CTCL [27].  
Table 39 Estimated number of patients with CTCL each year by stage of disease 
CTCL subtype Early stage, n Advanced stage, n 
MF 74 110 
SS 0 8 
CD30+ LPDs 27 5 
Othera 91 16 
Total 192 140 
CD30+ LPDs= primary cutaneous CD30-positive lymphoproliferative disorders; CTCL=cutaneous T-cell lymphoma; MF=mycosis 
fungoides; SS=Sézary syndrome 
a Other included patients categorised subcutaneous panniculitis-like T-cell lymphoma, cutaneous peripheral T-cell lymphoma-not 
otherwise specified, CD30+ LPDs, extranodal NK/T-cell lymphoma, nasal type  and primary cutaneous gamma-delta T-cell 
lymphoma  
Source: ERG estimates using data from Public Health England 2016 [10] 
Not all new cases of advanced stage CTCL would receive treatment with BV. First, as 
highlighted above, not all patients would have CD30+ CTCL, the proportion of patients with 
CD30+ CTCL being unclear (see Section 2.2). However, if it is also assumed only 23% of 
patients with MF/SS have CD30+ CTCL, then the incidence of patients with advanced stage 
CTCL diagnosed with advanced stage disease in England each year may be as low as 
approximately 50 patients (Table 40). Second, based on the treatment pathway proposed in 
the CS (see also Section 2.3.2 of this ERG report), most newly diagnosed patients would 
probably initially receive a Category A therapy with only a proportion of these patients failing 
treatment and, therefore, being eligible to receive BV within the same year. Eventually, 
however, a reasonable proportion of patients would become candidates for treatment with BV.  
Table 40 Estimated number of patients with CTCL each year by stage of disease, assuming 
only 23% of patients with MF/SS have CD30+ CTCL 
CTCL subtype Early stage, n Advanced stage, n 
MF 17 25 
SS 0 2 
CD30+ LPDs 27 5 
Othera 91 16 
Total 135 48 
CD30+ LPDs= primary cutaneous CD30-positive lymphoproliferative disorders; CTCL=cutaneous T-cell lymphoma; MF=mycosis 
fungoides; SS=Sézary syndrome 
a Other included patients categorised subcutaneous panniculitis-like T-cell lymphoma, cutaneous peripheral T-cell lymphoma-not 
otherwise specified, CD30+ LPDs, extranodal NK/T-cell lymphoma, nasal type  and primary cutaneous gamma-delta T-cell 
lymphoma  
Source: ERG estimates using data from Public Health England 2016 [10] 
In summary, there is considerable uncertainty as to how many patients would be eligible for 
treatment with BV in England each year. 
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9.3 Appendix 3: Risk of bias assessment 





Was randomisation carried out appropriately? Yes Agree 
Was the concealment of treatment allocation 
adequate? 
Unclear Agree 
Were the groups similar at the outset of the 
study in terms of prognostic factors? 
Yes Agree 
Were the care providers, participants and 
outcome assessors blind to treatment 
allocation? 
No Agree, the open-label nature of the trials 
provides an opportunity for subjective 
results and investigator-assessed 
outcomes to be biased 
Were there any unexpected imbalances in 
drop-outs between groups? 
No Agree 
Is there any evidence to suggest that the 
authors measured more outcomes than they 
reported? 
No Agree, the company made available the 
clinical study report, protocol and statistical 
analysis plan alongside its submission 
Did the analysis include an intention-to-treat 
analysis? If so, was this appropriate? 
Yes Agree 
Were appropriate methods used to account for 
missing data? 
Yes Agree 
Source: CS, Appendix D.1.5 (Table 24) and ERG comment 
 
  
   Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 150 of 172 
 
9.4 Appendix 4: ERG testing of proportional hazards for data from the 
ALCANZA trial  
The validity of the PH assumption within the trial is best assessed by considering the H-H plot 
which shows the relationship between the cumulative hazard for each trial event at common 
time points in the two trial arms (IRF-assessed PFS, Figure 16; time to subsequent anticancer 
therapy, Figure 17). For the PH assumption to be valid, two criteria must be met: 
 the data should follow a straight line trend, with individual data points randomly 
distributed close to and on either side of the trend line 
 the linear trend line should pass through the graph origin (zero value on both axes). 
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9.4.1 Progression-free survival (assessment by independent review 
facility, subgroup of patients with advanced stage CTCL) 
The H-H plot for the IRF-assessed PFS data from the advanced stage CTCL patient subgroup 
of the ALCANZA trial is provided in Figure 16. It is clear that the data do not follow a straight 
line trend; the linear model appears to underestimate PFS in the BV arm in the early and late 
stages of the trial, and overestimate PFS in the BV arm in the intervening period. However, 
the linear regression model does not estimate a statistically significant deviation from the origin 
of -0.085 (95% CI: -0.171 to 0.000). Nonetheless, based on visual inspection of the H-H plot, 
the ERG considers that the PH assumption may be violated for IRF-assessed PFS data from 
the subgroup of patients with advanced stage CTCL. 
 
Figure 16 H-H plot for IRF-assessed PFS data from the advanced stage CTCL patient 
subgroup of the ALCANZA trial 
BV=brentuximab vedotin; CTCL=cutaneous T cell lymphoma; IRF=independent review facility; PC=physician’s choice; 
PFS=progression-free survival 
Source: Company clarification response, question B1 
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9.4.2 Time to subsequent anticancer therapy (subgroup of patients with 
advanced stage CTCL) 
Visual inspection of Figure 17 indicates that the PH assumption may not hold for time to 
subsequent anticancer therapy from the ALCANZA trial; the data do not follow a straight line 
trend. However, the linear regression model does not estimate a statistically significant 
deviation from the origin of -0.019 (95% CI: -0.092 to 0.054). Nonetheless, based on visual 
inspection of the H-H plot, the ERG considers that the PH assumption may be violated for time 
to subsequent anticancer therapy data from the subgroup of patients with advanced stage 
CTCL. 
 
Figure 17 H-H plot for TTSAT data from the advanced stage CTCL patient subgroup of the 
ALCANZA trial 
BV=brentuximab vedotin; CTCL=cutaneous T cell lymphoma; PC=physician’s choice; TTSAT=time to subsequent anticancer 
therapy 
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9.5 Appendix 5: Common types of any-grade adverse events  
The frequency of common any-grade TEAEs (occurring in ≥10% of patients after a median of 
22.9 months follow-up) for all patients in the ALCANZA trial is presented in Table 20 of the 
CS. Data are presented for MTX and BEX separately in this table. The ERG notes that 
although labelled as TRAEs, the incidence of each AE in each arm is identical to the data 
presented in the published paper, labelled as TEAEs [66]. During the clarification process, the 
ERG requested the same data for the advanced stage subgroup after a median of 33.9 months 
follow-up. The company provided these data which were labelled as TEAEs and not TRAEs. 
The company also provided the CSR for the ALCANZA trial for the primary data-analysis 
(median 22.9 months follow-up). It is evident from consulting this document (Table 12.g) that 
the data presented in Table 20 of the CS are not in fact TRAEs but are TEAEs.  
In total, in the overall trial population, 16 types of TEAEs occurred in ≥10% of patients in the 
BV arm, compared with six types of TEAEs for patients treated with MTX and six types of 
TEAEs for patients treated with BEX. In the advanced stage subgroup, 15 types of TEAEs 
occurred in ≥10% of patients in the BV arm, compared with eight types of TEAEs for patients 
treated with MTX and 11 types of TEAEs for patients treated with BEX. However, it should be 
noted that in the advanced stage subgroup of the ALCANZA trial, the 10% threshold was met 
if only two patients treated with MTX had a TEAE or three patients treated with BEX had a 
TEAE. Focusing instead on AEs that occurred in ≥15% of patients, the ERG highlights the 
most common TEAEs in Table 42.  
Table 42 Most common (≥15%) any-grade treatment-emergent adverse events occurring in 
the ALCANZA trial 
Type of adverse event, n (%) Overall trial population, median 
22.9 months follow-up  
Advanced stage subgroup, 













Peripheral sensory neuropathy  30 (45) 1 (4) 0 25 (51) 0 0 
Nausea 24 (36) 4 (16) 4 (11) 18 (37) 4 (20) 4 (17) 
Fatigue 19 (29) 5 (20) 12 (32) 11 (22) 5 (25) 6 (25) 
Pyrexia (Fever) 11 (17) 7 (28) 4 (11) 6 (12) 6 (30) 3 (13) 
Hypertriglyceridaemia 1 (2) 0 11 (30) 0 0 7 (29) 
BEX=bexarotene; BV=brentuximab vedotin; MTX=methotrexate 
Source: CS, adapted from Table 20 and clarification response, A12 (adapted from Table 8) 
In the advanced subgroup, peripheral sensory neuropathy (a type of peripheral neuropathy), 
occurred in half of all patients treated with BV, pyrexia (fever) occurred in nearly a third of all 
patients treated with MTX and hypertriglyceridemia occurred in nearly a third of all patients 
treated with BEX. Nausea and fatigue were common AEs associated with all three therapies.  
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In addition, diarrhoea was reported by 29% of patients in the BV arm of the overall ALCANZA 
trial population but only 12% in the subgroup with advanced stage CTCL. Vomiting and 
alopecia were also common AEs associated with treatment with BV (both occurring in 14% of 
patients with advanced stage CTCL treated with BV). 
AEs reported in the prospective observational studies [18, 76] are described as TRAEs (CS, 
Appendix F). The most common TRAE reported in the observational studies was peripheral 
neuropathy (any-grade 67% in Duvic et al 2015 [18], 66% in Kim et al 2015 [76]). The 
frequencies of peripheral neuropathy were very similar to the frequency of peripheral 
neuropathy reported as a TEAE in the overall ALCANZA trial population after a median of 22.9 
months follow-up (67%). However, with the exception of diarrhoea and nausea, which were 
reported less frequently in the observational studies than in the overall trial population of the 
ALCANZA trial, the frequencies of the most common AEs tended to be higher in the 
prospective observational studies [18, 76] than in the ALCANZA trial. Most notably, any-grade 
fatigue and any-grade neutropenia was experienced by 47% and 19% of patients respectively 
in the study by Kim et al 2015 [76] compared to 29% and 8% of patients respectively in the 
overall ALCANZA trial population [66] (or 22% and 10% respectively in the advanced stage 
subgroup, see company clarification response, A12 [Table 8] and A15 [Table 10]).  
In the retrospective analysis by Mathieu et al 2016 [75], peripheral neuropathy was reported 
by only 7 (22%) patients. Referring to the two previous observational studies [18, 76], the 
authors state in their abstract that: “They [the authors of the observational studies] also report 
fatigue, skin rashes, diarrhoea and neutropenia more often than we do.” 
As reported in the EPAR for BV (p85) [30], Wieser at al 2016 [116] conducted a retrospective 
study of 180 patients with LyP of whom 21 patients received BV. The most commonly reported 
AE was peripheral neuropathy (in 9 [43%] patients). Information on other AEs was not 
provided in the publication. 
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9.6 Appendix 6: HRQoL results from the overall ALCANZA trial 
population 
9.6.1 FACT-G 
FACT-G results are not reported in the CS. After a median follow-up of 22.9 months, it is, 
however, reported in the published paper [66] that there were no statistically significant 
differences between arms in all patients. It is reported in the EPAR for BV (p50) [30] that 
compliance was high in both arms over time. 
*********************************************************************************************************
*********************************************************************************** Whilst compliance 
was reported to be high over time from baseline to EOT (i.e., most of those eligible to complete 
questionnaires did so), the number of eligible patients at each point in time decreased, 
reflecting the higher number of patients who had disease progression. 
9.6.2 Skindex-29 
Statistically significant improvements in symptoms measured by Skindex-29 were reported for 
patients treated with BV compared to those in the PC arm (CS, pp72 to 73). After a median 
follow-up of 22.9 months, the mean maximum reduction from baseline in the ITT population 
was -27.96 in the BV arm and -8.62 in the PC arm (p<0.0001). After a median follow-up of 
33.9 months, patients treated with BV continued to experience significantly greater symptom 
reduction versus those treated with PC (mean maximum reduction, -28.08 versus -8.62, 
respectively; p<0.001). As described in the EPAR for BV (p34 and p48) [30], the company 
also calculated whether the change was of clinical significance by determining the minimal 
important difference (MID) by three methods. The calculated MID in the reduction in Skindex-
29 symptom domain score was 12.3 using half of a standard deviation of change in score, 
11.2 using Cohen’s effect size, and 9.1 using standard error of measurement. The difference 
between the treatment arms for the maximum reduction from baseline after a median of 22.9 
months and a median of 33.9 months exceeded all the MID thresholds, demonstrating a 
clinically meaningful response. 
The ERG notes that, as reported in the EPAR for BV (p49) [30] and published paper [66] but 
not in the CS, other domains (emotions, functioning) of Skindex-29 were also measured in the 
ALCANZA trial. It is reported in the published paper (p560) that “No substantial difference in 
Skindex-29 emotional or functioning domains was seen over time” [66]; however, skin disease 
at end of treatment had less of an effect in patients in the BV arm than the PC arm for both 
domains. Results for the total score of the Skindex-29 are presented in the EPAR (Figure 21) 
[30]. The results mirror those of the emotional and functioning domains. 
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Compliance with Skindex-29 assessments was reported to be high. It is reported in the CSR 
(p142) that compliance 
*********************************************************************************************************
*******************************************************************************************************. 
Whilst compliance was reported to be high over time from baseline to EOT, as with the FACT-
G questionnaires, the number of eligible patients at each point in time decreased, reflecting 
the higher number of patients who had disease progression. 
9.6.3 EQ-5D-3L and EQ-5D-VAS 
Similar to the results from the analysis of FACT-G, there were no statistically significant 
differences between arms for EQ-5D-3L US time trade-off, EQ-5D-3L UK time trade-off, or 
EQ-5D VAS scores. Again, it is reported in the EPAR for BV (p50) [30] that compliance was 
high in both arms over time. 
*********************************************************************************************************
************************************************************************************ Whilst compliance 
was reported to be high over time from baseline to EOT, as with the FACT-G and Skindex-29 
questionnaires, the number of eligible patients at each point in time decreased, reflecting the 
higher number of patients who had disease progression. 
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9.7 Appendix 7: Resource use 
Table 43 Resource use in the active therapy phase of the post-progression health state 







Dose Unit Average 
weekly cost 
Source 
Hospital outpatient   
Clinical nurse specialist 100% 0.38 N/A N/A N/A £32.77 NHS Reference Costs 2016/17 [147] WF01A:370 
Total outpatient attendances, Non-consultant led,  
Medical oncology 
Dermatologist visit 100% 0.50 £50.27 NHS Reference Costs 2016/17 [147] WF01A:330 
Consultant led- Non-Admitted Face-to-Face 
Attendance, Follow-up 
Oncologist outpatient visit 100% 0.38 £60.43 NHS Reference Costs 2016/17 [147] WF01A:370 
Total Outpatient Attendances, Medical Oncology 
Consultant oncologist visit 100% 0.54 £95.46 NHS Reference Costs 2016/17 [147] WF01A:370 
Total outpatient attendances, Consultant led,  Medical 
oncology 
Home visit   
District nurse 100% 2.60 N/A N/A N/A £96.01 NHS Reference Costs 2016/17 [147] - N02AF Total 
Other Currencies, District Nurse, Adult, Face to face 
Investigations and tests  
Complete blood count 100% 0.67 N/A N/A N/A £2.04 NHS Reference Costs 2016/17 [147] - DAPS05 
Haematology 
Liver function test 100% 0.33 £4.20 NHS Reference Costs 2016/17 [147] - DAPS09 Other 
- 5 tests required  
U&Es (urea and electrolytes 
test) 
100% 0.33 £0.38 NHS Reference Costs 2016/17 [147] - DAPS04 
Clinical Biochemistry 
LDH (lactate dehydrogenase) 100% 0.33 £0.84 NHS Reference Costs 2016/17 [147] - DAPS09, 
DAPS, Other 
Computed tomography scan 50% 0.17 £10.19 NHS Reference Costs 2016/17 [147] - RD26Z, Total 
HRGs, Computerised Tomography Scan of Three 
Areas, with Contrast 
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Dose Unit Average 
weekly cost 
Source 
Imaging - PET 50% 0.17 £39.88 NHS Reference Costs 2016/17 [147] - RN07A - 
Positron Emission Tomography (PET), 19 years and 
over 
Dressings  
Full body coverage 0% 0 N/A 0 Dressings £0.00 The use of various sizes of allevyn, mepitel and 
mepilex dressings are assumed along with elasticated 
vest and leggings garments. The costs are all sourced 
from the BNF. 
Localised coverage 60% 7 7 Dressings £510.38 
Other drug treatments  
Pain relief  
Oramorph 0% 14.00 N/A 60 mg £0.00 eMit [149] where available or MIMs [165] 
Oromorph (breakthrough pain 
/ iv) 
80% 1.00 10 mg £0.08 
Antihistamines   
Hydroxyzine 50% 4.67   25 mg £0.05 eMit [149]  where available or MIMs [165] 
Gabapentin 33.33% 14.00   300 mg £0.38 
Antidepressants   
Mirtazapine 50% 7.00   30 mg £0.13 eMit [149]  where available or MIMs [165] 
Pregabalin 50% 7.00   300 mg £0.34 
Antibiotics  
Flucloxacillin 100% 4.83 N/A 500 mg £0.39 eMit [149]  where available or MIMs [165] 
Aciclovir 25% 28.00 N/A 200 mg £0.23 
PET=positron emission tomography; IV= intravenous 
Source: CS, adapted from Section B.3.5.2, Table 48 and company model 
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Table 44 Resource use in the end-stage management phase of the post-progression health state 











Hospital outpatient   
Clinical nurse 
specialist 
100% 2.25 N/A N/A N/A £196.65 NHS Reference Costs 2016/17 [147] WF01A:370 Total 
outpatient attendances, Non-consultant led,  Medical 
oncology 
Dermatologist visit 100% 0.17 £16.76 NHS Reference Costs 2016/17 [147] WF01A:330 Consultant 
led- Non-Admitted Face-to-Face Attendance, Follow-up 
Consultant oncologist 
visit 
100% 0.17 £29.37 NHS Reference Costs 2016/17 [147] WF01A:370 Total 
outpatient attendances, Consultant led,  Medical oncology 
Psychologist 50% 0.25 1 N/A Hours £6.63 PSSRU 2017 [148], Band 7 Clinical psychologist, per working 
hour 
Hospital inpatient   
Dermatology Day 
Centre or Oncology 
Ward 
20% 0.11 N/A   £117.48 Cost per admittance to control skin outbreak. Assumes 
similar cost to generic lymphoma admittance and inpatient 
stay 
NHS Reference Costs 2016/17 [147] 
Malignant Lymphoma, including Hodgkin's and Non-
Hodgkin's (all CC scores). SA31A: SA31F. 
Home visit   
District nurse 100% 2.63 N/A N/A N/A £96.93 NHS Reference Costs 2016/17 [147] 
N02AF Total Other Currencies, District Nurse, Adult, Face to 
face 
Macmillan nurse / 
Social services 




100% 2.00 N/A N/A £284.00 NHS Reference Costs 2016/17 [147]: Outpatient - medical 
specialist palliative care attendance SD04A 
Skin and wound care   
Radiotherapy 90% 0.11 N/A 2 Fractions £96.01 NHS Reference Costs 2016/17 [147]: Preparation for Simple 
Radiotherapy with Imaging and Dosimetry, outpatient 
(SC45Z) + Deliver a Fraction of Treatment on a Superficial or 
Orthovoltage Machine, outpatient (SC21Z) 
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Topical steroids   
Betnovate 100% 0.34 N/A  £1.40 eMit [149] where available or MIMs [165] 
Dressings   
Full body coverage including elasticated garments   
Mepitel dressings 25% 7 N/A 3 Dressings £74.81 The use of various sizes of allevyn, mepitel and mepilex 
dressings are assumed along with elasticated vest and 
leggings garments. The costs are all sourced from the BNF. Mepilex large sheet 
dressings 
25% 7 2 Dressings £222.74 
Mepilex small 
dressings 
25% 7 3 Dressings £53.39 
Mepliex heels 25% 7 2 Dressings £45.05 
Elasticated garments 25% 1 1 Garments £6.53 
Localised coverage   
Medium allevyn 75% 7 N/A 7 Dressings £637.98 The use of various sizes of allevyn, mepitel and mepilex 
dressings are assumed along with elasticated vest and 
leggings garments. The costs are all sourced from the BNF. 
Other drug treatments  
Pain relief  
Oramorph 100% 14.00 N/A 60 mg £7.94 eMit [149] where available or MIMs [165] 
Oromorph (Morphine 
sulphate 
[breakthrough pain / 
iv]) 
80% 0.25 10 mg £0.02 
Antihistamines  
Hydroxyzine 100% 4.67 N/A 25 mg £0.10 eMit  [149] where available or MIMs [165] 
Gabapentin 50% 14.00 N/A 300 mg £0.57 
  
   Confidential until published 
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma [ID 1190] 
ERG Report 
Page 161 of 172 
 












Mirtazapine 50% 7.00 N/A 30 mg £0.13 eMit  [149]where available or MIMs [165] 
Pregabalin 50% 7.00 N/A 300 mg £0.34 
Antibiotics  
Flucloxacillin 100% 3.22 N/A 500 mg £0.26 eMit  [149]where available or MIMs [165] 
Aciclovir 25% 28.00 N/A 200 mg £0.23 
Antifungal  
Fucitec  80% 0.02 N/A 30 g £0.10 eMit  [149]where available or MIMs [165] 
IV= intravenous 
Source: CS, adapted from, Section B.3.5.2 Table 49 and company model 
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9.8 Appendix 8: “Payoff” approach 
In the company’s payoff approach, transition probabilities for progression and death are 
calculated from parametric curves fitted to PFS and OS K-M data from the ALCANZA trial. 
The proportion of patients in the post-progression state in each model cycle is calculated by 
subtracting PFS from OS. Mean post-progression survival (PPS) is then calculated using an 
area under the curve (AUC) approach.  Mean time spent in an intermediate subsequent active 
therapy phase is calculated using registry data (see Section 5.2.8) and subtracted from mean 
PPS to give mean time spent in end-stage care. Mean costs and QALYs for active subsequent 
therapy and end-stage care are multiplied by the time spent in those phases and then summed 
to give mean costs and QALYs for the whole post-progression state. These mean post-
progression costs are then applied on a cycle basis to patients newly entering the post-
progression state based on the transition probabilities calculated from the modelled PFS and 
OS curves. The basic structure of the post-progression state in the company model is shown 
in Figure 18 and Figure 19.  
 
Figure 18 Simplified structure of calculation of mean PPS costs and QALYs in the company 
model 
Note: the company base case includes further intermediate calculations to include costs and QALYs for alloSCT but the principles 
are as outlined in Figure 18
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Superseded – see erratum
 
 
Figure 19 Simplified structure of calculation of total PPS costs and QALYs in the company 
base case 
Note: the company base case includes further intermediate calculations to include costs and QALYs for alloSCT but the principles 
are as outlined in Figure 19 
 
The company applies discounting in the post-progression state as a ratio of the difference in 
the exponentiated time entering a state and the time leaving versus time spent in the state 
(Equation 1). This method models a difference in discount rates applied to mean PPS costs 
and QALYs depending on the time an individual enters the post-progression state. However, 
the company method of discounting costs and benefits in the post-progression state also 
imposes a parametric structure on the transitions between the subsequent active therapy and 
end-stage care phases. The risks of moving from active subsequent therapy to end-stage 
care, and from end-stage care to death are assumed to be constant (albeit different) as a 
result of the exponential nature of the discount-rate calculation. 
Equation 1 Company model post-progression state cycle discount rate calculation 
	 	 																		
	 ∗ 	 	
	
	 ∗ 	 	
	
	 	 	
  (1) 
⇒
exp 	 	 exp 	 	
	 	 	
 
This means that the shape of the OS curve has no relevance to model outcomes once patients 
have progressed and the impact of uncertainty in the survival trajectory – beyond estimating 
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9.9 ERG Revisions to company’s model 
All revisions are activated by a logic switch. Logic switches are indicated by named range variables Mod_number where number = 1 to 8. A menu 
of revisions and Mod names appears below and on the ‘Results’ worksheet in the ERG amended model. 
Instructions for modifying the updated company model  
 
For individual revisions: 
1. Populate the following named switch values in the ‘Results’ sheet 
   
Name Switch Details 
Mod_1 0 R1) Remove alloSCT 
Mod_2 0 R2) Utility estimates: observed EQ-5D-3L utility estimates from the ALCANZA trial 
Mod_3 0 R3) Utility estimates: PFS utility equal for treatment with BV and treatment with PC (includes R2) 
Mod_4 0 R4) Utility estimates: removal of AE decrements 
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Sheet Cells Modified formulae 
R1) Remove 
alloSCT 
Mod_1 Controls I133 
=IF(Mod_1=0,"Yes","No") 
 










utility equal for 
treatment with BV 
and treatment 
























utility equal for 
treatment with BV 
and treatment 
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utility equal for 
treatment with BV 
and treatment 
























utility equal for 
treatment with BV 
and treatment 

















removal of AE 
decrements 
Mod_4 Controls I93 
=IF(Mod_4=0,"Yes","No") 
 
Amend named range control_inc_AE_dec to point to Controls!$I$93 
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Sheet Cells Modified formulae 




Mod_5 Costs C177 
=(IF(ctrl_oraladmincost="Admin cost only",p_admincost_oral_NHSref,IF(ctrl_oraladmincost="Admin cost plus 
dispensing cost",p_admincost_oral_NHSref+p_admincost_oral_disp,"Error")))*IF(Mod_5=0,1,0) 




Mod_5 Costs C178 





1. Populate the following named switch values in the ‘Results’ sheet 
   
Name Switch Details 
Mod_6 0 S1) Changes to post-progression pathway 
Mod_7 0 S2) Changes to resource use frequencies 
Mod_8 0 S3) Assuming an OS gain for treatment with BV equal to company base case (1.2 years) 
 
N.B. Revisions R1, R3, R4 and R5 (Mod_1, Mod_3, Mod_4 and Mod_5) should also be switched on when running each of the ERG’s 
scenarios 
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Sheet Cells Modified formulae 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N25 




Assign name to value ERG_endstage_duration 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N26 




Assign name to value ERG_BSC_duration 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N27 




Assign name to cell ERG_ActiveDuration_BV 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N28 




Assign name to cell ERG_ActiveDuration_PC 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N29 




Assign name to cell ERG_utility_BSC 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N30 
=p_active_nonSCT_PPS_drugcosts/SUM('Subsequent therapy'!F79:F82) 
 
Assign name to cell ERG_ActiveDrugCost_weekly 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N31 
=p_active_nonSCT_PPS_admincosts/SUM('Subsequent therapy'!F88:F91) 
 
Assign name to cell ERG_ActiveAdminCost_weekly 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N32 
=ERG_ActiveDrugCost_weekly*ERG_ActiveDuration_BV*52 
 
Assign name to cell ERG_ActiveDrugCost_total_BV 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N33 
=ERG_ActiveAdminCost_weekly*ERG_ActiveDuration_BV*52 
 
Assign name to cell ERG_ActiveAdminCost_total_BV 
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Sheet Cells Modified formulae 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N32 
=ERG_ActiveDrugCost_weekly*ERG_ActiveDuration_PC*52 
 
Assign name to cell ERG_ActiveDrugCost_total_PC 
S1) Changes to 
post-progression 
pathway 
Mod_6 Results N33 
=ERG_ActiveAdminCost_weekly*ERG_ActiveDuration_BV*52 
 
Assign name to cell ERG_ActiveAdminCost_total_PC 
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Sheet Cells Modified formulae 




























































S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D115 =(0.5+(0.5*C136*D136))*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C136 =60%*IF(Mod_7=0,1,0)+37.5%*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D165 =(0.5+(0.5*C186*D186))*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C186 =60%*IF(Mod_7=0,1,0)+37.5%*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D210 
=(1/2+N("Routine visit every 2 weeks") 
+(C239*D239)+N("All full body coverage dressings by CNS"))*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C211 =100%*IF(Mod_7=0,1,0)+0.5*IF(Mod_7=1,1,0) 
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Sheet Cells Modified formulae 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C214 =50%*IF(Mod_7=0,1,0)+0.05*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D218 =(0.5*C245*D245+N("50% localised dressing applied by district nurse"))*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D219 =1*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use D220 =2*IF(Mod_7=0,1,0)+0.25*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C239 =25%*IF(Mod_7=0,1,0)+0.125*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C240 =25%*IF(Mod_7=0,1,0)+0.125*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C241 =25%*IF(Mod_7=0,1,0)+0.125*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C242 =25%*IF(Mod_7=0,1,0)+0.125*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C243 =25%*IF(Mod_7=0,1,0)+0.125*IF(Mod_7=1,1,0) 
S2) Changes to 
resource use 
frequencies 
Mod_7 Resource use C245 =75%*IF(Mod_7=0,1,0)+0.375*IF(Mod_7=1,1,0) 
S3) Assuming an 
OS gain for 
treatment with BV 
Mod_8 Results N40 




Assign name to value ERG_OS_AF 
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Sheet Cells Modified formulae 
S3) Assuming an 
OS gain for 
treatment with BV 
Mod_8 OS I47:I2396 
=(IF(control_BV_OS_source="ALCANZA PC 
arm",J47,IF(ctrl_BV_OS_noninferiority="No",IF(ctrl_population="Severe",AQ47,BJ47),IF(K47<=J47,I46*(J47/J46),IF(ctrl
_population="Severe",AQ47,BJ47)))))*IF(Mod_8=0,1,0)+1/(1+((((H47*ERG_OS_AF)*EXP(-1*$BE$33))^(1/(EXP(-
1*$BE$32))))))* IF(Mod_8=1,1,0) 
 
 
 
